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CHAPTER I 
OVERVIEW 
 
Mycobacterium tuberculosis (MTB) infection and subsequent tuberculosis (TB) is the 
second-leading cause of mortality from a single infectious agent worldwide, after the human 
immunodeficiency virus (HIV)
1,2
. In 2013, 9 million new cases of clinical tuberculosis were 
diagnosed and 1.5 million deaths were attributed to the disease
2
. An estimated 1.1 million new 
cases and 360,000 of the deaths occurred in people co-infected with HIV
2
. The 
immunosuppression resulting from HIV infection increases the risk of progression to active 
disease following new exposure to MTB, or reactivation of latent MTB in patients with prior 
infection
3,4
. Sub-Saharan Africa is the location where most HIV/TB co-infection occurs, with 
75% of all cases reporting coinfection
1,2
. The influence of host genetics on tuberculosis disease 
has been extensively studied, mostly in HIV-negative patients, and revealed that variation in 
pathways pertinent to macrophage and Type 1 helper T cell (TH1) signaling, among others, 
modulate disease risk
5-11
. Generally, HIV seropositive status has been viewed as a confounder in 
such studies and it is either adjusted for or used as an exclusion criterion.  
In the current project we present a novel hypothesis for studying resistance to either TB 
disease or MTB infection, using the immunosuppression of HIV-positive patients to identify an 
extreme phenotype. Namely, we posit that HIV-positive patients living in areas endemic for 
MTB who do not develop TB are resistant, and that this protection has a genetic component with 
an effect size large enough to permit using a smaller sample size than those seen in prior 
genome-wide association studies (GWAS) on TB
10,11
. The goal of the following chapters is to 
evaluate this hypothesis as it pertains to resistance to TB disease and MTB infection, in single 
variant and epistatic models.   
2 
 
Background information pertinent to this project is described in part A of Chapter II, 
including clinical presentation, diagnostics, treatments, a summary of the worldwide burden of 
tuberculosis as well as a description of prior genetic variants associating with TB.  Previous 
study designs are discussed, as well as the approach we are taking to analyze this complex 
phenotype. Explicit hypotheses and specific aims are presented in part B of Chapter II. 
A genome-wide association study of common genetic variants and with TB resistance in 
HIV-positive patients is described in Chapter III. Of note, I recruited patients on-site and isolated 
DNA in one of the cohorts, the DarDar vaccine trial extended follow up, in Dar es Salaam, 
Tanzania. I also isolated DNA from samples collected in two other studies, the DarDar Women’s 
Nutrition Study from Tanzania and the Household Contacts Study from Kampala, Uganda. The 
samples for the Nutrition and Household Contacts Studies were made available to us by fellow 
investigators. In a study combining the cohorts, we found a common variant associating at the 
genome-wide significance threshold in the IL12B region. Linkage disequilibrium (LD) patterns 
in the region suggested that the region is conserved and integrated haplotype score analyses 
using sub-Saharan populations demonstrated that the LD block containing rs4921437 has 
undergone selection. The single nucleotide polymorphism (SNP) of interest is located in an area 
enriched for a histone acetylation mark often found in active regulatory elements, suggesting 
possible functionality and a genetic-epigenetic interaction at the site. Further studies of this 
interaction are warranted.  
Chapter IV describes two approaches used to evaluate the genetics of MTB infection. In 
Part A, we used a genome-wide approach to identify variants associating with MTB infection. 
We discovered a novel association to MTB infection, variant rs877356 near IL9, a gene with a 
substantial role in airway inflammation and bronchial asthma. Observational studies have 
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reported a pattern of inverse incidence of asthma and tuberculosis, and we believe that IL9, a 
gene whose over expression plays a significant role in the pathogenesis of asthma, also prevents 
MTB infection by the same mechanism.  In Part B, we validated and fine-mapped regions 
previously associated through genome-wide linkage analyses, SLC6A3 +/- 0.5 mb
12
, 2q14
13
, 
2q21-2q24
13
, 5p13-5q22
13
 and chromosome 11 p14.1
12
. We discovered an infection 
susceptibility locus rs10834029 on chromosome 11 near GAS2, a gene previously associated 
with the apoptotic pathway.   
The immune response to MTB infection and resultant disease is complex
8,14-17
. The 
molecular signaling profile and extent tissue involvement change over the course of disease. 
Therefore, it is likely that no single factor alone can adequately explain risk of TB disease or 
MTB infection risk. In Chapter V we present a study in which we examined multi-locus 
relationships between previously associated candidate genes and TB disease in Part A, and MTB 
infection in Part B, using Multifactor Dimensionality Reduction (MDR) software
18,19
. We found 
an association of TB disease and a three-locus interaction of variants near IL12B, TNF-α, and 
CR1. The products of IL12B and TNF-α have some redundant and some concordant effects in the 
inflammatory response to MTB, while CR1 plays a role in phagocytosis of MTB by 
macrophages, also a key step in immune response to MTB. In Part B, we found an association 
between MTB infection and a three-locus interaction between variants near IL9, SLC6A3, and 
RAB6C. Importantly, each three-locus interaction had consistent effects in the Ugandan and 
Tanzanian cohorts.  
Since the majority of our Tanzanian participants were previously enrolled in a Phase III 
whole cell SRL 172 vaccine trial, we wanted to evaluate whether host genetic components affect 
protective outcomes. The vaccine confers protection against definite TB in HIV positive adults 
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who had a childhood BCG vaccination. Response to the vaccine was variable with SRL 172 
showing a 39% efficacy; therefore it is of interest whether its effectiveness is modulated by 
polymorphisms in our either our candidate gene/loci list, or any other available variants
17
. 
However, as described in Chapter VI, we were unable to recruit enough definite or probable TB 
cases from the extended follow up cohort of this trial to have adequate power for this aim.  
Chapter VII summarizes the conclusions of this project and proposes future directions. 
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CHAPTER II 
INTRODUCTION 
 
A. BACKGROUND 
 
Clinical presentation of tuberculosis  
 
Pathogenesis 
 
Tuberculosis is an infectious disease caused by the inhalation of 1-3 droplet nuclei 
containing Mycobacterium tuberculosis, emitted by individuals with active respiratory disease 
via coughing, sneezing or spitting
2,20
. Differentiating TB infection from TB disease is essential, 
in that infection simply means the presence of M. tuberculosis organisms in a host, whether it 
leads to disease or not. In fact, 90-95% of people infected with M. tuberculosis will contain the 
initial infection without symptoms and develop a latent infection, while the remaining 5-10% 
will develop active TB disease soon after exposure (primary tuberculosis), with symptoms such 
as cough, fever, weight loss and night sweats
21
.
 
The pattern of lung involvement in primary 
tuberculosis results in consolidation of the lower and middle lung lobes, along with hilar 
adenopathy, and very rarely cavitation. Latent infections can be activated (secondary 
tuberculosis) by immunosuppression caused by age, malnutrition, or HIV infection, among other 
factors. Cavitation occurs readily in secondary tuberculosis, and it is generally localized in upper 
lobe apices of the lungs
21
. TB disease is lethal in two thirds of the patients who do not receive 
proper treatment
2
. The causal organism, M. tuberculosis, is an aerobic acid fast bacterium that 
divides very slowly relative to other bacteria, once every 15-20 hours, which makes it very 
difficult to grow in culture and consequently diagnose. Like Gram positive bacteria, M. 
tuberculosis has an outer membrane lipid bilayer containing peptidoglycan; however the bilayer 
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is filled with other lipids (liparabinomannan) and the peptidoglycan is linked to arabinogalactan 
bound to mycolic acids that makes it very difficult to Gram stain
15
. The acid fast Ziehl-Neelsen 
stain is usually used instead of Gram staining when TB is a part of the differential diagnosis. The 
small shape and unique cell wall lipid profile make M. tuberculosis very resilient, even when 
exposed to desiccation or disinfectants
15
. 
Once the droplet nuclei containing M. tuberculosis move into the lungs of a naïve 
individual, the bacteria enter macrophages and grow in intracellular membrane bound vesicles 
(Figure 2-1). This allows M. tuberculosis to avoid degradation by the immune system because 
these vesicles do not bind to lysosomes. Since the vesicles are intracellular, the M. tuberculosis 
molecules are not exposed to cytosolic proteasomes and less efficient intravesicular proteases 
must degrade the bacteria instead. Therefore, in the first 3 weeks after infection in a non-
sensitized individual, the bacteremia is largely unchecked by innate immunity and the 
mycobacteria can seed multiple sites and airspaces
21
.
  
Roughly three weeks following the infection, the host starts to mount an adaptive 
response by inducing the differentiation of T cells. There are two main types of CD4 expressing 
T helper cells, TH1 and TH2
22
. TH1 cells control infections by intracellular pathogens while TH2 
cells are responsible for extracellular pathogens and they induce B cells to produce antibodies
22
. 
Upon M. tuberculosis digestion and peptide presentation with major histocompatibility complex 
(MHC) class II molecules, Toll-like receptor 2 (TLR2) binding to dendritic cells stimulates an 
IL-12 response which in turn activates the differentiation of TH1 CD4 T cells
21
. The mature TH1 
cells mount an interferon gamma (IFN-γ) response and activate phagolysosomes in M. 
tuberculosis containing macrophages, and induce the production of nitric oxide and reactive 
oxygen species
21
.
 
These activated macrophages also use tumor necrosis factor (TNF) signaling in 
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a localized inflammatory response that leads to the formation of granuloma. The granuloma is 
comprised of activated macrophages that differentiate into epithelioid histiocytes, and may fuse 
forming giant cells. In the case of M. tuberculosis TB, the granuloma consists of a central core of 
macrophages, organized into progressively necrotic multinucleated giant cells, and surrounded 
by CD4 T cells
21
. The M. tuberculosis bacteria survive within the granulomas even in the 
presence of widespread necrosis
22
. If the granuloma is macroscopic in size, the central portion is 
yellowish/white upon dissection, and the term caseous necrosis is used
21
. Complete clearance of 
the bacteria is rarely achieved, and the lesions become fibrocalcific nodules known as Ghon foci 
(Ghon complexes if lymph node granulomas are involved) forming at the site of the infection. 
Viable M. tuberculosis organisms can survive there for many years until reactivation, thereby 
establishing a latent infection
21
. In the 5-10% of patients who progress to active TB disease, the 
immune system is unable to wall off the infection via the granulomas and the bacteria multiply, 
with significant caseation, cavitation and tissue destruction
21
. 80% of such disease is restricted to 
the lungs, with symptoms such as prolonged cough, hemoptysis and chest pain
23
. In rare cases, 
mostly in children and immunosuppressed patients, M. tuberculosis can enter systemic 
circulation by draining into systemic veins via lymph nodes or directly entering the pulmonary 
vein and cause disseminated disease usually localizing to pleura, bones, and joints (miliary 
tuberculosis) or the CNS (tuberculosis meningitis)
21
.
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Figure 2-1. Progression of primary pulmonary tuberculosis upon inhalation of Mycobacterium 
tuberculosis containing droplet nuclei, prior (A) and following (B) adaptive immune response
21
; 
image from: http://dr.klinikbtp.com/tuberculosis-pathogenesis-and-immunity/
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Diagnostics and treatment 
 
The broad spectrum of possible symptoms for both pulmonary and extra-pulmonary 
tuberculosis makes it difficult to diagnose based solely on clinical presentation, as the disease 
can mimic many conditions such as other bacterial infections or a variety of malignancies
15
. The 
above mentioned problems with staining and culturing of M. tuberculosis compound this 
problem. Due to the predominant involvement of lower lobes, diagnosis of primary tuberculosis 
is difficult because it resembles primary progressive pneumonia
21
. On the other hand, secondary 
tuberculosis usually features the consolidation and cavitation of tissues found in apices of the 
upper lobes of the lungs, which can be detected with a chest X ray
21
.  
While most cases of primary TB are restricted to the lungs, in HIV infected individuals 
the disease causes extra-pulmonary disease more often, with such localizations being found in 
53-63% of such patients
24,25
. The presentation is usually contingent on the CD4
+
 count; patients 
with >300 cells/mm
3
 will resemble secondary tuberculosis symptoms, while those <200 
cells/mm
3
 resemble progressive primary tuberculosis
21
. Primary prophylaxis of daily or twice 
weekly isoniazid for 9 months has been recommended for HIV-positive individuals with latent 
TB or recent TB exposure. This has been proven effective in preventing subsequent disease and 
it does not cause any adverse interactions with highly active anti-retroviral therapy
26
.  
The Mantoux tuberculin skin test (TST) is the most common technique used to ascertain 
M. tuberculosis exposure and subsequent response. The involvement of T-cell mediated 
immunity in combating M. tuberculosis infection allows for the use of delayed hypersensitivity 
to its antigens as a diagnostic
21
. A TST consists of an intradermal injection of a standard dose of 
M. tuberculosis purified protein derivatives (PPD) into the forearm of a patient; in those 
previously exposed to the bacteria, this will induce a palpable and visible induration that attains 
10 
 
its maximal size within 48-72 hours post injection
21
. TST results are, therefore, classified in the 
48-72 hour period after the injection, and are interpreted in light of recent travel to endemic 
countries, HIV status and contact with TB patients, among others, and in the highest risk group 
an induration >5mm indicates a positive reaction.  
The TST does not distinguish between M. tuberculosis infection and TB disease, and a 
childhood Bacillus Calmette-Guerin (BCG) vaccination or exposure to other mycobacteria can 
lead to false positive results
21
. False negative results can be a result of anergy caused by severe 
immunosuppression, as caused by HIV or malnutrition. In recent years alternatives to the long 
used TST have been developed. Two Interferon Gamma Release Assay (IGRA) tests, the 
QuantiFERON®-TB Gold In-Tube test (QFT-GIT) and T-SPOT®.TB test (T-Spot), are now 
commercially available and approved by the U.S. Food and Drug Administration. The Centers 
for Disease Control and Prevention recommend the use of IGRAs in certain populations, 
especially in settings where people do not return for TST readings or in those with previous BCG 
vaccination
27
. The QFT-GIT uses ELISA to detect the concentration of IFN-γ in response to the 
use of a mixture of TB-specific antigens, culture filtered protein (CFP)-10, TB7.7 and early 
secretory antigenic target (ESAT)-6 on whole blood
27,28
.
 
Whole blood samples must be processed 
within 16 hours of the phlebotomy
27
. The specificity of the test is >99% regardless of BCG 
vaccination status. The QFT-GIT antigens are encoded by a region of the M. tuberculosis 
genome not present in the BCG strains and most other mycobacteria
27
. However, like the TST, 
QFT-GIT does not differentiate between latent TB infection and TB disease. The T-spot utilizes 
the enzyme-linked immunospot (ELISpot) assay, and requires peripheral blood mononuclear 
cells (PBMCs) that need to be processed 8-30 hours after the phlebotomy depending on the 
technique used. The test uses separate mixtures of synthetic peptides CFP-10 and ESAT-6, and 
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measures the proportion of IFN-γ producing T-cells to the total number of PBMCs on the plate29. 
The T-Spot has a sensitivity of ~95%; however, as with other described tests, it cannot 
discriminate between latent TB and TB disease
29,30
. 
  Treatment modalities for TB disease vary depending on the antibiotic resistance of the 
infecting MTB strain and the presence of other comorbidities
31
. It is important to note that many 
regimens have been approved, and only a few are listed below. There are four first line drugs 
approved by the Food and Drug Administration for treatment of TB in otherwise healthy 
individuals in the USA: isoniazid (INH), rifampin (RIF), ethambutol (EMB) and pyrazinamide 
(PZA)
31
. The standard regimen calls for daily use of each of the first line medications for 8 
weeks, followed by daily INH and RIF for 18 months
31
. An important caveat to treating patients 
coinfected with TB and HIV is the interaction between RIF and nonnucleoside reverse 
transcriptase inhibitors or certain protease inhibitors
31
. In those cases, rifabutin replaces RIF
31
. 
For latent TB infection, a daily nine-month regimen of INH is indicated. In cases of drug 
resistant TB, EMB is indicated along with a combination of fluoroquinilones (levofloxacin, 
moxyfloxacin) and aminoglycosides (amikacin, streptomycin, kanamycin), despite the 
substantial ototoxicity/nephrotoxicity associated with prolonged use of the latter class
31,32
.   
 
Epidemiology of tuberculosis 
 
Global statistics 
 
  Mycobacterium tuberculosis infection and subsequent tuberculosis is the second-leading 
single infectious cause of mortality worldwide, after the human immunodeficiency virus 
(HIV)
1,2
. M. tuberculosis is the most common cause of human Mycobacterial disease and it 
alone is responsible for most of the 1.5 million deaths annually attributed to clinical 
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tuberculosis
2,15
. In 2013, 9 million new cases of clinical tuberculosis were diagnosed
2
. Over half 
of the new cases (56%) developed in South East Asia and Oceania, with 24% occurring in India 
alone
2
. Another quarter of the global TB incidence that year was reported in Africa
2
.  
The spread of drug resistant tuberculosis is an important aspect of TB epidemiology. 
While rates of TB have decreased since 1990, multi-drug resistant tuberculosis (MDR-TB) is 
rising. MDR-TB is defined as tuberculosis resistant to rifampicin and isoniazid, and it requires a 
longer treatment course using drugs with worse toxicity profiles
31
. 3.7% of new TB cases are 
MDR, as are 20% of previously treated cases
2
. This translates to 480,000 new cases of MDR-TB 
worldwide in 2013. Furthermore, 9% of MDR cases are resistant to other TB drugs, and are 
considered extensively drug resistant (XDR) TB cases. Most XDR cases are seen in Russia, 
China, and India
2
.      
An estimated 60% of incident cases and mortality from tuberculosis is observed in 
males
2
. In 2013, 5.7 million new cases of TB were diagnosed in males. The cause of this gender 
bias remains unexplained. Underreporting of cases in females due to social barriers in access to 
healthcare in the developing world has been suggested as a possible cause; however large 
prevalence studies suggest that biological differences between the sexes most likely account for 
this disparity
33
.    
TB/HIV coinfection 
 
  An estimated 360,000 of the 1.5 million TB deaths in 2013 occurred in people co-
infected with HIV
2
. Of the 9 million new cases, 1.1 million developed in patients who were 
HIV-positive
2
. The immunosuppression resulting from HIV infection increases the risk of 
progression to active disease following new exposure to MTB, or reactivation of latent TB in 
patients with prior infection
3,4
. Sub-Saharan Africa is the location where most HIV/TB co-
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infections occur, with 75% of all reported cases
1,2
. Tuberculosis in turn is the most common 
cause of death in people infected with HIV worldwide
34
. Of note, 50% of the HIV/TB positive 
patient deaths occurred in females; therefore, the gender bias in mortality is not observed in this 
patient population
2,33
. The gender distribution of the 1.1 million cases of tuberculosis in HIV 
positive patients was not reported.  
 
SRL 172 vaccine 
 
Considering the extent of morbidity and mortality caused by tuberculosis in HIV-positive 
patients, finding clinical solutions specific to that population is a public health priority
34
. 
Recently, a new means of preventing the development of tuberculosis in HIV positive patients 
has been developed. An inactivated whole cell SRL 172 vaccine was shown to be effective in 
preventing definite tuberculosis when administered as a booster for patients who received the 
Bacillus Calmette-Guérin vaccine as children in the DarDar vaccine trial cohort in Tanzania
17
. 
All diagnoses were obtained via a thorough evaluation comprised of a physical examination, a 
chest radiograph, three sputum samples for staining and culture, as well as an automated 
mycobacterial blood culture. Definite tuberculosis was defined as one or more of the following: 
at least one M. tuberculosis positive blood culture; sputum culture (with ≥10 colony-forming 
units, CFU); or at least 2 sputum cultures with CFU 1-9
17
. Other definite tuberculosis criteria 
involved at least 2 sputum smears with ≥2 acid fast bacilli (AFB) per 100 oil immersion fields; 
≥1 positive culture or AFB smear and caseous necrosis from a sterile site other than blood17. The 
criteria for probable tuberculosis were: caseous necrosis on biopsy; a positive chest radiograph 
with either one AFB positive sputum film or one sputum culture with CFU 1-9; or clinical 
symptoms with either one AFB positive sputum film or one sputum culture with CFU 1-9. Other 
criteria included a positive chest X ray or other imaging, clinical signs and symptoms along with 
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response to TB therapy; as well as a positive AFB smear from a sterile site with clinical signs 
and symptoms
17
. The trial was randomized, double blind, and placebo-controlled. The five dose 
regimen was shown to provide 39% protection from definite tuberculosis in patients with a CD4 
cell count greater than 200 cells/µl
17
.  
The original end point for the trial was the prevention of disseminated tuberculosis; 
however the number of cases in both the vaccine and placebo arm was insufficient to definitively 
prove effectiveness, even though the trend supported the original hypothesis that inactivated 
whole cell SRL 172 does indeed protect from developing disseminated symptoms
17
. The host 
genetics underlying the efficacy of the SRL 172 booster in this population were not part of the 
original study, and such an analysis would also be helpful in identifying the target population for 
its use as well as helping explain the mechanism of its action.      
Genetic studies of tuberculosis 
 
Genome-wide association studies 
 
  Two genome-wide association studies for tuberculosis susceptibility have been published 
to date
10,11
. A 2010 study discovered an association in a gene desert on chromosome 18q11.2, 
with a combined p value of 6.8 x 10
-9
 and an odds ratio of 1.19 of the G allele of rs4331426 in a 
combined Ghanaian, Gambian and Malawian cohort
10
. This cross sectional case-control study 
analyzed a total of 7,501 controls and 3,632 cases. Availability of 1000 Genomes Project data 
released in August of 2010 allowed the authors to impute SNPs into the Ghanaian cohort of the 
2010 study and a genome-wide significant association for the A allele of variant rs2057178 was 
discovered, with a p value of 2.63 x 10
-9
 and an odds ratio of 0.77, that was replicated in the 
Gambia, Indonesia and Russia
11
. The variant is 46 kb downstream of WT1, which encodes a 
transcription factor known to activate the vitamin D receptor and suppress IL10 levels
35,36
. The 
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initial cohort in which genome-wide significance was attained was 5,636 controls and 2,127 
cases, and the cohort including the replication analyses totaled 13,859 controls and 8,821 cases. 
 
Overview of established candidate genes 
 
Human genetic variants can impact susceptibility/resistance to M. tuberculosis 
infection/disease and if strong effect sizes are present, they could guide public health policy. 
Previous murine and human studies have described genetic variants that affect tuberculosis 
pathogenesis. The oldest studies of human genetic association with tuberculosis are in the major 
histocompatibility complex region, in particular the HLA-DR2 region, the importance of which 
was first recognized in Northern India in 1983
15,37
.  
In 1993, polymorphisms in NRAMP1 (also known as SLC11A1) were found to impact 
resistance/susceptibility to a spectrum of Mycobacterial infections in a murine model
5,38
. 
NRAMP1 is a transmembrane protein in the lysosomal and endosomal membranes that functions 
as a divalent ion pump removing them into the cytosol
15,21
. It was postulated that in doing so, it 
deprives bacteria such as M. tuberculosis of essential elements such as iron, thereby inhibiting 
growth
21
. Polymorphisms that impair proper function of NRAMP1 inhibit the ability of an 
infected macrophage to clear the infection, and individuals carrying such mutations are more 
likely to develop TB disease. This murine finding has been recapitulated in human population 
studies from the Gambia
39
, Japan
40
, Cambodia
41
, South Korea
42
 and the United States
43
.  
The SP110 gene product has also been shown to associate with tuberculosis susceptibility 
in mice, as it potentiates macrophage apoptosis in vivo and in vitro.
44
 This finding was later 
confirmed in its human homologue in a Gambian population
45
. To date, genes from various other 
pathways have been associated with tuberculosis. Polymorphisms in cytokines/chemokines 
utilized in macrophage and TH1 cell signaling such as IFN-γ
15
, CCL2
46
, IL-8
9
, IL-1B
47
, IL-10
48
, 
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IL-4
49
, and the IL-4delta2
50
 splice variant, have been shown to affect M. tuberculosis infection 
outcomes in an array of populations. Variants in immunomodulatory receptors such as PTX3
51
, 
CR1
52
, VDR
51,53
, CD209
51,54
, P2RX7
55
, also show modest, population specific effects. CR1 is of 
particular interest for this study because it was shown to modulate M. tuberculosis infection in an 
HIV dependent manner. Homozygosity for a particular mutation associated with TB 
susceptibility in an HIV-negative population from Northern Malawi, but not in an HIV-positive 
population
52
. Pattern recognition molecules are another important category associated with 
response to M. tuberculosis infections. Complement activator MBL2
56
 or TLR2
57,58
 and TLR4
59
, 
as well as their downstream effector TIRAP
60
, are all essential in activating immune cell 
responses, and have variants that have been associated with tuberculosis outcomes.  
Importantly, variants in these candidate genes did not associate with active tuberculosis 
below a genome-wide significant threshold in the GWAS studies by Thye et al
10,11
. The possible 
reasons for this observation are manifold. Some of the candidate genes have been discovered 
with linkage methods in individuals carrying rare mutations that cause a loss of function of a 
gene, as in the case of IL12
7
. Rare variants were removed in the quality control steps of the Thye 
et al studies; therefore, their effects could not be observed. Another possibility for why variants 
in candidate genes were not statistically significant at a multiple testing corrected threshold in the 
GWAS studies is that their effects might be population specific and, thereby, not relevant in 
modulating disease risk in Ghana or Gambia. Also of note, since the study from 2010 was not 
able to identify the significant imputed region reported in 2012, using a very similar patient 
population, it is possible that the array used simply was not dense enough to cover all relevant 
variants in or around the candidate genes. 
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The genetics of Tuberculin Skin Test reactivity have also been studied. Using a genome-
wide linkage approach, Cobat et al. showed that TST1 exclusively governs TST positivity in a 
binary fashion while SLC6A3 controls the extent of reactivity to TST as a quantitative trait
12
. In a 
similar study of household contacts in Kampala, Uganda, Stein et al discovered associations with 
persistently negative TST scores in the 2q14, 2q21-2q24 and 5p13-5q22 regions
13
. In their 
review of ~650 thousand TST results of Navy recruits Rose et al. found that a negative TST rules 
out M. tuberculosis disease; therefore, it has been postulated that a gene variant that guarantees a 
TST response of zero is a marker of protection
12,61
. Unfortunately polymorphisms in genes that 
differentiate disease manifestation on a population scale have shown to have only modest effects, 
proving that the genetics of tuberculosis susceptibility and resistance are complex. To date, 
candidate gene approaches have been most effective in finding these variants
15
, and even though 
recent GWAS have identified new loci, they carried very small effect sizes. While the 
overarching goal of finding a polygenic variant of predisposition/resistance remains elusive, such 
studies aid in understanding the pathogenesis of TB disease and the consequent immunological 
response.  
 
B. HYPOTHESES AND SPECIFIC AIMS 
 
To date, many studies of tuberculosis susceptibility have been performed, including 
GWAS, but the majority have identified variants of weak genetic effects
10,11,15
. We hypothesize 
that HIV-positive patients who live in areas endemic for MTB but continue to remain 
disease free, and separately infection free, have genetic protection from doing so, and, 
moreover, they present an extreme phenotype that will allow the discovery of variants with 
stronger effect sizes.   
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HIV positive patients can remain TB negative if they do not get exposed to MTB, if their 
immune system upon exposure is strong enough to prevent infection, if their immune system 
remains strong enough to prevent disease, or if they have strong protective host genetic variants 
to prevent either infection or disease. Since the patients in our studies all live in highly endemic 
regions, it is reasonable to assume that virtually all have been exposed to M. tuberculosis. 
Furthermore, the design of one of our cohorts, the Household Contacts Study, guarantees it. 
Studying HIV positive individuals who do not develop TB in this setting allows us to study those 
truly resistant to TB disease, and studying those who do not get infected allows insight into 
resistance to MTB infection. We propose a two-tiered approach. First, we will carry out single 
SNP associations in a genome wide analysis. Second, we will leverage prior knowledge that TB 
disease and infection are complex biological processes involving many pathways, and look to 
epistatic models in a candidate gene approach to evaluate the effect of higher order interactions 
on TB disease and MTB infection.  
Since one of the cohorts used in this study was a follow up to a Phase 3 vaccine trial, we 
want to elaborate on the whole cell SRL 172 trial results by studying the host genetic 
components that govern protective outcomes. The vaccine confers protection against definite TB 
in HIV positive adults with a childhood BCG vaccine, and it is of interest to determine if its 
effectiveness is modulated by polymorphisms in our candidate gene/loci list to further 
understanding the variability of vaccine efficacy
17
. 
Specific Aim 1: Determine whether HIV positive subjects who do not show signs of TB 
disease are protected from active TB based on a genetic resistance. 
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1.1 Recruit HIV-positive subjects from the extended follow up of the DarDar vaccine trial. 
Obtain additional samples from HIV-positive patients the DarDar Nutrition Study, and 
the Uganda Household Contacts Study. 
1.2 Genotype available samples using the Human Exome Beadchip platform.  
1.3 Using a genome-wide approach, compare TB disease risk in cases versus controls, 
adjusting for relevant covariates and principal components, if necessary.  
Separate logistic regression analyses will be performed for the all study participants from 
Uganda, for both studies from Tanzania, and for the combined cohort. Available covariates will 
be associated with the phenotype in univariate analyses, and those with significant association at 
the 0.05 level will be adjusted for in the logistic regression analyses. Since available samples are 
from major urban centers, Dar es Salaam, Tanzania, and Kampala, Uganda, principal 
components will be separately calculated for samples from each country and adjusted for in the 
logistic regression analyses. Haplotype analyses will be performed using UNPHASED
62
. 
Functional annotation will be carried out using data from the ENCODE Project.   
Specific Aim 2: Determine whether HIV positive subjects who did not develop latent 
infection with Mycobacterium tuberculosis despite living in endemic areas are protected 
from MTB infection based on a genetic resistance.  
2.1 Test the association of TB skin test results, both continuous and binary, <5mm versus 
≥5mm, using a genome-wide approach. 
2.2 Fine map associations from genome-wide linkage studies of TB skin test results, 
continuous and binary corresponding to the outcome in prior studies. Using a candidate 
region approach of SLC6A3 encoding dopamine transporter 1, the TST1 region on 
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chromosome 11p14, 2q14, 2q21-2q24 and 5p13-5q22 regions, evaluate association with 
TST results. 
Carry out separate logistic regression analyses using the binary outcome, and linear regression 
analyses for the continuous skin test induration measurement for study participants from Uganda, 
for both studies from Tanzania, and for the combined cohort to correspond with the study that 
reported the association. Available covariates will be associated with the phenotype in univariate 
analyses, and those with significant association at the 0.05 level will be adjusted for in the 
logistic regression analyses. Since available samples are from major urban centers, Dar es 
Salaam, Tanzania, and Kampala, Uganda, principal components will be calculated and adjusted 
for in the logistic regression analyses. Use TST results at time of enrollment to limit possible 
immune anergy caused by immunosuppression in patients with low CD4 counts. Assess IFN-γ 
response to verify whether immune anergy occurred, and if present, use anergy as an exclusion 
criterion. 
Specific Aim 3: Evaluate epistatic effects on TB disease and MTB infection using a 
candidate gene approach  
3.1 Use multifactor dimensionality reduction software to evaluate epistasis between genes 
previously associated with TB disease and associated in our current single SNP study 
(Chapter III) 
3.2 Use multifactor dimensionality reduction software to evaluate epistasis between genes 
previously associated with MTB infection and associated in our current single SNP study 
(Chapter IV) 
The candidate gene list for TB disease is comprised of the following: HLA-DR2
15,37
, 
SLC11A1
5,38
, SP110
44,45
, IFN-γ15, IFNGR163, IL12B7,8, IL12BR164, UBE3A65, TNF-α66, CCL246, 
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IL-8
9
, IL-1B
47
, IL-10
48,66
, IL-4
49
, IL-4delta2
50
, PTX3
51
, CR1
52
, VDR
51,53
, CD209
51,54
, P2RX7
55
, 
CR1
52
, MBL2
56
, TLR2
57,58
, TLR4
59
, and TIRAP
60
. The candidate gene list for MTB infection 
includes SLC6A3
12,61
, the TST1
12,61
 region on chromosome 11p14, and the 2q14, 2q21-2q24 and 
5p13-5q22 regions
13
. Analyses will be performed for the all study participants from Uganda, for 
both studies from Tanzania, and for the combined cohort.  
Specific Aim 4: Determine the genetic factors that govern response to a multiple-dose series 
of an inactivated SRL 172 whole cell vaccine in its prevention of HIV-associated 
tuberculosis in patients with a prior BCG vaccination.  
4.1   Perform logistic regression analyses using subsequent TB disease status in the vaccine 
arm of the trial cohort as the outcome using a candidate gene approach 
Available covariates from the vaccine arm of the study will be associated with TB disease in 
univariate analyses, and those with significant association at the 0.05 level will be adjusted for in 
the logistic regression analyses.  
 
 Identification of genes that affect risk of tuberculosis disease and MTB infection has 
many potential clinical implications. Candidate genes with large effect sizes provide targets for 
the development of therapeutics and diagnostics, or if relevant drugs already exist, assessing 
their efficacy for treatment of tuberculosis. SNPs with large effect sizes can also be used as 
genetic markers for developing disease. Moreover, discovery of novel genes associating with TB 
disease or MTB infection can further our understanding of the pathophysiology and resultant 
immune response, as well as provide novel targets for functional follow up studies in cell lines 
and model organisms.    
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CHAPTER III 
GENOME-WIDE ASSOCIATION STUDY IDENTIFIES TUBERCULOSIS 
RESISTANCE LOCUS NEAR IL12B IN IMMUNOSUPPRESSED PATIENTS FROM 
TANZANIA AND UGANDA 
 
Introduction 
 
Mycobacterium tuberculosis (MTB) infection and subsequent tuberculosis (TB) is the 
second-leading infectious cause of mortality worldwide, after the human immunodeficiency 
virus (HIV)
1,2
. In 2013, 9 million new cases of clinical tuberculosis were diagnosed and 1.5 
million deaths were attributed to the disease
2
. An estimated 360,000 deaths occurred in people 
co-infected with HIV
2
. The immunosuppression resulting from HIV infection increases the risk 
of progression to active disease following exposure to MTB, or reactivation of latent TB in 
patients with prior infection
3,4
. Sub-Saharan Africa harbors the majority of HIV/TB co-infection, 
with 75% of all reported cases
1,2
. The influence of host genetics on tuberculosis disease has been 
extensively studied, mostly in HIV-negative patients, and revealed that variation in pathways 
pertinent to macrophage and TH1 signaling, among others, modulate disease risk
5-11
. In these, 
HIV seropositive was viewed as a confounder and was either adjusted for or used as an exclusion 
criterion.  
In the current study, we hypothesize that HIV-positive patients living in areas endemic 
for MTB who do not develop TB can be defined as highly resistant. We posit that these 
individuals carry significant genetic protection and will represent a more phenotypically 
homogenous group than those studied in prior genome-wide association studies (GWAS) on 
TB
10,11
. If true, this will increase the measured effect sizes, permitting a much smaller sample 
size. To test this hypothesis we genotyped 639 HIV-positive individuals from East Africa using 
23 
 
the Human Exome Beadchip and had data available from the Illumina HumanOmni5-Quad 
BeadChip for 65 others. After quality control, data for 175,906 variants were available for 267 
cases of TB and 314 controls followed throughout recently completed prospective cohorts of TB, 
the DarDar Vaccine Trial and Nutrition Study both carried out in Dar es Salaam, Tanzania, and 
the Household Contacts study in Kampala, Uganda
17,67,68
.  
Methods 
 
Study populations 
 
Tanzania 
 
We recruited patients from the extended follow-up cohort of the DarDar vaccine trial and 
used previously collected samples from the DarDar Nutrition Study in Dar es Salaam, Tanzania. 
Both cohorts have been previously described
17,67
. Briefly, the DarDar trial was a randomized 
double blind phase III trial of an inactivated whole cell mycobacterial vaccine (SRL 172). 
Subject enrollment occurred between 2001 and 2005, and the study was concluded in 2008. All 
enrolled patients were HIV-positive adults (>18 years old) with a CD4 count >200 cells/μl, had 
to have a Bacille Calmette-Guérin childhood vaccination scar, and were TB-negative at the time 
of enrollment. The final study population consisted of 1007 patients in the placebo arm, and 
1006 receiving the vaccine. Participants were routinely followed up every 3 months and 
evaluated for active TB through a physical examination, a chest radiograph, sputum samples for 
culture and AFB stain, and phlebotomy for an automated mycobacterial blood culture. At the 
conclusion of the study, a cohort of 800 participants in both the placebo and vaccine arm was 
selected for extended follow-up. These patients have been evaluated for active TB once a year 
since the conclusion of the study. We recruited 304 of the extended follow-up participants 
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between September and December, 2013, during their routine visits. 36 of the patients had been 
diagnosed with definite or probable tuberculosis since the onset of the trial. Diagnostic criteria 
described in von Reyn et al.
17
 Patients who did not develop tuberculosis during the trial, but 
stated that they had previous active TB were excluded from the study, as those diagnoses could 
not be confirmed. The DarDar Nutrition Study was a randomized, controlled trial assessing the 
effectiveness of a protein-calorie supplement (PCS) to standard tuberculosis and HIV treatment 
in women.  All enrolled women were HIV-positive adults (>18 years old) and had newly 
diagnosed active TB. 150 participants were randomized to either a PCS arm or a multivitamin 
control. WHO recommended treatment protocols were followed through the Tanzanian Ministry 
of Health National Tuberculosis and Leprosy Program. Subjects were followed monthly until the 
completion of the study in 2014. Samples from 85 participants of the DarDar Nutrition Study 
were used in this analysis.  
Uganda 
 
We used samples from participants of the Household Contact Study (HHC), conducted in 
Kampala, Uganda from 2002 to 2014. This cohort has been previously described
14,68
. Briefly, the 
HHC combines a case-control and a family based design to analyze the genetic epidemiology of 
tuberculosis. Patients diagnosed with new active tuberculosis were referred to the study through 
the Uganda National Tuberculosis and Leprosy Programme, and those who consented were 
enrolled as index cases. Relatives and unrelated individuals living within the same household 
were subsequently enrolled and evaluated for active TB, latent TB, and HIV. Both index and 
incident cases of active TB were given the recommended therapy
69
.  Importantly, selecting cases 
and controls from the HHC guarantees exposure of the controls to the index case during the 
follow up
68
. We analyzed samples from 263 HIV-positive adult patients (>18 years old). Patients 
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who did not develop tuberculosis during the course of the study, but stated that they had previous 
active TB were excluded from the study, as those diagnoses could not be confirmed. 
DNA isolation and genotyping 
 
For participants from the DarDar vaccine trial, 5ml of whole blood was drawn into 
EDTA coated tubes (BD Biosciences) and immediately stored at 4°C in Dar es Salaam. DNA 
was extracted the day of the phlebotomy using the Gentra Puregene Blood kit (QIAGEN) in 
accordance with the manufacturer’s recommendations. For participants of the DarDar Nutrition 
and the Household Contacts Study, buffy coats were isolated on site and shipped to Dartmouth 
College for DNA extraction.  DNA was isolated from buffy coats using the QIAamp DNA Blood 
Mini Kit (QIAGEN). All DNA samples were stored at -80°C prior to genotyping.  
Samples from the DarDar vaccine trial (n=304), the DarDar Nutrition Study (n=85) and 
the Household Contact Study (n=263) were submitted for genotyping. DNA quality was 
evaluated with the 260/280 ratio using a NanoDrop 2000 spectrophotometer (Thermo Scientific) 
and an Electrophoresis Quality Score. Following quality control, a total of 639 samples were 
genotyped using the Human Core Exome Beadchip (542,585 SNPs) at the Hussman Institute for 
Human Genetics, Miami, Florida. SNPs with a genotyping call rate > 0.95 and a Hardy-
Weinberg equilibrium p value > 1*10E-4 were retained. All remaining participants had a per 
individual genotyping call rate > 0.95. A sex check was performed, and cryptic relatedness was 
evaluated in PLINK(v1.07)
70,71
. One individual was randomly removed in pairs of related study 
participants (pi-hat > 0.20). The final study population genotyped on the Exome Beadchip 
included 278 participants from the DarDar vaccine trial extended follow up, 65 participants from 
the DarDar Nutrition study, and 213 participants from the Household Contact Study.     
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Samples from 64 additional HIV-positive Ugandan HHC participants were previously 
genotyped using an Illumina HumanOmni5-Quad BeadChip (4.8 million SNPs) and made 
available for this study. DNA was extracted from buffy coats using the QIAamp mini DNA kit 
(Qiagen), and quantified using Nanodrop and Qubit. Genotyping and DNA quality checking 
were done at the Genomics Core at Case Western Reserve University. Further quality control 
steps for samples included checking for sex mismatch errors, relationship errors (within the 
larger dataset of 483 samples), consistency of blind duplicates, call rate (> 95%), 10th percentile 
GenCall score (> 0.42), visual inspection of BAF plot of samples with < 98% call rate, and 
unusually high autosomal heterozygosity. Individuals <18 years old and those related to the 
participants genotyped with the Exome Beadchip (pi-hat > 0.20) were excluded. 25 of the 
additional 64 individuals remained after applying these exclusion criteria. 
Statistical Analyses 
 
Logistic regression was used to test the association between single SNPs in an additive 
model and active tuberculosis case/control status using PLINK(v1.07)
70,71
. Results from 
dominant and recessive models are presented in the Appendix (Appendix Tables 3-1, 3-2, 3-3). A 
priori power analyses were carried out using Quanto
72
 and revealed that to discover an 
association with an odds ratio of 2.0 below two-sided p value threshold of 0.05, we needed to set 
the minor allele frequency (MAF) at > 0.2 for the single SNP association analyses (Appendix 
Table 3-4). Summary statistics for available covariates were calculated in STATA(v11.2)
73
.  
Covariates significant in univariate logistic regression analyses with case/control status were 
included in the final models. The Tanzanian cohorts were recruited in Dar es Salaam, and the 
Ugandan cohort was recruited in Kampala, both large urban centers, making admixture a likely 
confounder in this study. Importantly, vaccine status did not associate with active tuberculosis in 
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the DarDar extended follow-up cohort (p 0.107); therefore it was not adjusted for. To adjust for 
population structure within each cohort, principal components were calculated using SNPs with 
r
2 
< 0.1, MAF > 0.2, and a genotype call rate > 0.95 using the SNPRelate package in R
74,75
. Self-
reported tribal identity data was available for the patients from Uganda. The first, sixth and 
seventh principal components were significant in predicting membership from the predominant 
tribe, Muganda (63% of the participants), versus all others; therefore all analyses were adjusted 
for a standard of 10 principal components (Appendix Tables 3-5, 3-6). Manhattan and qq plots 
were generated using the qqman package in R
76
. Locus zoom was used to plot the region of the 
SNP with the strongest association
77
. SNPs in the region of interest (rs4921437 position +/- 1 
megabase) were imputed with IMPUTE2 (v2.3.1), using one phased reference panel from all 
populations of the 1000 Genomes project
78-80
. 
Unimputed SNPs with an MAF > 0.05 were included in the haplotype analyses of the 
region of interest. Haplotype plots were generated using Haploview
81
. Haplotype association 
analyses were performed using UNPHASED(v3.1.7)
62
, adjusting for the same covariates as in 
the single SNP association analyses above. We studied all pairwise haplotypes for 11 available 
SNPs spanning the 2 genes in the region of interest in each cohort, and in the combined cohort. 
We then performed a 3-way haplotype analysis for the 2 haplotypes with the most significant 
associations in pairwise analyses. For each cohort, haplotypes from cases only, controls only, 
and the entire dataset were compared to corresponding haplotypes in all available Phase 3 
samples of the HapMap project
82,83
, using a chi squared test in STATA(v11.2)
73
. 
Immune Assays 
 
All patients from the Nutrition study were cases of tuberculosis, and the design of the 
Household Contacts Study in Uganda guaranteed exposure to MTB. To address confounding of 
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our results by possible lack of exposure in the extended follow up of the DarDar vaccine trial, we 
leveraged available interferon-gamma release assay (IGRA) data. Immune response to 
Mycobacteria was assessed with an interferon gamma (IFN-γ) enzyme linked immunosorbent 
assay (ELISA), a tritiated thymidine lymphocyte proliferation assay (LPA) and ELISA for 
antibodies to the MTB glycolipid lipoarabinomannan (LAM). The assays used in this study have 
been previously described
84
. Briefly, IFN-γ and LPA assays used four different antigens: 
Mycobacterium vaccae sonicate (2 mcg/ml), MTB Antigen 85 (Ag85; 1 mcg/ml), MTB early 
secretory antigenic target 6 (ESAT-6; 2 mcg/ml), and MTB whole cell lysate (WCL; 
1 mcg/ml)
84
. Media alone served as a negative control and phytohemagglutinin (PHA, 
2.5 mcg/mL; Sigma, St. Louis, MO) was used as a positive control
84
. 
Selection Analysis 
 
Phase was inferred using the Beagle software package85. Unrelated individuals from two 
HapMap3 release 2 populations83, the Yoruba from Ibadan, Nigeria (YRI) and Luhya from 
Webuye, Kenya (LWK), 25 males and 25 females from each, were used to generate a fine-scale 
recombination map with LDhat(v2.1)86. The ancestral allele for each SNP included in this 
analysis was established using genome-wide sequences of non-human primates, the chimpanzee, 
orangutan, and rhesus macaque, downloaded from the UCSC Genome Browser website87.  
Approximately 5% of available SNPs could not be assigned an unambiguous ancestral state, and 
were removed prior to selection analysis, as were SNPs with MAF <0.0588. Selection was 
assessed using the integrated haplotype score test (iHS)88. iHS scores were standardized to a 
mean of zero and a unit variance with respect to SNPs with similar derived allele frequencies88. 
iHS values in the upper 0.1% of the distribution of absolute values were considered top 
candidates for having undergone recent selection.    
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In this analysis, we included individuals from a previous selection study of six 
populations in Cameroon (n = 125)89. The Baka, Bakola, and Bedzan are Niger-Kordofanian 
Bantu-speaking hunting and gathering populations designated here as Western Pygmy, and the 
Ngumba, Southern Tikar, and Lemande are neighboring Niger-Kordofanian Bantu-speaking 
agricultural populations, designated as Niger-Congo West. Data was also available for an 
additional 12 Yoruba individuals, living in Nigeria, and for 18 Datog living in Tanzania. 
Following phlebotomy, we isolated white blood cells using a modified salting out procedure90, 
and DNA was extracted with a Purgene DNA extraction kit (Gentra Systems Inc., Minneapolis, 
MN)89.  
The samples were genotyped using the Illumina Human 1M-Duo BeadChip
89
.  We 
evaluated cryptic relatedness, randomly removing individuals with pi-hat>0.25, and SNP with 
call rates less than 95% were removed. All quality control measures were done in 
PLINK(v1.07)
70,71
. Admixture was evaluated using Principal Component Analysis in R
74
, and 
STRUCTURE, as previously described
89
.  
Functional Annotation 
 
The ENCODE Project
91
 was accessed via the UCSC Genome Browser
87
 and Histone 
modification data provided by the Bernstein lab at the Broad Institute was used for functional 
annotation.  
Ethics 
 
Informed consent was obtained directly from all patients in the DarDar follow-up cohort 
and the Women’s Nutrition Study at the Dar es Salaam clinic. This study was approved by the 
research ethics committee at the Muhimbili University of Health and Allied Sciences and the 
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Committee for the Protection of Human Subjects at Dartmouth College and the Dartmouth-
Hitchcock Medical Center.  Informed consent was obtained directly from the index case and 
household members in the HHC study. This study was approved by institutional review boards at 
the Uganda Council for Science and Technology and the University Hospitals of Cleveland.  
Appropriate IRB approval for the selection cohorts used in this project was obtained from 
both the University of Maryland and the University of Pennsylvania. Prior to sample collection, 
informed consent was obtained from all research participants, and permits were received from 
the Ministry of Health and National Committee of Ethics in Cameroon, Nigeria and Tanzania. 
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Results and Discussion 
 
Gender was significantly associated with active tuberculosis in the Uganda cohort (OR 
for males 2.06, 95% CI = 1.15-3.69, p value = 0.015; Table 3-1C), and when the two cohorts 
were combined (OR 1.78, 95% CI = 1.23-2.57, p value = 0.002; Table 3-1D). Gender was not 
significant in the DarDar vaccine trial (p value = 0.858; Table 3-1A); however since we had to 
add samples from the DarDar Women’s Nutrition Study (Table 3-1B) to increase the number of 
cases and consequently statistical power, we decided to adjust the combined Tanzania cohort for 
gender as well. Age was not a significant covariate in either of the cohorts individually, or 
combined (Table 3-1A-D); therefore it was not adjusted for. The studies were conducted in 
major urban centers; therefore population stratification was a concern. Following adjustment for 
principal components calculated separately for samples originating in each country, the genomic 
inflation factor (λ) was 1.023 for samples from Tanzania, 1.056 for Uganda, and 1.029 for 
analysis of the cohorts combined. 
In logistic regression analyses, we observed an association between common variant 
rs4921437 and active TB in Uganda (OR = 0.28, 95% CI = 0.17-0.47, p = 1.18 x 10
-6
; Appendix 
Table 3-7A, Appendix Figure 3-5) and Tanzania (OR = 0.48, 95% CI = 0.30-0.79, p = 3.84 x 10
-
3
; Appendix Table 3-7B, Appendix Figure 3-6). When we analyzed the cohorts combined, 
rs4921437 associated with TB below the genome-wide significance threshold (OR = 0.37, 95% 
CI = 0.27-0.53, p = 2.11 x 10
-8
; Table 3-2, Appendix Figures 3-3 through 3-6).  
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Table 3-1. Summary statistics of patients with active tuberculosis, cases, and study participants 
who did not develop tuberculosis during the duration of follow up, controls, from A) the DarDar 
vaccine trial in Tanzania, B) the DarDar Nutrition Study in Tanzania, C) the Household Contacts 
Study in Uganda, and D) the combined cohorts 
 
A)  
  
Cases Controls 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
n^  31 (11.3) 243 (88.7)   
Age* (years) 35.76 ± 7.97 34.23 ± 8.02 1.02 (0.98, 1.07) 0.298 
Gender^ Male 6 (11.5) 46 (88.5)   
  Female 25 (11.3) 197 (88.7) 0.92 (0.36, 2.35) 0.858 
 
B) 
  Cases 
n 69 
Age* (years) 39.01 ± 8.51 
Gender Male 0 
  Female 69 
 
C) 
  
Cases Controls 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
n^  167 (70.2) 71 (29.8)   
Age* (years) 32.38 ± 7.92 31.23 ± 7.58 1.02 (0.98, 1.06) 0.296 
Gender^ Male 83 (78.3) 23 (21.7)   
  Female 84 (63.6) 48 (36.4) 2.06 (1.15, 3.69) 0.015 
 
D) 
  
Cases Controls 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
n^  267 (46.0) 314 (54.0)   
Age* (years) 34.46 ± 8.53 33.55 ± 8.01 1.01 (0.99, 1.03) 0.186 
Gender^ Male 89 (56.3) 69 (43.7)   
  Female 178 (42.1) 245 (57.9) 1.78 (1.23, 2.57) 0.002 
*mean ± standard deviation; ^ n (% of row) 
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Table 3-2. Single nucleotide polymorphisms associating with active tuberculosis below a 1x10
-5
 p value threshold in the combined 
cohort adjusted for principal components, sex, and cohort of origin  
 
SNP CHR 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
p value Nearest gene 
rs4921437 5 T 0.21 0.37 (0.27, 0.53) 2.11E-08 UBLCP1/IL12B* 
rs8028149 15 C 0.42 0.51 (0.39, 0.67) 1.96E-06 VPS13C 
rs1616723 6 G 0.20 0.44 (0.31, 0.62) 4.13E-06 GLO1 
rs955263 4 T 0.34 1.85 (1.39, 2.45) 2.26E-05 SORBS2 
rs12636260 3 T 0.26 1.98 (1.44, 2.71) 2.26E-05 ZPLD1 
rs4768760 12 C 0.41 0.56 (0.43, 0.73) 2.57E-05 SLC38A4 
rs844669 7 G 0.30 0.52 (0.38, 0.71) 2.68E-05 CALN1 
rs4236914 8 T 0.24 1.91 (1.41, 2.59) 2.84E-05 SFRP1* 
rs4860106 4 G 0.46 0.58 (0.45, 0.75) 3.03E-05 LPHN3 
rs1482868 6 T 0.28 0.54 (0.41, 0.73) 4.29E-05 F13A1 
rs2346943 16 G 0.33 1.79 (1.35, 2.37) 4.48E-05 RBFOX1 
*previously associated with tuberculosis disease
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In order to evaluate SNPs in the region not included on the genotyping array, we used 
IMPUTE2 (v2.3.1)
79,80
 software to impute SNPs within 1 megabase of rs4921437. rs10515780, 
in high linkage disequilibrium (LD) with rs4921437 (D’ = 1 in both cohorts, r2 = 0.84 in 
Tanzania, 0.89 in Uganda) and 842 bases away, is the variant with the most significant 
association to TB in the region (combined cohort OR = 0.34, 95% CI = 0.24-0.49, p = 6.21x10
-9
; 
Figure 3-1, Appendix Table 3-8, 3-9). Both rs4921437 and rs10515780 map to an intron of 
ubiquitin-like domain containing C-terminal domain phosphatase 1, UBLCP1. Variants in this 
gene have been previously associated with carotid stenosis
92
, psoriasis
93
, and platelet 
aggregation
94. Importantly, rs4921437 is 51,240 base pairs away from the 3’ UTR of IL12B, a 
gene extensively associated with TB
8,16,64,95,96
 and leprosy tuberculosis
97
. IL12B variants also 
have been associated with carotid stenosis
98
 and psoriasis
99,100
, suggesting possible linkage 
disequilibrium between SNPs in the two genes. IL12B encodes for p40, one of two subunits of 
IL12
101
 and IL23
102
.  
IL12 is a cytokine secreted by phagocytes and dendritic cells that causes differentiation 
of naïve T cells into TH1 cells, and stimulates interferon-gamma production from T cells and 
natural killer cells
103,104
. In experimental models, IL12 restricted MTB proliferation throughout 
the course of infection as a necessary factor in granuloma formation and antigen-specific delayed 
type hypersensitivity
105-107
. Previous studies demonstrated that IL12 deficiency in humans was 
associated with predisposition to infections with Mycobacteria
7,108,109
. IL23 contributes to the 
differentiation of T helper 17 cells (TH17) responsible for the production of IL17. IL17 signaling 
is essential in control of MTB infection, as it is necessary for targeting of neutrophils to the site 
of infection and mice deficient for this interleukin are unable to control highly virulent MTB 
strains
110-112
.    
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Figure 3-1. Locus zoom of imputed data using the combined cohort with a 50 kb region around rs4921437, along with the 
corresponding UCSC genome browser window displaying the layered H3K27Ac histone mark; imputed SNP with the most significant 
association in a purple 
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The Encyclopedia of DNA Elements (ENCODE) was used for functional annotation of 
rs4921437, and it revealed that the SNP is located in a region of substantial regulatory potential, 
an H3K27Ac mark (Figure 3-1, bottom panel)
87,91
. This type of histone modification has been 
shown to act in combination with H3K4Me1 and differentiate active enhancer elements from 
poised/inactive ones
113,114
. Such chromatin modifications are associated with higher regulatory 
responses at enhancer transcription factor binding sites
113
, possibly potentiating the effect of 
DNA polymorphisms in the region. Enhancers have highly cell-type-specific histone 
modification patterns, and cause cell-type-specific gene expression profiles
113
. It is therefore 
noteworthy that two of the cell lines in which the H3K27Ac mark was found have implications 
in immunity, the GM12878 and K562, from B-lymphocytes and chronic myelogenous leukemia, 
respectively
91
.  
We studied the LD pattern in the UBCLP1/IL12B region in the unimputed dataset and 
found blocks of LD between rs4921437 and variants in IL12B in the Ugandan and Tanzanian 
cohorts, as well as all African origin data from Phase 3 of the HapMap Project
83
 (Figure 3-2, 
Appendix Figure 3-7). Association analyses between haplotypes in the region and TB were 
performed using UNPHASED(v3.1.7)
62
. A three variant haplotype of rs4921437, rs4921468 
(intergenic), and rs3213094 (intronic in IL12B) had a more significant association than 
rs4921437 alone in the Ugandan and Tanzanian cohorts (p = 1.98 x 10
-11
 and 4.56 x 10
-5
, 
respectively), and the combined cohort (p value = 4.56 x 10
-15
) (Table 3-3, Appendix Table 3-
10). When we conditioned the analysis on the main effect variant, rs4921437, the combined 
cohort haplotype was still significant at the multiple testing corrected level (p value = 1.19 x 10
-
7
). A chi-squared analysis testing the difference between the frequencies of the three variant 
haplotype in the Ugandan and Tanzanian cohorts was not significant (Appendix Table 3-11). No 
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significant differences were discovered when comparing the three variant haplotypes between 
the study cohorts and founders of the Luhya in Webuye, Kenya and African ancestry in 
Southwest USA populations from Phase 3 of HapMap
78
 (Appendix Table 3-11). Comparisons of 
the frequencies of this three variant haplotype observed in Uganda and Tanzania was 
significantly different from all other Phase 3 HapMap populations (Appendix Tables 3-11, 3-12). 
The conservation of the haplotype frequencies in several African populations was unexpected 
given the diverse history of these populations.     
We also noted that the LD patterns of the entire IL12B region, not only the three variant 
haplotype, were similar between the Ugandan and Tanzanian cohorts. Considering previously 
noted patterns of shorter LD ranges in African populations
115
, this suggested possible selection in 
the region (Figure 3-2, Appendix Figures 3-7 through 3-9). T, the ancestral, minor allele of 
rs4912437 associated with the TB resistance effect in this analysis, has a minor allele frequency 
of ~0.21 in our study cohorts and an MAF between 0.11 and 0.36 in the African, European and 
South Asian origin populations from Phase 3 of the HapMap Project
83
 and the 1000 Genomes 
Project
78
 (Appendix Figure 3-10, Appendix Tables 3-13, 3-14). The minor allele frequency 
reaches as high as 0.454 in the Biaka Pygmy and and 0.461 Mbuti Pygmy populations from the 
Human Genome Diversity Project
116,117
. Of note, the variant has nearly disappeared in East 
Asian populations (MAF < 0.025 in all available populations), suggesting either a loss due to an 
out of Africa bottleneck event or its maintenance due to balancing selection in Europe, South 
Asia and Africa.  
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Table 3-3. Association of the rs4921437, rs4921468 and rs3213094 haplotype in the IL12B 
region using an additive model in A) the combined cohort, B) Tanzanian and C) Ugandan cohort 
 
A) 
Haplotype Case Control 
Case 
frequency 
Control 
frequency 
C-A-T 5 6 0.0098 0.0098 
C-A-C 96 102 0.18 0.16 
C-G-T 242 223 0.45 0.36 
C-G-C 115 130 0.21 0.21 
T-G-T 5 7 0.0071 0.012 
T-A-C 6 12 0.0094 0.02 
T-G-C 65 147 0.13 0.23 
Likelihood ratio chisq = 79.49 df = 6 p-value = 4.56E-15* 
 
B) 
Haplotype Case Control 
Case 
frequency 
Control 
frequency 
C-A-T 5 6 0.024 0.013 
C-A-C 36 81 0.18 0.17 
C-G-T 92 176 0.46 0.36 
C-G-C 40 107 0.20 0.22 
T-G-T 1 4 0.005 0.0087 
T-A-C 1 8 0.005 0.017 
T-G-C 25 103 0.12 0.21 
Likelihood ratio chisq = 31.75 df = 6 p-value = 1.82E-05^ 
 
C) 
Haplotype Case Control 
Case 
frequency 
Control 
frequency 
C-A-C 60 21 0.18 0.15 
C-G-T 150 47 0.45 0.33 
C-G-C 75 23 0.22 0.16 
T-G-T 4 3 0.012 0.022 
T-A-C 5 4 0.015 0.028 
T-G-C 40 44 0.12 0.31 
Likelihood ratio chisq = 58.98 df = 5 p-value = 1.98E-11^ 
* adjusted for principal components, sex, and cohort of origin 
^ adjusted for principal components and sex 
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Figure 3-2. Haploview plots of D’ in the IL12B region (96 kb range) of the study populations 
from A) Uganda and B) Tanzania, and in African HapMap populations C) MKK, D) LWK, E) 
ASW, and F) YRI  
 
A)               B) 
   
 
C) D) 
  
 
E) F) 
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We evaluated signatures of selection using the absolute value of iHS
88
 in less admixed 
equatorial African populations for which we had available data with greater coverage than 
provided by the Human Exome Beadchip
118
. The iHS test is most sensitive to recent adaptive 
events (<25 thousand years ago), which is appropriate for TB as its selective pressure became 
more prominent following recent increases in population density associated with agriculture
88,118
. 
We found two intronic SNPs in IL12B in the upper 0.1% of the distribution of absolute values of 
iHS scores of 1 million genotyped SNPs in two of these populations. The region surrounding 
rs3213093 has a signature of selection in the upper 0.1% of the distribution in the Datog 
population sample and nearly meets the criterion in the Niger-Kordofanian-west population 
samples, while the region centered on rs2421047 has a signature of selection in the upper 0.1% 
of the distribution in the Niger Kordofanian West population samples and nearly meets the 
criterion in the Datog (Appendix Table 3-15). The |iHS| scores were not as extreme in the 
Western Pygmy populations, though they were both >2.5. The two SNPs are 4,672 bases apart. 
In our study cohorts, rs3213093 and rs2421047 are in high LD with each other (D’ = 0.98 - 1.0), 
and, importantly, with rs4921437 (D’ = 0.79 - 0.92). The iHS scores of rs4921437 were not as 
extreme, potentially because the SNP is near the end of an UBCLP1/IL12B haplotype block 
(Appendix Table 3-15)
88
. The Datog live in Tanzania, practice agro-pastoral subsistence, and 
speak a language belonging to the Nilo-Saharan language family that includes the majority of 
languages spoken in Uganda and Tanzania. The Niger Kordofanian West population sample used 
in this study includes Yoruba (living in Nigeria), Southern Tikar, Ngumba, Lemande (living in 
Cameroon), all speaking languages belonging to the Niger-Kordofanian language family and all 
practicing agriculture. In toto, this demonstrates strong selection in the region of interest in 
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populations related to our study cohorts, although the selection signature appears to be strongest 
within the IL12B gene and not in the regulatory region in which rs4921437 is located.  
The Household Contacts Study design guarantees exposure of the TB-negative patients to 
MTB. All patients from the DarDar Nutrition Study were cases of tuberculosis. Direct contact 
with index cases of active TB was not assessed in the DarDar vaccine trial. Importantly, 8 years 
elapsed between the completion of enrollment for the vaccine trial and the recruitment into this 
study; therefore these participants were HIV-positive and living in an MTB hyperendemic area 
for at least that long. To further address possible confounding by lack of MTB exposure, we 
assessed response to interferon gamma release assays and lymphocyte proliferation assays by 
case control status, and no statistically significant differences were observed (Appendix Table 3-
16).  
We validated previously reported TB-association variants present on the Human Exome 
Beadchip. Variants rs2057178 and rs4331426, previously associated with TB in genome-wide 
analyses had similar odds ratios to those previously reported (rs2057178, OR = 0.84 in our 
combined cohort versus 0.77 in Thye et al, 2012, and rs4331426, OR = 1.16 in our combined 
cohort versus 1.18 in Thye et al, 2010). However, our sample size is smaller than the reported 
studies and the SNPs were not significant at the replication threshold of 0.05 in our analyses 
(Table 3-4). We also observed that a SNP in PTX3, rs3816527, associated with TB at a p value 
of 4.69x10
-4
. This SNP is 715 bases away from rs1840680, a previously associated variant, and it 
is in strong LD with it in the LWK 1000 Genomes population (r
2
 = 0.86). We imputed 
rs1840680, and the SNP associated with a p value of 0.0013, and an odds ratio of 1.63 (Table 3-
4).  
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Table 3-4. Test of replication of polymorphisms from other TB studies adjusted for principal 
components, sex, and cohort of origin 
 
SNP Study Chr. 
Minor 
Allele 
n 
Odds 
Ratio 
95% CI p value Gene 
rs2057178 Thye T. et al 2012 11 A 581 0.84 (0.64, 1.10) 0.200 WT1 
rs4331426 Thye T. et al 2010 18 G 556 1.16 (0.68, 1.51) 0.259 GATA6 
rs3212227 Morris G.A.J. et al 
2011 
5 G 581 1.37 (1.05, 1.79) 0.0209 IL12B 
rs1840680* Olesen R. et al 2007 3 A 581 1.63 (1.21, 2.21) 0.0013 PTX3 
 *imputed SNP
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There are several weaknesses in the described analyses. The choice of an extreme 
phenotype limited the recruitment into our study. As a consequence, a small sample size was 
used in this study relative to the other published GWAS of tuberculosis. Furthermore, we were 
only able to recruit very few cases of active tuberculosis in the DarDar vaccine trial extended 
follow up. To increase the statistical power in analyses of the Tanzanian study population, we 
added samples from the Nutrition Study, which enrolled only female participants. This 
recruitment bias makes it likely that the gender balance between cases and controls in our study 
cohort is not representative of the general population in Tanzania. However, in the combined 
cohort analyses, the odds of active tuberculosis associated with male sex are roughly the same as 
that observed in the general population. Another weakness stems from the fact that the low 
density of the Exome Beadchip prevented us from using our own data in selection analyses. 
Instead we used other available data from equatorial Africa, and while we were able to 
demonstrate that populations in that region have recently undergone positive selection around 
IL12B, we cannot definitively state that the same was observed in our own data. Finally, we did 
not have CD4 data available for most participants from the Household Contacts Study. 
Consequently, we did not adjust for the variable, as it would drop our sample size by 160 
participants. In the DarDar vaccine trial extended follow up, the mean CD4 was higher in cases 
than it was in controls, but since we did not have the variable for all participants, it is possible 
that it would confound results.  
In summary, we present a novel approach to the study of TB genetics, examining 
resistance as opposed to susceptibility. Specifically, we hypothesized that immunocompromised 
individuals who resist TB represent an extreme phenotype that can provide new insights into 
pathogenesis. Within our HIV-positive cohorts we found a variant in the previously associated 
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IL12B region that had a much larger effect size than all previously associated common variants, 
an effect remarkably detected with a sample size far below generally-accepted GWAS power 
criteria. Selection of extreme phenotypes can be a powerful strategy for unravelling genetic 
susceptibility to complex infectious disease, as it reduces noise associated with both phenotypic 
and genetic heterogeneity and facilitates detection of signals from major genes even in 
apparently “underpowered” samples.  In our study, we identified a locus encompassing a classic 
gene, IL-12B, already shown to underlie monogenic immunodeficiency and high susceptibility to 
mycobacterial infections
7,108,109
. Immunocompromised by HIV in lieu of congenital immune 
deficiency, our patients are positioned at the opposite end of the genetic- phenotypic spectrum, 
carrying variants for resistance rather than susceptibility to infection. Unlike immunodeficiency-
causing mutations identified because they determine disease, such variants can only be found 
when looking for protection against disease, i.e. under strong selective pressure provided by 
HIV, from which they emerge conferring noticeable resistance in subjects otherwise expected to 
be diseased. Furthermore, our results in the IL12B region indicated unexpectedly high 
concordance of LD patterns across several African-descent populations, and analyses using other 
sub-Saharan populations demonstrated that the IL12B region has undergone positive selection. 
Our SNP of interest is located in an area enriched for a histone acetylation mark often found in 
active regulatory elements, suggesting possible functionality and a genetic-epigenetic interaction 
at the site. Further studies of this interaction are warranted.     
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CHAPTER IV 
GENOME-WIDE ASSOCIATION STUDY IDENTIFIES A RESISTANCE LOCUS TO 
MYCOBACTERIUM TUBERCULOSIS INFECTION IN THE SLC25A48/IL9 REGION 
PREVIOUSLY ASSOCIATED WITH BRONCHIAL HYPERRESPONSIVENESS 
 
A. Genome-wide association study of tuberculin skin test response 
 
Introduction 
 
One third of the world’s population has been infected with Mycobacterium tuberculosis 
(MTB)
2,119
. Subsequent tuberculosis disease (TB) occurs during the lifespan of about 10% of 
those infected
2,119,120
.  Tuberculosis is a major cause of morbidity and mortality worldwide, with 
1.5 million deaths and 9 million new cases of active disease reported in 2013
2
. Tuberculosis is 
the primary cause of death in people co-infected with the human immunodeficiency virus (HIV), 
and 360,000 of the TB deaths occurred in this patient population
1,2
. The immunosuppression 
from HIV facilitates progression to active disease directly following infection, or by the 
reactivation of a latent MTB infection
3,4
. While the clinical trajectory of a given MTB infection 
has many determinants and possible outcomes, infection itself is a necessary prerequisite. Of 
note, about 20% of people living in areas hyperendemic for MTB, virtually guaranteeing 
repeated exposure, appear to be resistant to infection
12,61,121,122
.    
Historically, MTB infection has been evaluated with a tuberculin skin test (TST) that 
measures the induration caused by a delayed type hypersensitivity reaction to an intradermal 
injection of an MTB purified protein derivative (PPD)
21,123
. In endemic areas, induration ≥ 5mm 
measured between 48 and 72 hours after the injection is indicative of an MTB infection. A 
sibling study of TST reactivity demonstrated high heritability, suggesting a possible genetic 
component to the MTB infection resistance phenotype
124
. Several studies have capitalized on this 
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finding and identified loci relevant to the MTB infection phenotype. A family-based linkage 
analysis of TST response identified SLC6A3 and a region on chromosome 11 (p14) as loci that 
associate with MTB infection
12
. A full genome microsatellite scan comparing persistent MTB 
negative patients to those with latent infections identified an association with the SLC11A1 gene, 
and candidate regions on chromosomes 2 (q14, q21-q24) and 5 (p13-q22)
13
.  
Recently, novel methods for evaluating MTB infection status have been developed. 
Interferon-gamma release assays (IGRA) detect the concentration of IFN-γ in response a mixture 
of MTB-specific antigens
27,28
. The purified protein derivative used in TST has some antigenic 
overlap with the Bacille Calmette-Guérin (BCG) vaccination; therefore it is impossible to 
distinguish between a TST reaction to an MTB infection or to childhood BCG in individuals who 
received the vaccine. IGRA antigens have no overlap with the BCG vaccine, and maintain 
excellent specificity in individuals who had childhood BCG vaccinations
27,28
. Additionally, in 
people with compromised immune systems, anergy may prevent detection of a positive TST 
and/or IGRA in individuals previously exposed to the MTB. Lack of response to an IGRA 
positive control identifies individuals with possible immune anergy. Using these methods, we 
can identify a more refined phenotype that minimizes both false positives and false negatives.   
We used a genome-wide approach to evaluate common variants that associate with TST 
response in a patient population that hypothetically allows us to identify extreme effects. 
Namely, we hypothesized that HIV-positive individuals who live in areas endemic for MTB but 
do not get infected are genetically resistant. Using two recently concluded prospective cohorts of 
tuberculosis disease from Tanzania and Uganda, with available TST and interferon gamma 
release assay results, we identified a variant in the SLC25A48/IL9 region that confers resistance 
to MTB infection.   
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Methods 
 
Study populations 
 
Tanzania 
 
Patients from the extended follow-up cohort of the DarDar vaccine trial in Dar es Salaam, 
Tanzania were recruited for this study. The full cohort has been described elsewhere
17
. Briefly, 
the DarDar trial was a phase III randomized trial of SRL 172, an inactivated whole cell 
mycobacterial vaccine booster to a childhood Bacille Calmette-Guérin (BCG) vaccination. 
Subjects were enrolled between 2001 and 2005. Follow-up continued until the study was 
concluded in 2008. Recruited patients had to be HIV-positive adults (≥18 years old) with a BCG 
scar, and had to have a CD4 count >200 cells/μl and be TB-negative at the time of enrollment. 
TST reactivity was measured at enrollment, preventing any confounding by the effects of the 
vaccine. A saline placebo was administered to 1007 patients, while 1006 patients received 5 
doses of the vaccine. A routine follow up for active TB (physical examination, chest radiograph, 
sputum samples for culture and AFB stain, and phlebotomy for an automated mycobacterial 
blood culture) was performed every 3 months for the duration of the study. Upon conclusion of 
the trial, an extended follow up cohort of 800 participants from both the placebo and vaccine arm 
was selected for annual evaluation for active TB. Between September and December of 2013, 
304 patients from the extended follow-up were recruited during their routine visits. 
Uganda 
 
We obtained 263 samples from HIV-positive participants from the Household Contact 
Study (HHC), conducted in Kampala, Uganda. This cohort has been previously described in 
detail
14,68
. Briefly, the Uganda National Tuberculosis and Leprosy Programme referred patients 
diagnosed with new active tuberculosis to the study, and patients who consented were enrolled as 
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index cases. Household contacts were defined as individuals living in the same household as the 
index case for at least 7 consecutive days in the 3 month period leading up to the diagnosis of the 
index case
122
. Household contacts were subsequently enrolled and evaluated for active TB, latent 
TB, and HIV. Recommended therapy was administered to all cases of active TB
69
.  Of note, the 
HHC study design guarantees exposure of the controls to MTB during the follow up
68
. We only 
analyzed adult participants (≥18 years old) of the HCC.  
DNA isolation and genotyping 
 
For participants from the extended follow-up of the DarDar vaccine trial, 5ml of whole 
blood was drawn upon enrollment, and DNA was extracted the day of the phlebotomy using the 
Gentra Puregene Blood kit (QIAGEN) in accordance with the manufacturer’s recommendations. 
For participants of the Household Contacts Study, buffy coats were isolated on site and shipped 
to Dartmouth College for DNA extraction. The QIAamp DNA Blood Mini Kit (QIAGEN) was 
used to isolate DNA from the buffy coats. DNA samples were stored at -80°C before genotyping.  
Samples from the DarDar vaccine trial (n=304) and the Household Contact Study 
(n=263) were submitted for genotyping at the Hussman Institute for Human Genetics, Miami, 
Florida. DNA quality was evaluated with the 260/280 ratio using a NanoDrop 2000 
spectrophotometer at Dartmouth College (Thermo Scientific) and an Electrophoresis Quality 
Score at the University of Miami. A total of 567 samples passed quality control measures and 
were genotyped using the Human Core Exome Beadchip (542,585 SNPs). SNPs with a 
genotyping call rate < 0.95 and a Hardy-Weinberg equilibrium p value < 1*10x10
-4
 were 
excluded. Participants with a per individual genotyping call rate < 0.95 were excluded. 
Concordance of reported and genotypic gender was verified. In case of relatedness among study 
participants (pi-hat > 0.20), one individual was randomly removed. All quality controls were 
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performed in PLINK(v1.07)
70,71
. The final study population included 278 participants from the 
extended follow up of the DarDar vaccine trial and 213 participants from the Household Contact 
Study.    
Immune Assays 
 
Tanzania 
 
Intradermal injections of purified protein derivative (0.1 ml, RT-23, State Serum 
Institute, Copenhagen) on the forearm were administered to all enrolled patients prior to 
vaccination, and resultant skin induration size was measured by trained personnel after 48–
72 hours. Preventative isoniazid treatment (300 mg daily for 6 months) was offered to subjects 
with a positive reaction using the criterion for HIV-positive patients (≥5 mm as positive). 
Immune response to Mycobacteria was assessed with an interferon gamma (IFN-γ) 
enzyme linked immunosorbent assay (ELISA), a tritiated thymidine lymphocyte proliferation 
assay (LPA) and an ELISA for antibodies to the glycolipid lipoarabinomannan of MTB (LAM). 
The assays used in this study have been described in detail elsewhere
84
. Briefly, phlebotomy was 
performed prior to vaccination and at the conclusion of the study, and peripheral blood 
mononuclear cells (PBMCs) were isolated by ficoll density gradient centrifugation for IFN-γ and 
LPA assays, performed on site. Centrifuged, frozen serum was sent to Dartmouth College for 
LAM assays.  
IFN-γ and LPA assays used four different antigens: Mycobacterium Vaccae sonicate 
(2 mcg/ml), MTB Antigen 85 (Ag85; 1 mcg/ml), MTB early secretory antigenic target 6 (ESAT-
6; 2 mcg/ml), and MTB whole cell lysate (WCL; 1 mcg/ml)
84
. Importantly, ESAT-6 is not 
present in the childhood Bacille Calmette-Guérin (BCG) vaccine that is commonplace in East 
Africa; therefore confounding by BCG status can be controlled for with these additional data.  
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Media alone was used as a negative control and phytohemagglutinin (PHA, 2.5 mcg/mL; Sigma, 
St. Louis, MO) was used as a positive control
84
.  
Uganda 
Intradermal injections of purified protein derivative (5 tuberculin units) on the forearm 
were administered to study participants at enrollment, after 3, 6, 12, and 24 months if the tests 
were negative at earlier time points
122
. The size of skin induration was measured by trained 
personnel 48–72 hours after each injection. For patients measured at multiple time points the 
largest TST reaction was used in analysis. In Phase II of the HHC study, daily isoniazid 
treatment was offered to all participants with positive TST results (≥5 mm)13,122. 
The immune assays used in this study have been detailed elsewhere
13,122,125
. Briefly, 
phlebotomy was performed at enrollment. Whole blood was stimulated with MTB antigens:  
MTB culture filtrate CXFT, ESAT-6, and CFP10
122,125
, and the IFN-γ response was measured by 
ELISA (Thermo Scientific, Rockford, IL). Whole blood cultured without antigen stimulation 
served as a negative control. Phytohemagglutinin (PHA; Sigma, St. Louis, MO) was used as a 
positive control, while the IFN-γ response to media was subtracted from antigen-stimulated 
readings
122,125
. Negative differences were considered a 0.  
Statistical Analyses 
 
TST data were evaluated using additive, dominant, and recessive genetic models both as 
a continuous variable using linear regression, and as a binary variable (< versus ≥ 5mm) with 
logistic regression in PLINK(v1.07)
70,71
. A priori power analyses in Quanto
72
 revealed that to 
discover an association with an odds ratio of 2.0 for the binary TST outcome below two-sided p 
value threshold of 0.05, we needed to set the minor allele frequency (MAF) at > 0.2 for the 
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single SNP association analyses (Appendix Table 4-1). A total of 162,228 SNPs passed the 
inclusion criteria at an MAF > 0.20. If we consider the SNPs passing quality control as 
independent tests, the corresponding Bonferroni corrected multiple testing threshold is 3.08x10
-7
. 
Summary statistics and univariate logistic regression models of TST case/control status with 
available covariates were calculated in STATA(v11.2)
73
. Covariates associating with 
case/control status at the 0.05 level were included in the final models. 
Participants from the extended follow up of the DarDar vaccine trial were recruited in 
Dar es Salaam, Tanzania, and the patients in the Household Contact study were recruited in 
Kampala, Uganda, both large urban centers. To adjust for possible admixture within each cohort, 
principal components were calculated using SNPs with r
2 
< 0.1 and MAF > 0.2 using the 
SNPRelate package in R
74,75
. All analyses were adjusted for 10 principal components, and 
analyses of the cohorts combined were adjusted for a cohort variable. The qqman package in R 
was used to generate Manhattan and qq plots
76
. Locus zoom was used to plot the region of the 
SNP with the strongest association
77
. SNPs in the region of interest (rs877356 position +/- 0.5 
megabase) were imputed with IMPUTE2 (v2.3.1), using one phased reference panel from the 
1000 Genomes project
78-80
. All SNPs with an MAF > 0.05 in each cohort were included in the 
haplotype analyses of the region of interest. Haplotype plots were generated using Haploview
81
. 
We used UNPHASED(v3.1.7)
62
 to perform two and three SNP haplotype association analyses, 
adjusting for the same covariates as in the single SNP association analyses above. We studied all 
pairwise haplotypes for 30 available SNPs with a minor allele frequency >0.05, within 250kb of 
the SNP with the most significant association in the combined cohort. We then performed a 
three-SNP haplotype analysis using the two most significant haplotypes in pairwise analyses, as 
one of the SNPs was common to both. 
52 
 
There are three major ways to remain TST negative given an exposure to M. tuberculosis: 
1) MTB can be inhaled but mechanically prevented from seeding the lungs, 2) it can seed the 
lungs but be cleared before immune memory is invoked, or 3) it can establish a latent infection 
but host immunosuppression and an inability to mount a delayed type hypersensitivity response 
can prevent a positive TST test, i.e. anergy. To adjust for possible immune anergy in Tanzania, 
we removed all patients who had negative responses to all interferon-gamma release assay 
(IGRA) antigens, and negative responses to the positive control antigen, PHA, in IGRA (defined 
as a PHA < 300pg/mL) and lymphocyte proliferation assays (LPA) (defined as a proliferative 
index < 3). LPA data was not available for the Ugandan cohort; therefore we removed all 
patients who were IGRA negative to all available antigens and to PHA (PHA < 300pg/mL). 
Patients who were PHA positive but IGRA negative for all antigens remained in the study. IGRA 
assays were not performed on 102 patients from the HHC cohort and 33 patients from the 
DarDar vaccine trial extended follow up. Of the patients with missing IGRA assays, 71 had TST 
measurements ≥ 5mm, and 31 < 5mm in Uganda, and 10 had TST ≥ 5mm, and 23 < 5mm in 
Tanzania. Logistic regression models of TST case/control status adjusting for missing IGRA data 
were performed to prevent confounding by missing data. Patients who stated that they had 
previous active TB, but had a TST of 0mm were excluded from the main analyses presented 
below. Logistic regression models of TST case/control status including this patient population 
are presented in the supplement. 
To evaluate the effect of possible false negative TST responses on our association results, 
additional logistic regression analyses were performed removing individuals with a 0mm TST 
induration who had a substantial INF-γ response (> mean in cases) to any of the tested antigens 
at the time of the TST induration measurement. The effect of possible false positive TST results 
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due to BCG vaccination was evaluated by performing logistic regression analyses removing 
individuals with a positive TST scores but low IGRA response (< mean of controls) to any of the 
tested antigens. 
Functional Annotation 
 
The ENCODE Project
91
 was accessed via the UCSC Genome Browser
87
 and used for 
functional annotation.  
Ethics 
 
Informed consent was obtained from all patients in the extended DarDar follow-up 
cohort, at the Dar es Salaam clinic. The research ethics committee at the Muhimbili University of 
Health and Allied Sciences and the Committee for the Protection of Human Subjects at 
Dartmouth College and the Dartmouth-Hitchcock Medical Center approved this study.  Informed 
consent was obtained from all subjects in the Household Contacts study in Kampala, Uganda. 
The institutional review boards at the Uganda Council for Science and Technology and the 
University Hospitals of Cleveland approved this study.  
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Results 
 
Gender was not significantly associated with TST case/control status in Uganda (p = 
0.76; Table 4-1A) nor Tanzania (p = 0.349; Table 4-1B), but it did associate in the combined 
cohort (Odds ratio for males 1.91, 95% CI = 1.27-2.86, p value = 0.002; Table 4-1C). Age was 
not significantly associated with TST case/control status in Uganda (p = 0.384; Table 4-1A), 
Tanzania (p = 0.153; Table 4-1B), nor in the combined cohort (p = 0.108; Table 4-1C). 
Therefore, all analyses below were adjusted for gender, along with 10 principal components, and 
cohort of origin, where appropriate.    
In logistic regression analysis, we observed a genome-wide significant association 
between a dominant genetic model of common variation in rs877356 and binary TST status in 
the combined cohort (Odds ratio = 0.27, 95% CI = 0.17-0.42, p = 1.22x10
-8
; Table 4-2A, 
Appendix Figures 4-1 through 4-3). The variant had consistent effects in Uganda (OR = 0.17, 
95% CI = 0.078-0.37, p = 9.18x10
-6
; Table 4-2B, Appendix Figure 4-4) and Tanzania (OR = 
0.3295, 95% CI 0.1843-0.5892, p = 1.81x10
-4
; Table 4-2C, Appendix Figure 4-5). Linear 
regression analyses of continuous TST scores in a dominant genetic model produced similar 
results (combined cohort beta = -4.14, 95% CI = -5.55 to -2.74, p = 1.45x10
-8
; Appendix Tables 
4-2). Variant rs877356 was below the multiple testing adjusted threshold for this study (3.08x10
-
7
) and nearly genome-wide significant in an additive model using a binary TST designation (OR 
= 0.33, 95% CI = 0.22-0.49, p = 5.45x10
-8
; Appendix Table 4-3), and continuous TST scores 
(combined cohort beta = -3.34, 95% CI = -4.53 to -2.14, p = 6.95x10
-8
; Appendix Table 4-4). No 
other SNPs were significant at the multiple testing corrected threshold in any of the genetic 
models tested (Table 4-2, Appendix Tables 4-2 through 4-6). 
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Table 4-1. Summary statistics of study participants from by TST case/control status (≥ versus < 
5mm, respectively) in A) the extended follow up of the DarDar vaccine trial in Tanzania, B) the 
Household Contacts Study in Uganda, and C) the combined cohorts 
 
A) 
  
Cases Controls 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
n^  150 (75.4) 49 (24.6)   
Age* (years) 32.72 ± 7.78 31.57 ± 8.76 1.02 (0.98, 1.06) 0.384 
Gender^ Male 68 (76.4) 21 (23.6)   
  Female 82 (74.5) 28 (25.5) 1.11 (0.58, 2.12) 0.762 
 
B)  
  
Cases Controls 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
n^  94 (34.8) 176 (65.2)   
Age* (years) 33.50 ± 8.56 34.95 ± 7.61 0.98 (0.95, 1.01) 0.153 
Gender^ Male 21 (40.4) 31 (59.6)   
  Female 73 (33.5) 145 (66.5) 1.35 (0.72, 2.50) 0.349 
 
C) 
  
Cases Controls 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
n^  244 (50.9) 235 (49.1)   
Age* (years) 32.43 ± 8.02 34.49 ± 7.96 0.98 (0.96, 1.01) 0.108 
Gender^ Male 89 (63.1) 52 (36.9)   
  Female 155 (47.3) 173 (52.7) 1.91 (1.27, 2.86) 0.002 
*mean ± standard deviation; ^ n (% of row) 
 
 
 
56 
 
Table 4-2. Single nucleotide polymorphisms associating with case/control tuberculin skin test induration status (< versus ≥ 5mm) 
below a 5x10
-5
 p value using a dominant genetic model in A) the combined cohort*, B) the Ugandan cohort^, and C) the Tanzanian 
cohort^ 
 
A) 
SNP Chr. 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value Nearby gene 
rs877356 5 T 0.23 469 0.27 (0.17, 0.42) 1.22E-08 SLC25A48/IL9 
rs7808481 7 A 0.22 469 2.52 (1.63, 3.91) 3.33E-05 Loc340268 
rs1880386 10 A 0.21 469 2.46 (1.59, 3.80) 4.85E-05 GRID1 
 
B) 
SNP Chr. 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value Nearby gene 
rs877356 5 T 0.23 199 0.17 (0.078, 0.37) 9.18E-06 SLC25A48/IL9 
rs654718 11 G 0.21 199 0.19 (0.089, 0.41) 1.81E-05 MRE11A 
rs7944514 11 C 0.41 199 5.28 (2.46, 11.36) 2.03E-05 POLD3 
rs7837658 8 T 0.45 199 4.84 (2.32, 10.11) 2.67E-05 RNF19A 
 
C) 
SNP Chr. 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
 
Nearby gene 
rs17062122 6 C 0.33 270 0.28 (0.16, 0.49) 6.20E-06  Loc285735 
rs8142256 22 C 0.35 270 0.31 (0.18, 0.54) 2.87E-05  FAM19A5 
rs10998959 10 T 0.25 270 0.31 (0.17, 0.54) 4.33E-05  Loc100129281 
rs11736841 4 T 0.26 270 3.09 (1.79, 5.33) 4.96E-05  ODZ3 
… … … … … … …     …  … 
rs877356 5 T 0.23 270 0.33 (0.18, 0.59) 1.81E-04  SLC25A48/IL9 
* adjusted for 10 principal components, sex, and cohort of origin 
^ adjusted for 10 principal components and sex 
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To evaluate SNPs in the region not included on our genotyping array, we used IMPUTE2 
(v2.3.1)
79,80
 software to impute SNPs within 0.5 megabases of rs877356. rs17169187, in high 
linkage disequilibrium (LD) with rs877356 (D’ = 1 in both cohorts, r2 = 0.99 in Tanzania, 0.98 in 
Uganda) and 2,340 bases away, is the variant with the most significant association to TST 
case/control status using a dominant model (combined cohort OR = 0.25, 95% CI = 0.16-0.40, p 
= 4.57x10
-9
; Figure 4-1, Appendix Table 4-7A). The results were consistent when we used linear 
regression on TST induration as a continuous variable (combined cohort beta = -4.28, 95% CI = 
-5.69 to -2.88, p = 4.58x10
-9
; Appendix Table 4-8A). The variant is also genome-wide significant 
in additive modeling of both a dichotomous TST designation (combined cohort OR = 0.3196, 
95% CI = 0.22-0.48, p = 2.56x10
-8
; Figure 4-1, Appendix Table 4-7B) and continuous TST 
induration (combined cohort beta = -3.43, 95% CI = -4.62 to -2.24, p = 2.84x10
-8
; Appendix 
Table 4-8B).   
In the Tanzanian cohort, IGRA responses did not differ between TST cases/controls in 
positive (PHA) and negative controls (MEDIUM), but were significantly higher in TST cases for 
all test antigens (Appendix Table 4-9B). In Uganda, we observed the same trends; however, due 
to smaller sample sizes, the comparisons were not statistically significant (Appendix Table 4-
9A). When we removed 16 patients with TST results of 0 mm but at least one IGRA > than the 
mean observed in patients with TST > 5 mm, the results of the association remained consistent 
and a dominant model of rs8773556 was significant at the genome-wide significance threshold 
with both the binary and continuous TST outcomes (Appendix Table 4-10). When we removed 
20 patients from the analysis because of possible positive TST reaction to a childhood BCG 
vaccination, a dominant model of rs877356 was significant adjusted for multiple testing for both 
outcomes and nearly genome-wide significant for binary TST (p value = 5.58x10
-8
; Appendix 
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Table 4-11). The association was also robust to removing all 36 patients with either suspected 
false positive or false negative TST results, as the associations remained significant at a multiple 
testing adjusted threshold (Appendix Table 4-12). The dominant model of rs877356 remained 
genome-wide significant for either outcome when the analysis was adjusted for a missing IGRA 
variable (Appendix Table 4-13). The variant was also genome-wide significant when we 
included patients with prior tuberculosis into the study cohort (Appendix Table 4-14). 
We found the strongest single variant association using a dominant model of rs877356; 
therefore, we used dominant coding of the SNP in 2-variant haplotype in the SLC25A48 region 
while using additive models of all other SNPs. An rs877356-rs2069885 haplotype had the 
strongest association in this analysis (p value 1.59x10
-12
 in the combined cohort; Table 4-3). The 
haplotype had similar effects in the Ugandan (p value = 2.51x10
-8
; Table 4-3B) and Tanzanian 
cohorts (p value = 1.37x10
-11
; Table 4-3C), with the protective T-G haplotype case/control 
frequencies of 0.32/0.60 and 0.20/0.45, respectively. The risk haplotype, C-G, also had a 
consistent distribution between the cohorts, with a case/control frequency of 0.58/0.33 in Uganda 
and 0.68/0.48 in Tanzania (Table 4-3B and C). The results were consistent in additive modeling 
of both SNPs (p value = 2.59x10
-9
 in the combined cohort; Table 4-3). The haplotype had similar 
effects in the Ugandan (p value = 1.03x10
-5
; Table 4-3B) and Tanzanian cohorts (p value = 
6.35x10
-5
; Table 4-3C).  
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Table 4-3. Association of the 2-variant haplotype using a dominant model of rs877356 with an 
additive model of rs2069885 with TST induration case/control status (< versus ≥ 5mm) in the 
SLC25A48/IL9 region in A) the combined cohort, B) the Ugandan cohort and C) the Tanzanian 
cohort 
 
A) 
Haplotype Case Control Ca-Freq Co-Freq 
C-A 33 12 0.068 0.027 
C-G 301 202 0.62 0.45 
T-A 17 17 0.035 0.038 
T-G 135 219 0.28 0.49 
Likelihood ratio chisq = 57.97 df = 3 p-value = 1.59E-12* 
 
B) 
Haplotype Case Control Ca-Freq Co-Freq 
C-A 19 2 0.063 0.020 
C-G 175 32 0.58 0.33 
T-A 9 5 0.030 0.051 
T-G 97 59 0.32 0.60 
Likelihood ratio chisq = 38.25 df = 3 p-value = 2.51E-08^ 
 
C) 
Haplotype Case Control Ca-Freq Co-Freq 
C-A 14 10 0.075 0.028 
C-G 126 170 0.68 0.48 
T-A 8 12 0.043 0.034 
T-G 38 160 0.20 0.45 
Likelihood ratio chisq = 53.59 df = 3 p-value = 1.37E-11^ 
* adjusted for principal components, sex, and cohort of origin 
^ adjusted for principal components and sex 
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Figure 4-1. Locus zoom plot of results from a logistic regression association of case/control tuberculin skin test induration status (< 
versus ≥ 5mm) with a dominant genetic model of imputed SNPs in the SLC25A48/IL9 region in the in the combined cohort, adjusted 
for 10 principal components, sex, and cohort of origin; SNP with the most significant association in the Exome Beadchip analysis in 
purple 
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Discussion 
 
In this study we examined the association of common genetic variants with 
Mycobacterium tuberculosis infection in HIV-positive patients from the extended follow up of 
the DarDar vaccine trial in Tanzania and the Household Contacts study in Uganda. We 
hypothesized that immunosuppressed patients who live in MTB endemic areas but do not get 
infected have genetic resistance. We identified a novel association between resistance to MTB 
infection and rs877356, a variant 9,119 bases upstream of the coding region of SLC25A48
87
, a 
Homo sapiens solute carrier family 25, member 48. SLC25A48 is a mitochondrial carrier of 
amino acids
126,127
. The variant of interest is also 57,662 bases downstream from IL9.  
The involvement of IL9 as the potentially causal gene in our association study was further 
supported by our haplotype analyses. The rs877356-rs2069885 haplotype had the most 
significant association in the SLC25A48/IL9 region. rs2069885, 66kb away from rs877356, is a 
missense variant in IL9 (Threonine (ACG) ->Methionine (ATG))
87
. While rs2069885 was not 
significant in univariate analyses (p value 0.0907 in the combined cohort, binary TST, additive 
model), the association of the haplotype was more significant than that of rs877356 alone. 
IL9 is a particularly interesting candidate for MTB infection because it is a cytokine 
previously associated with bronchial hyperresponsiveness, a heightened bronchoconstriction in 
response to external stimuli
128
. Bronchial hyperresponsiveness is hereditary, and is a risk factor 
for subsequent development of asthma
128-130
. Asthma is a chronic condition with symptoms of 
wheezing, shortness of breath, chest tightness and cough
131
. Of note, the prevalence of asthma in 
East Africa is very high, especially in urban settings
132
. Childhood MTB infection protects 
patients from developing asthma, and an inverse relationship between incidence of active TB and 
asthma has been reported
133,134
. We posit that our variant associates with heightened 
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inflammation and bronchoconstriction, and that this hyperresponsiveness plays a key role in 
preventing MTB infection. 
A recent review of Mycobacterium tuberculosis host evasion suggests a possible 
mechanism for how airway inflammation prevents MTB infection
20
. In an animal model, large 
aerosolized particles containing >10,000 bacteria do not readily initiate infection because they 
get trapped in the upper airway
135
. Microbicidal macrophages in the upper airway are recruited 
by toll-like receptor signaling upon immune system recognition of bacterial pathogen-associated 
molecular patterns (PAMP). This mechanism is used to keep mucosal commensal pathogens 
from migrating into the lower respiratory tract. MTB readily infect macrophages without 
activating interferon-gamma signaling because they mask their PAMP using a surface lipid 
phthiocerol dimycocerosate
136
. However, the presence of other TLR-stimulating commensals in 
the upper airway activates the microbicidal macrophages and MTB is killed as collateral
20
. In 
order to circumvent this response, MTB travels in small droplet nuclei containing as few as 1-3 
bacteria, delivering them directly to the lower lung. There, with less immune stimulation by 
other pathogens, MTB initiates infection in unactivated macrophages
137
. A persistent state of 
increased upper airway inflammation would make passage into the preferred alveolar spaces 
more difficult, and MTB droplet nuclei would be sequestered and consequently killed before 
reaching the lower lung. 
The IL9 cytokine was originally described as a T cell and mast cell growth factor, but has 
since been found to have further pleiotropic effects on the immune system
138-140
. It is produced 
by TH2 cells, naïve CD4+ cells, Th17 cells, Mast cells, TH9 cells and possibly Treg cells
138,141-143
. 
TH9 cells are primed for IL9 production and are stimulated to differentiate by pleural mesothelial 
cells in the presence of MTB infection
144,145
. In B cells, IL9 promotes IL4-mediated production 
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of IgE and IgG antibodies
146,147
. Of note, bronchial hyperresponsiveness is associated with 
elevated serum IgE levels
128,148
. IL9 also promotes proliferation of hematopoietic progenitor 
cells
149,150
, and it has specific effects on lungs. In airway smooth muscle cells, IL9 induces the 
expression of chemokine CCL11, thereby inducing eosinophil chemotaxis and allergic reactions, 
and in airway epithelial cells, IL9 directly induces mucous production and stimulates IL13, 
which leads to further airway inflammation
138,139,151,152
.  
The TST phenotype can be studied both as a binary variable, < versus ≥ 5mm induration, 
or as a continuous outcome. Our single SNP association results were consistent using both 
outcome types. Variant rs877356 was genome-wide significant in both logistic and linear 
regression models in the combined cohort using a dominant genetic model. The variant was also 
significant at a multiple testing corrected level in additive modeling. The most significant 
imputed variant in the region, rs17169187, was genome-wide significant for both outcomes in 
additive and dominant modeling.    
Immune anergy is an important confounder in studies of TST reactivity in an HIV-
positive context. TST responses can be < 5mm because a patient has not been infected with 
MTB, or in case of infection, they are unable to mount a hypersensitivity reaction to purified 
protein derivatives on account of their immunosuppresion. We leveraged existing interferon 
gamma release assay data in both cohorts to evaluate confounding by immunosuppression. We 
removed all patients suspected of immune anergy prior to analysis, and further adjustment for a 
missing IGRA variable did not affect the association of our variant, demonstrating the robustness 
of our findings.   
This study demonstrates that the choice of an extreme phenotype, HIV-positive patients 
who live in MTB endemic areas but do not get infected, allows for the use of relatively small 
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sample size even in a genome-wide association study. Although the small sample size is the 
biggest weakness in this study, the large effect size observed in this unique study population 
allowed us to find significant associations in an apparently relevant region of the genome. The 
variant with the most significant association is near IL9, a gene with a substantial role in airway 
inflammation, bronchial asthma, and other respiratory infections
153,154
. This, along with some 
observational studies of the inverse incidence of asthma and tuberculosis, leads to the conclusion 
that the same gene whose over expression plays a significant role in the pathogenesis of asthma, 
also prevents MTB infection by the same mechanism.  
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B. Fine mapping of regions previously associated through genome-wide linkage studies 
 
Introduction 
 
Availability of tuberculin skin test measurements and dense variant coverage of our 
genotyping array allowed us to follow up on prior studies of MTB infection. A study by Cobat et 
al. used a genome-wide linkage approach to identify a signal in the chromosome 11p14.1 region 
for tuberculin skin test reactivity as a binary variable, and the SLC6A3 region on chromosome 5 
when using a TST as a continuous variable
12
. The SLC6A3 region was fine mapped in a follow 
up analysis, and SNP rs250682 was the most significant variant. The region on chromosome 11 
spanned from 22.35 to 28.82mb and was termed TST1. No fine mapping follow up analysis was 
performed on TST1; therefore, no single SNP could be identified as associating with the 
phenotype. The study evaluated TST reactivity in 128 families, comprised of 186 parents and 
350 offspring from the Western Cape region of South Africa. Importantly, HIV positive 
participants were excluded from analyses
12
. 
A genome-wide linkage analysis by Stein et al. compared persistently TST negative 
patients to individuals with latent infection
13
. None of the analyses were significant when 
adjusted for multiple testing; however three regions approached significance, 2q14, 2q21-2q24 
and 5p13-5q22 (p value < 0.005 for all). The study population was comprised of 193 families 
and a total of 803 participants, 130 of whom were HIV-positive. HIV-positive patients were 
included in the analysis, and the final model was adjusted for HIV status
13
.  
We used the genome-wide data from the Human Exome Beadchip to evaluate if common 
variants in these previously identified regions associate with TST response in HIV-positive 
individuals who live in areas endemic for MTB but do not get infected. Using two recently 
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concluded prospective cohorts of tuberculosis disease from Tanzania and Uganda, we fine 
mapped each area, and identified candidate SNPs in each region.  
 
Methods 
 
The study populations, genotyping, exclusion criteria, and covariates are described in the 
Methods section of Chapter IV Part A. SNPs in each respective region of interest (SLC6A3 +/- 
0.5 mb, chr11:22.35-28.82mb, 2q14, 2q21-2q24 and 5p13-5q22) with a minor allele frequency 
>0.10 were tested for association using the Exome Beadchip data in the combined cohort. 
Analyses were performed using the same outcomes (binary versus continuous TST) as described 
in the initial analyses; however, only covariates associating with the phenotype in our study 
cohorts were used in the final models (described in Part A). After identifying the most significant 
SNP within each region using our data from the Exome Beadchip, we imputed all ungenotyped 
SNPs +/- 0.5mb of the index SNP with IMPUTE2 (v2.3.1), using one phased reference panel 
from the 1000 Genomes project
78-80
. Association analyses were then performed on the imputed 
datasets.  
A prior study by Sobota and Shriner et al. demonstrated that linkage disequilibrium 
patterns make a strict Bonferroni adjustment (0.05/number of SNPs) of a p value threshold too 
conservative in genetic studies
115
. Since polymorphisms in the same region are not independent 
of each other, adjusting the p value by their total number is statistically punitive. Even in African 
populations, known for shorter LD blocks in comparison to other global populations, the 
Bonferroni adjusted p value threshold was observed to be about half an order of magnitude too 
conservative. Consequently, for fine mapped polymorphisms with a p value within a half order 
of magnitude for the multiple testing adjusted threshold, we used a linkage disequilibrium 
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pruning-based method to adjust the conservative Bonferroni significance threshold to a more 
natural one. 
 
Results 
 
Linear regression in the SLC6A3 region 
 
We were unable to validate any of the quantitative trait loci fine mapped in the SLC6A3 
region by Cobat et al using a standard statistical significance criterion. The most significant 
association was reported rs250682
12
; however, this variant did not associate with a continuous 
TST phenotype in our combined cohort analysis (p value = 0.72; Table 4-4). Of the most 
significant variants reported by Cobat et al, rs4975579 was closest to replicating in our study (p 
value = 0.0805; Table 4-4). Unfortunately, the authors did not disclose the risk allele or the effect 
size; therefore, we cannot even assess whether we are reporting an effect trending in the same 
direction.  
The most significant association for the Human Exome Beadchip variants within 0.5mb 
of rs250682 was rs10056116 (Beta = 1.89, 95% CI = 0.63-3.15, p value = 0.00351; Table 4-5A). 
There were 117 variants passing quality control in that region. Therefore, the top SNP did not 
pass a multiple testing criterion (threshold 4.27x10
-4
). After imputation, rs13186183 is the 
variant with the most significant association in the region (Beta = -2.85, 95% CI = -4.56 to -1.23, 
p value = 7.10x10
-4
; Table 4-5A).    
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Table 4-4. Association of variants in the SLC6A3 region significant in Cobat et al. with 
continuous TST scores in an additive genetic model in the combined Ugandan-Tanzanian cohort; 
adjusted for 10 principal components, sex, and cohort of origin 
 
SNP Minor Allele MAF Beta 
95% Confidence 
Interval 
p value 
rs4975579 G 0.43 -0.86 (-1.81, 0.10) 0.080 
rs6554677 A 0.21 -0.57 (-1.81, 0.66) 0.361 
rs1801075 C 0.16 -0.27 (-1.62, 1.08) 0.697 
rs250682 C 0.48 -0.19 (-1.19, 0.81) 0.715 
rs10475030 T 0.49 0.013 (-0.95, 0.97) 0.978 
rs1018120 T 0.088 -1.16 (-2.99, 0.67) 0.214 
rs2232376 T 0.24 0.31 (-0.85, 1.48) 0.600 
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Table 4-5. Fine mapping of available and imputed variants using an additive genetic model and continuous TST scores in A) the 
SLC6A3 region and binary TST scores in regions, B) chromosome 11p14, C) chromosome 2q14, D) chromosome 2q21-q24, and E) 
chromosome 5p13-q22; adjusted for 10 principal components, sex, and cohort of origin 
 
A) 
SNP Source Position 
Minor 
Allele 
MAF Beta 
95% Confidence 
Interval 
p value 
rs10056116 
Exome 
Beadchip 
1676638 A 0.18 1.89 (0.63, 3.15) 0.00351 
rs13186183 Imputed 1791180 T 0.096 -2.89 (-4.56, -1.23) 7.10E-04 
rs7715002 Imputed 1499057 T 0.067 3.36 (1.37, 5.35) 0.00102 
rs58371035 Imputed 1505771 A 0.062 3.39 (1.32, 5.46) 0.00144 
rs186894420 Imputed 1734126 C 0.015 5.97 (2.24, 9.70) 0.0018 
 
B) 
SNP Source Position 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
rs17234274 
Exome 
Beadchip 
23214366 C 0.37 0.58 (0.43, 0.78) 2.85E-04 
rs10834029 Imputed 23306545 G 0.49 1.80 (1.34, 2.43) 1.07E-04 
rs76936560 Imputed 23242837 A 0.39 0.55 (0.40, 0.75) 1.57E-04 
rs1384479 Imputed 23243454 T 0.37 0.55 (0.41, 0.76) 1.88E-04 
rs2449427 Imputed 23215101 C 0.39 0.57 (0.42, 0.77) 2.71E-04 
rs17234274 Imputed 23214366 C 0.37 0.57 (0.42, 0.77) 2.93E-04 
 
C) 
SNP Source Position 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
rs4848637 
Exome 
Beadchip 
121579245 A 0.16 0.52 (0.35, 0.77) 0.0013 
rs4848638 Imputed 121579604 A 0.16 0.51 (0.34, 0.77) 0.00122 
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rs12612236 Imputed 121459243 A 0.32 0.60 (0.44, 0.83) 0.00168 
rs199672409 Imputed 121522007 CT 0.18 1.88 (1.26, 2.80) 0.00181 
rs12996197 Imputed 121464285 A 0.33 0.60 (0.43, 0.83) 0.00198 
 
D) 
SNP Source Position 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
rs2521933 
Exome 
Beadchip 
130457465 T 0.20 2.02 (1.41, 2.88) 1.13E-04 
rs2521927 Imputed 130456688 A 0.20 2.03 (1.42, 2.91) 1.12E-04 
rs2704538 Imputed 130403009 T 0.20 0.50 (0.34, 0.74) 5.03E-04 
rs2521927 Imputed 130404123 T 0.20 0.51 (0.34, 0.75) 6.56E-04 
rs2704538 Imputed 130401545 T 0.20 0.51 (0.35, 0.75) 7.38E-04 
 
E) 
SNP Source Position 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
rs13156567 
Exome 
Beadchip 
57122376 A 0.11 2.37 (1.50, 3.74) 2.12E-04 
rs72751331 Imputed 57125178 T 0.11 2.44 (1.53, 3.91) 1.95E-04 
rs10487616 Imputed 57105894 G 0.10 2.48 (1.53, 4.01) 2.21E-04 
rs1968422 Imputed 57138990 C 0.31 1.80 (1.31, 2.46) 2.44E-04 
rs13169816 Imputed 57145564 T 0.11 2.46 (1.50, 4.02) 3.46E-04 
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Logistic regression in the chromosome 11p14.1 region 
 
A total of 714 variants from the Human Exome Beadchip passed quality control in the 
chromosome 11p14 region (22.35 to 28.82mb). SNP rs17234274 had the strongest association 
with a binary TST outcome in logistic regression analyses (OR = 0.58, 95% = CI 0.43-0.78, p 
value = 2.85x10
-4
; Table 4-5B). This variant did not pass a Bonferroni-adjusted multiple testing 
criterion (threshold 7.00x10
-5
). When the LD pruning method for adjusting the multiple testing 
threshold was applied, there were 402 independent SNPs in the region, and the new criterion 
became 1.24x10
-4
. After imputation, rs10834029 was the variant with the most significant 
association in the region (OR = 1.80, 95% = CI 1.34-2.43, p value = 1.07x10
-4
; Table 4-5B). The 
variant is significant when an LD-pruning based multiple testing criterion is used (LD pruning of 
imputed data also yielded 402 independent SNPs in the region). Importantly rs10834029 has the 
genomic position of 23306545, which roughly corresponds to one of the apices of LOD scores 
observed by Cobat et al. (Figure 4-2)
12
.     
 
Logistic regression in the chromosome 2q14 region 
 
The most significant association for the Human Exome Beadchip variants in the 
chromosome 2q14 region (114.40 to 129.90mb) was rs4848637 (OR = 0.52, 95% = CI 0.35-0.77, 
p value = 0.0013; Table 4-5C). There were 1103 variants passing quality control in that region, 
and the most significant SNP did not pass a multiple testing adjusted criterion (threshold 
4.53x10
-5
). After imputation, rs4848637 was the variant with the most significant association in 
the region (OR = 0.51, 95% = CI 0.34-0.77, p value = 0.00122; Table 4-5C). The two SNPs are 
in perfect LD with each other, and the slight discrepancies in the reported odds ratio and p value 
are due to a missing observation for rs4848637 in our study cohorts. 
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Figure 4-2. Linkage map from Cobat et al using a binary TST outcome of A) the entire genome 
and B) the chromosome 11 region with the highest LOD score  
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Logistic regression in the chromosome 2q21-2q24 region 
 
The most significant association for the available Human Exome Beadchip variants in the 
chromosome 2q21-q24 region (129.90 – 169.70mb) was rs2521933 (OR = 2.02, 95% = CI 1.41-
2.88, p value = 1.13x10
-4
; Table 4-5D). There were 2731 variants passing quality control in the 
chromosome 2q21-q24 region, and the most significant SNP did not pass a multiple testing 
adjusted criterion (threshold 1.83x10
-5
). After imputation, rs2521927 was the variant with the 
most significant association in the region (OR = 2.03, 95% CI = 1.42-2.91, p value = 1.12x10
-4
; 
Table 4-5D). The most significant SNP from the Exome Beadchip and the most significant 
imputed SNP are in very high LD.  
 
Logistic regression in the chromosome 5p13-5q22 region 
 
The chromosome 5p13-q22 region does not contain rs877356, the variant associated with 
TST in Part A of this Chapter. The most significant association for the Human Exome Beadchip 
variants in this region (28.90 to 115.20mb) was rs13156567 (OR = 2.37, 95% = CI 1.50-3.74, p 
value = 2.12x10
-4
; Table 4-5E). There were 5683 variants passing quality control on 
chromosome 5p13-q22, and the most significant SNP did not pass a multiple testing adjusted 
criterion (threshold 8.80x10
-6
). After imputation, rs72751331 is the variant with the most 
significant association in the region (OR = 2.44, 95% CI = 1.53-3.91, p value = 1.95x10
-4
; Table 
4-5E).    
 
Discussion 
 
We performed a fine mapping follow-up using an association approach in all genomic 
regions previously discovered in genome-wide linkage studies of TST. The SNP with the 
strongest association in the chromosome 11p14 region, rs10834029, overlapped with the second 
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highest LOD score observed in the original analysis by Cobat et al. The imputed variant was not 
significant when using a strict Bonferroni multiple testing correction, but became significant 
when a more natural threshold was used
115
. The variant is located in a gene desert, ~500mb away 
from the closest genes GAS2 and CCDC179. GAS2 encodes growth arrest-specific 2 protein that 
was originally identified in murine fibroblasts when cell cycle progression was stopped
155
. It is a 
caspase-3 substrate that regulates cell shape changes in apoptosis, and this association with cell 
death makes it a very good candidate for modulating MTB infection. Tumor necrosis factor 
alpha mediated apoptosis of MTB infected macrophages deprives the bacteria of the intracellular 
environment it needs for replication
156
. Several SNPs in the GAS2 coding region associate with 
the phenotype at a 0.05 threshold (Appendix Table 4-16), but not at any of the multiple testing 
adjusted thresholds.   
Variants with the most significant associations with TST outcomes in the other fine 
mapped regions are not in or near genes associated with immune function or tuberculosis. 
Variant rs4848637 in the 2q14 region is in an intron of GLI2, a zinc finger gene previously 
associated with cleft lip and cleft palate
157
. Variant rs2521933 in the 2q21-24 region is located in 
a gene desert. The only annotated gene within 0.5mb of the SNP is Loc151121, previously 
associated with alcohol abuse
158
. Variant rs13156567 in the 5p13-q22 region is closest to PLK2, 
a gene encoding a serine/threonine kinase that has been previously associated with multiple 
myeloma and breast cancer
159,160
.      
The size of each region identified in genome-wide linkage analyses was a major 
impediment in identifying the SNPs truly associating with the phenotype in fine mapping. The 
regions spanned up to 85 megabases and, consequently, the multiple testing adjusted thresholds 
were difficult to surpass. The large number of SNPs in those regions permitted us to find variants 
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significant at the standard validation criterion, p value of 0.05, but we were otherwise unable to 
discern type I errors from true findings. Our approach was tailored for finding resistance loci; 
therefore, the fact that neither study reported the direction of the observed effect may mean in 
some instances we were attempting to replicate susceptibility loci in a study population not 
suited to do so. HIV status is also an important consideration in attempting to validate findings 
from other studies in our Ugandan and Tanzanian cohorts. While Cobat et al. excluded these 
patients, and Stein et al. adjusted for HIV as a variable, our patients population was comprised 
entirely of HIV-seropositive adults
12,13,68
. This permitted us to find a resistance locus using a 
very small sample size for a genome-wide analysis, but it might not be ideal for replicating 
findings from the general patient population, where odds ratios are usually not as extreme.   
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CHAPTER V 
 
EXAMINING MULTILOCUS INTERACTIONS IN CANDIDATE GENES FOR 
TUBERCULOSIS RESISTANCE 
 
A. Multifactor Dimensionality Reduction Analysis of Active Tuberculosis Disease 
 
Introduction 
 
Tuberculosis (TB) has a significant heritable component
161
. The identification of genetic 
variants affecting disease risk has substantial implications in designing diagnostics, therapeutics, 
and vaccines. To date, most genetic studies of TB have used approaches associating individual 
variants to disease, assuming strong effect sizes of single genes
10,11,14,58
. Despite the use of dense 
genomic coverage and large sample sizes, most TB heritability remains unexplained. Recently, 
analyses of gene-gene interactions, which assume a complex genetic architecture to TB 
susceptibility, identified several important effects and demonstrated the potential of epistasis in 
explaining the missing heritability
162,163
.      
The immunological response to Mycobacterium tuberculosis (MTB) infection and 
resultant tuberculosis is complex. Numerous cells types, proteins, and signaling molecules are 
responsible for limiting symptoms, and the biological networks involved change during the 
course of disease
20
. To infect a naïve host, MTB must move through the upper respiratory system 
without being sequestered. If the MTB is trapped by macrophages in the upper respiratory 
system, the presence of commensal bacteria stimulates the macrophages through toll like 
receptors (TLR) to digest all phagocytosed bacteria including MTB
20
. However, once a lower 
respiratory tract infection is established, MTB enter macrophages in the alveolar spaces and use 
C-C motif ligand 2 (CCL2) signaling to recruit other macrophages to the region. MTB prevents 
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the binding of the phagosome in which it resides and the lysosome containing hydrolytic 
enzymes designed to degrade it; therefore, in the absence of commensal bacteria that stimulate 
macrophages, MTB survives
21
. The bacterium is thereby largely unrestricted by innate immunity 
early in the course of infection
21
.  
Subsequently, the host organism starts to mount an adaptive response. MTB are slowly 
digested by endosomal proteases and MTB peptides are loaded onto MHC class II molecules. 
TLR2 bind to antigen presenting cells and stimulate an IL-12 response which in turn activates 
the differentiation of TH1 CD4 T cells
21
. Mature TH1 cells mount an interferon gamma (IFN-γ) 
response and activate the binding of lysosomes with MTB containing endosomes in 
macrophages
21
.
 
The recognition of MTB peptides also stimulates tumor necrosis factor (TNF) 
signaling, generating a localized inflammatory response that leads to the formation of granuloma 
consisting of infected macrophages walled off by surrounding TH1 CD4 T cells. MTB survive 
within the granulomas even in the presence of widespread necrosis
22
; thereby maintaining a 
latent infection
21
. In 5-10% of patients, the immune system is unable to contain MTB with 
granulomas, the bacteria multiply, and patients progress to active TB disease shortly after 
infection, with significant caseation, cavitation and tissue destruction in the lungs
21
. The pattern 
of lung involvement in primary tuberculosis results in consolidation of the lower and middle lung 
lobes, along with hilar adenopathy, and very rarely cavitation. 
Latent infections can be activated by immunosuppression caused by age, malnutrition, or 
HIV infection, among other factors. The depletion of CD4 cells seen in HIV patients prevents the 
containment of MTB in granulomas. Cavitation occurs readily in secondary tuberculosis, and it 
is generally localized in upper lobe apices of the lungs
21
. In immunosuppressed patients, MTB 
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more readily enters the systemic circulation, causing disseminated disease usually localizing to 
pleura, bones, and joints (miliary tuberculosis) or the CNS (tuberculosis meningitis)
21
. 
The complex signaling involved in the pathogenesis of tuberculosis along with the array 
of tissues that are exposed to the bacteria, especially in HIV-positive patients, make single 
variants unlikely to account for most of the heritability observed for this disease
161
. Here, we 
proposed a two-tiered approach for studying gene-gene interactions in TB. We identified 
candidate genes with a literature search, and separated available variants in these genes by 
chromosome to identify cis acting interactions. We then applied a filter to lower the number of 
included variants and studied interactions between all candidate genes.   
 
 
Methods 
 
Study Populations 
 
 The participants of the Household Contact Study, DarDar Women’s Nutrition Study and 
the extended follow up of the DarDar vaccine trial used in the genome-wide association study of 
tuberculosis resistance in Chapter III were used to carry out this aim.  
 
Candidate Gene Selection 
 
We used a candidate gene approach selecting variants with a minor allele frequency > 
0.05 in and near genes (+/- 100 kb of coding region) previously associated with tuberculosis 
disease. The candidate gene list for TB disease is comprised of the following: the major 
histocompatibility complex region HLA-DR2
15,37
; a proton-coupled divalent metal ion transporter 
SLC11A1
5,38
; a solute carrier associated with MTB infection SLC6A3
12,14
; a ligase in the 
ubiquitin proteasome pathway: UBE3A
65
; cytokines and chemokines used in macrophage-TH1 
cell signaling: IFN-γ15, IFNGR163, IL12B7,8, IL12BR164, CCL246, IL-89, IL-1B47, IL-1048,66, IL-
79 
 
4
49
, and TNF-α66; a mediator of pleiotropic effects of IFN-γ: SP11044,45; variants in 
immunomodulatory receptors: PTX3
51
, CR1
52
, VDR
51,53
, CD209
51,54
, P2RX7
55
; complement 
activating pattern recognition molecules MBL2
56
, TLR2
57,58
, TLR4
59
, and their downstream 
effector TIRAP
60
. A total of 808 variants met the inclusion criteria.     
 
Multifactor Dimensionality Reduction 
 
We used Multifactor Dimensionality Reduction (MDR) software to study the association 
of gene-gene interactions with active tuberculosis
18,19
. Missing genotypes were imputed using the 
MDR data tool. All analyses were performed using the same random seed and up to 3 locus 
models of susceptibility, which allows the study of single variant effects along with 2 and 3 SNP 
interactions. The default setting assigning tied cells as cases and ten-fold cross-validation was 
used throughout. 
We evaluated epistasis in the combined cohort, as well as the Ugandan and Tanzanian 
cohorts individually. Analyses of the combined cohort were adjusted for variable designating 
Tanzanian or Ugandan origin. Top testing accuracy and cross validation consistency results in 
each model are reported. The combined cohort model with the highest testing accuracy with a 
cross-validation consistency of at least 8/10 was forced into the Ugandan and Tanzanian cohorts 
to assess replication. Using MDRpt, we performed 1000-fold permutation tests on all 2 or 3 
variant models from the combined cohort that replicated in both Ugandan and Tanzanian cohorts.     
We first restricted the analyses to SNPs on the same chromosome. We then used the 
ReliefF filter to select the top 40 SNPs for MDR analyses of interactions between variants from 
all candidate genes. ReliefF uses a computational algorithm to filter data and generate a subset of 
most informative SNPs. Statistically significant 2 or 3 locus interactions in the combined cohort 
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were followed up with logistic regression analyses in STATA(v11.2)
73
. BioGRID(v3.3) was used 
to assess biological interactions between significant genes
164
.  
All analyses were carried out on two sets of SNPs. We first performed MDR on all 
available variants, including rs4921437, which associated with TB disease at a genome wide 
significant threshold, as shown in Chapter III. We then evaluated epistasis without significant 
main effect SNPs, i.e. removing rs4921437 from analyses. 
Results 
 
Single chromosome analyses 
 
The two-locus interaction between rs4921437 and rs7737692 was the only higher order 
(>1 variant) model that met our criteria for follow up in the combined cohort analysis of variants 
from the same chromosome (Table 5-1A). The testing accuracy of this model was 0.63, and the 
cross-validation consistency was 10 out of 10. When we used cohort of origin as a covariate, 
instead of adjusting for it, the testing accuracy was 0.68, and the cross-validation consistency 
was 10 out of 10 (Appendix Table 5-1A). The rs4921437-rs7737692 interaction had a testing 
accuracy of 0.60 and a cross validation consistency of 10 out of 10 in the Ugandan cohort. In 
Tanzania, the testing accuracy was lower at 0.53; however, the cross-validation consistency was 
still 10 out of 10. The permutation test p value for the combined cohort analysis of the rs4921437 
and rs7737692 interaction was <0.001.  
Chromosome 5 analyses omitting rs4921437 did not produce results matching the MDR 
metric criteria for follow up permutation test analyses. None of the models had a testing accuracy 
>0.5, or cross-validation criteria > 4 out of 10, indicating the rs4921437 is the major factor for an 
effect either marginal or via an interaction (Appendix Table 5-2).  
  
81 
 
Table 5-1. MDR metrics of top loci and interactions associating with TB disease for variants on 
the same chromosome in A) the combined*, B) the Ugandan, and C) the Tanzanian cohort 
 
A) 
Variant Combinations Chr. 
Attribute 
Count 
Balanced 
Accuracy 
Training 
Balanced 
Accuracy 
Testing 
Cross 
Validation 
Consistency 
rs12622683 2 1 0.58 0.58 10/10 
rs4680367 3 1 0.58 0.54 8/10 
rs4921437 5 1 0.62 0.62 10/10 
rs7737692, rs4921437 5 2 0.64 0.63 10/10 
rs7095115 10 1 0.57 0.52 8/10 
rs7496458 15 1 0.55 0.54 10/10 
rs8069624 17 1 0.56 0.56 10/10 
*adjusted for cohort of origin 
 
B) 
Variant Combinations Chr. 
Attribute 
Count 
Balanced 
Accuracy 
Training 
Balanced 
Accuracy 
Testing 
Cross 
Validation 
Consistency 
rs1032980 1 1 0.61 0.61 10/10 
rs4921437 5 1 0.66 0.66 10/10 
rs7737692, rs4921437 5 2 0.66 0.60 10/10 
rs7852394 9 1 0.62 0.62 10/10 
rs7095115 10 1 0.60 0.54 8/10 
rs7917895, rs7474987 10 2 0.66 0.61 9/10 
rs570984 12 1 0.61 0.57 8/10 
rs8075846 17 1 0.61 0.61 10/10 
 
C) 
Variant Combinations Chr. 
Attribute 
Count 
Balanced 
Accuracy 
Training 
Balanced 
Accuracy 
Testing 
Cross 
Validation 
Consistency 
rs7540516 1 1 0.59 0.54 8/10 
rs4921437 5 1 0.59 0.59 10/10 
rs4921437, rs4262088 5 2 0.64 0.60 9/10 
rs7737692, rs4921437 5 2 0.60 0.53 10/10 
rs6916394 6 1 0.59 0.59 10/10 
rs7034845 9 1 0.57 0.57 10/10 
exm997700, rs4760673 12 2 0.67 0.67 10/10 
rs12441992, rs2340634, rs7496458 15 3 0.66 0.56 8/10 
rs8069624 17 1 0.58 0.53 8/10 
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Analyses of variants in all candidate genes 
 
A three-locus interaction between rs4921437, rs2242656, and rs2940252 had the best 
MDR metrics from a dataset filtered to 40 variants by ReliefF. The cross-validation consistency 
was 10 out of 10 in the combined cohort and in Uganda and Tanzania separately. The testing 
accuracy was 0.65 in the combined cohort, 0.67 in Uganda, and 0.58 in Tanzania (Table 5-2A, 
Figure 5-1). When we used cohort of origin as a covariate, instead of adjusting for it, the testing 
accuracy was 0.66, and the cross-validation consistency was 10 out of 10 (Appendix Table 5-
1B). Importantly, the testing accuracy for the 3-locus interaction performed better than the single 
locus rs4921437 model in the combined cohort and in Uganda (Table 5-2B). The permutation 
test p value for the top three-locus model in the combined cohort was estimated to be <0.001.  
Analyses omitting rs4921437 did not produce results matching the MDR metric criteria 
for follow up permutation test analyses. None of the Tanzanian nor combined cohort models had 
a testing accuracy >0.56, or cross-validation criteria > 4 out of 10 (Appendix Table 5-3). A two-
locus model, rs3129943 and rs12788021, had a testing accuracy of 0.70 and cross-validation 
consistency of 10 out of 10 in the Ugandan cohort. A three-locus model, rs6793453, rs1265761, 
and rs12788021, had a testing accuracy of 0.68 but a cross-validation consistency of 4 out of 10; 
therefore it was not generalizable. 
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Table 5-2. MDR metrics of the top model associating with TB disease using A) variants in or 
near IL12B (rs4921437), TNF-α (rs2242656), and CR1 (rs2940252), and B) the corresponding 
metrics for the top single SNP model of rs4921437 alone 
 
A) 
Cohort Testing balanced accuracy Cross-validation consistency 
Combined* 0.65 10/10 
Uganda 0.67 10/10 
Tanzania 0.58 10/10 
*adjusted for cohort of origin 
 
B) 
Cohort Testing balanced accuracy Cross-validation consistency 
Combined* 0.62 10/10 
Uganda 0.66 10/10 
Tanzania 0.59 10/10 
*adjusted for cohort of origin 
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Figure 5-1. Three locus MDR model of variants in or near IL12B (rs4921437), TNF-α 
(rs2242656), and CR1 (rs2940252) in A) the combined cohort, B) the Ugandan cohort, and C) 
the Tanzanian cohort; each cell is labeled with counts of the listed allele and represents a three 
variant haplotype that is designated as “high risk” or “low risk” based on a hypothetical 
distribution of cases (left bar in cell) and controls (right bar in cell) 
 
A) 
 
 
B) 
 
 
  
 
High-Risk 
Low-Risk 
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C) 
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Logistic Regression  
 
In the combined cohort, logistic regression of TB disease status was modeled with cohort 
of origin, rs4921437, rs7737692, and an interaction between the SNPs. Cohort of origin and 
variant rs4921437 were significant in this analysis (p values = 1.91x10
-21
 and 3.32x10
-5
, 
respectively), while rs7737692 and the interaction term were not (p values = 0.27 and 0.24, 
respectively). 
To follow up on the top MDR three-locus interaction model in the combined cohort, 
logistic regression of TB disease status was modeled with cohort of origin, rs4921437, 
rs2242656, rs2940252, all possible two locus interactions and an interaction between the three 
SNPs. Cohort of origin and variant rs4921437 were significant in this analysis (p values 7.51x10
-
20
 and 0.009, respectively), while variants rs2242656, rs2940252, and two-locus interactions 
rs2940252*rs4921437,  rs2940252*rs2242656, rs4921437*rs2242656 were not (p values = 0.23, 
0.79, 0.69, 0.48, and 0.37, respectively). The three-locus interaction term was nearly significant 
(Odds ratio = 2.04, 95% = CI 0.90-4.63, p value = 0.087). The minor, protective allele of 
rs4921437 described in Chapter III had a similar resistance effect in this model (Odds ratio = 
0.37, 95% CI = 0.18-0.78).  
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Discussion 
 
The most significant three locus model was found for variants from all candidate genes, 
namely rs4921437 near IL12B on chromosome 5, rs2242656 near TNF-α on chromosome 6, and 
rs2940252 near CR1 on chromosome 1. The functions of IL12 and TNF-α are complementary 
and in some instances redundant. The product of IL12B is a subunit of cytokines IL12 and IL23, 
secreted by macrophages and dendritic cells. IL12 causes differentiation of naïve T cells into TH1 
cells and stimulates interferon-gamma production from T cells and natural killer cells
103,104
. In 
the initial response to MTB infection, TNF-α potentiates the inflammatory response by recruiting 
macrophages and CD4+ T cells to the site of the infection
165
. TNF-α is also essential in the long-
term containment of MTB, as it is necessary in the formation and maintenance of the 
granuloma
165
. TNF-α signaling is used in the granuloma to induce apoptosis, which prohibitive 
to bacterial growth
166
. Since there is some redundancy in TNF-α and IL12 function, it is possible 
that diminished production of one could be compensated by the overexpression of the other 
leading to the observed interaction. Complement receptor 1, the product of CR1, is important in 
the phagocytosis of MTB by macrophages
167
. It is, therefore, essential in both the establishment 
of an MTB infection and in the initiation of an innate immune response. Antibodies against CR1 
substantially decrease MTB macrophage adherence
167
.  
The IL12B, TNF-α, CR1 interaction was identified in the analyses of the combined 
cohort; separate analyses of the Ugandan and Tanzanian participants demonstrate that the cross 
validation and testing accuracy replicated, which is rare in studies of epistasis. The three way 
interaction term was significant with a p value <0.001 in the MDR permutation testing and was 
nearly significant in logistic regression analyses. There are several possible reasons for this 
disparity. MDR is a model free, non-parametric approach to studying epistasis
18
. It uses 
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combinatorial-partitioning to reduce the genetic predictor space to a one dimensional variable, 
which allows for its use in small study populations without loss of power due to increasing the 
degrees of freedom
18
. Since a logistic regression model for a three-way interaction requires the 
inclusion of each possible two-way interaction, the number of degrees of freedom increases. 
Furthermore, empty cells, which are frequent in the study of higher-order interactions, inflate the 
standard errors during this estimation, and statistical significance becomes difficult to attain, 
especially in smaller studies
168
.       
The most significant two-locus interaction was found for variants on chromosome 5 only, 
rs4921437 near IL12B and rs7737692 near SLC6A3. The genes are ~157 megabases apart and 
the proteins they encode for appear functionally disparate, as no interactions have been reported 
in BioGRID. SLC6A3 encodes a transporter for the neurotransmitter dopamine. While the gene 
has been previously associated with MTB infection, no mechanism of action with respect to TB 
disease has been proposed
12,14
. Since the SLC6A3 product is a transmembrane protein involved in 
the removal of dopamine from the synaptic cleft, any direct interaction with IL12 is unlikely 
given current knowledge. This dopamine transporter has also been associated with addictive 
behavior, including tobacco use, and neoplasms in the lungs
169,170
. The testing accuracy of the 
identified IL12-SLC6A3 interaction was very good in the combined cohort, and the Ugandan 
cohort; however it was slightly higher than what is expected by chance in the Tanzanian cohort; 
therefore this might not be a true replication. The interaction term between rs4921437 and 
rs7737692 was not statistically significant in follow up logistic regression analyses.  
When we removed the SNP with the strongest main effect, rs4921437, none of the 
models in the combined cohort produced testing accuracy >0.60 or cross validation consistency 
>4 out of 10. Of note, the two-locus model rs3129943 and rs12788021 had good MDR metrics in 
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the Ugandan cohort, but did not replicate in Tanzania. Since epistasis studies often do not 
replicate, we evaluated the possible biological consequences of this interaction. Variant 
rs3129943 is in the HLA-DRA region on chromosome 6 which encodes for the DR alpha chain of 
the HLA class II major histocompatibility complex cell surface receptor. MHC class II receptors 
are present on macrophages and other antigen presenting cells, and they present foreign peptides 
to CD4+ helper T-cells which eventually leads to the production of antibodies against the peptide 
protein it is derived from
22
. HLA-DR is a heterodimer comprised of an alpha and beta subunit. 
The beta subunit has multiple variants, but the alpha protein is invariable in humans
64
. 
Polymorphisms in this receptor play a role in dictating the specificity, extent and type of T cell 
response to MTB
171
. The other variant in this interaction, rs12788021, is near TIRAP on 
chromosome 11. TIRAP is an adapter molecule downstream of Toll-like receptors, used in the 
MTB context to activate a cytokine response leading to the fusion of an endosome and a 
lysosome
20
. TLRs are important in eliminating MTB in the upper respiratory system because 
they are activated by the presence of commensal bacteria
20
. Once MTB is in the alveolar spaces, 
TLRs contain chronic MTB infection
172,173
. The interacting variants in this analysis are both 
involved in the chronic containment of tuberculosis. This aspect of immune response to MTB is 
particularly important in HIV-positive patients.  
In summary we found significant two and three-variant interactions in HIV-positive 
tuberculosis cases and controls from Uganda and Tanzania. Importantly, the three-locus 
interaction of variants near IL12B, near TNF-α, and near CR1 was consistent in both cohorts, 
which is rare in studies of epistasis. Functional follow-up analyses are necessary to evaluate the 
effects we observed with MDR. 
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B. Multifactor Dimensionality Reduction Analysis of Host Resistance to Mycobacterium 
tuberculosis Infection 
 
Introduction 
 
One in three people have been infected with Mycobacterium tuberculosis (MTB)
2,119
. 
Many individuals who remain uninfected live in highly endemic areas, virtually guaranteeing 
exposure to the bacteria.  The tuberculin skin test (TST) is the standard for assessing exposure to 
MTB. TST measures delayed type hypersensitivity to a purified protein derivative; thereby 
assessing whether a person has immune memory from an MTB exposure
21
. There are three major 
ways to remain TST negative given an exposure to M. tuberculosis: MTB can be inhaled but 
mechanically prevented from seeding the lungs, it can seed the lungs but be cleared before 
immune memory is invoked, or it can establish a latent infection but host immunosuppression 
can lead to a false negative result
21
. We hypothesize that the clearance of MTB either before or 
after it reaches the alveolar spaces of lungs has a genetic component with a complex architecture. 
To date, studies of MTB infection genetics have predominantly used single SNP association 
approaches or genome-wide linkage, assuming detectable single locus effects
12,13
. Identifying the 
genetic variants associated with MTB infection predisposition/resistance is of great global health 
importance. 
The immune response to an MTB infection is complex; therefore, it is likely that single 
variants cannot account for most of the heritability observed in the MTB infection phenotype. 
We used two recently concluded prospective cohorts of tuberculosis from Uganda and Tanzania 
to evaluate epistatic effects on MTB infection. Study design and available immunological data 
were leveraged to assure that all patients in this analysis have been exposed to MTB, and that 
immunosuppression did not confound the results with false negative data. We used a two-tiered 
approach leveraging candidate genes for studying epistasis. First, we studied effects for all 
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variants on the same chromosome. We then applied a filter to lower the number of included 
variants and studied interactions between all candidate genes within and among chromosomes. 
The first step served to reduce the number of potentially interacting variants along a 
chromosome, effectively identifying key SNPs on each, and the second to reduce the total 
number of total comparisons made.  
 
Methods 
 
Study Populations 
 
 The participants of the Household Contact Study and the extended follow up of the 
DarDar vaccine trial used in the genome-wide association study of resistance to Mycobacterium 
tuberculosis infection in Chapter IV were used to carry out this aim. Individuals who reported 
prior tuberculosis disease but had a negative TST result were removed from this analysis. 
  
Candidate Gene Selection 
 
We used a candidate gene approach selecting variants with a minor allele frequency > 
0.05 in genes (+/- 100 kb of coding region) and regions previously associated with MTB 
infection. The candidate gene/region list is comprised of the dopamine neurotrasporter SLC6A3, 
the proton-coupled divalent cation pump SLC11A1, and regions on chromosomes 2q14, 2q21-
q24, 5p13-q22, and 11p14. The SLC25A48/IL9 region associated with MTB infection in Chapter 
IV Part A was included in this analysis.  
 
Multifactor Dimensionality Reduction 
 
Binary tuberculin skin test status (induration size < versus ≥ 5mm) was used as the 
outcome in this study. The MDR modeling and variant selection criteria were the same as those 
described in Chapter V Part A. Follow up logistic regression analyses were also carried out in 
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STATA(v11.2)
73
, and BioGRID(v3.3)
164
 was used to assess prior evidence of interactions, as 
described in Part A.  
 
Results 
 
Single chromosome analyses 
 
The two-locus interaction between rs931709 and rs877356 was the only multilocus 
model (>1 variant) that met our criteria for follow up in the combined cohort analysis of variants 
from the same chromosome (Table 5-3A, Figure 5-2). The testing accuracy of this model was 
0.65, and the cross-validation consistency was 10 out of 10. When we used cohort of origin as a 
covariate, instead of adjusting for it, the testing accuracy was 0.66, and the cross-validation 
consistency was 10 out of 10 (Appendix Table 5-4A). In the Ugandan cohort the rs931709-
rs877356 model had a testing accuracy of 0.65 and in Tanzania it had a testing accuracy of 0.64. 
The cross-validation consistency was at 10 out of 10 in both cohorts. Examining the high and 
low risk two-locus genotypes, it is apparent that there is substantial consistency across these 
locations. The permutation test p value for the top two-locus model in the combined cohort was 
estimated to be 0.003-0.004. 
Chromosome 5 analyses omitting rs877356 did not produce two-locus results with a cross 
validation consistency greater or equal to 8 out of 10 (Appendix Table 5-5A). An interaction 
between rs12515850, rs981883, and rs17169129 had a testing accuracy of 0.66 and a cross-
validation consistency of 9 out of 10 in the combined cohort (Appendix Table 5-5B). However, 
the model did not meet the replication criteria in the Ugandan and Tanzanian cohorts when 
analyzed separately.  
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Table 5-3. MDR metrics of top loci and interactions associating with MTB infection for variants 
on the same chromosome in A) the combined*, B) the Ugandan, and C) the Tanzanian cohort 
 
A) 
Variant Combinations Chr. 
Attribute 
Count 
Balanced 
Accuracy 
Training 
Balanced 
Accuracy 
Testing 
Cross 
Validation 
Consistency 
rs2521933 2 1 0.59 0.59 10/10 
rs877356 5 1 0.64 0.64 10/10 
rs931709,rs877356 5 2 0.65 0.65 10/10 
rs10833965 11 1 0.59 0.59 10/10 
*adjusted for cohort of origin 
 
B) 
Variant Combinations Chr. 
Attribute 
Count 
Balanced 
Accuracy 
Training 
Balanced 
Accuracy 
Testing 
Cross 
Validation 
Consistency 
rs2521933 2 1 0.61 0.58 9/10 
rs877356 5 1 0.65 0.65 10/10 
rs931709,rs877356 5 2 0.67 0.65 10/10 
rs1835874,rs877356 5 2 0.67 0.63 9/10 
rs10833965,rs922858 11 2 0.70 0.61 8/10 
rs10833965 11 1 0.65 0.62 9/10 
 
C) 
Variant Combinations Chr. 
Attribute 
Count 
Balanced 
Accuracy 
Training 
Balanced 
Accuracy 
Testing 
Cross 
Validation 
Consistency 
rs4848628 2 1 0.61 0.59 9/10 
rs877356 5 1 0.62 0.62 10/10 
rs1835874,rs877356 5 2 0.67 0.63 9/10 
rs931709,rs877356 5 2 0.64 0.64 10/10 
rs17306503 11 1 0.56 0.51 8/10 
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Figure 5-2. Two locus MDR model of variants associating with MTB infection in or near IL9 
(rs877356), and SLC6A3 (rs931709) in A) the combined cohort, B) the Ugandan cohort, and C) 
the Tanzanian cohort; each cell is labeled with counts of the listed allele and represents a two 
variant haplotype that is designated as “high risk” or “low risk” based on a hypothetical 
distribution of cases (left bar in cell) and controls (right bar in cell) 
 
A) 
 
 
 
B) 
 
 
  
 
High-Risk 
Low-Risk 
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C) 
 
  
96 
 
Analyses of variants in all candidate genes 
 
A three-variant interaction between SNPs rs877356, rs2521933, and rs17597967 had the 
best MDR metrics in analyses of all candidate genes (Table 5-4, Figure 5-3). The testing 
accuracy was 0.68 in the combined cohort, 0.73 in Uganda, and 0.60 in Tanzania. Cross-
validation consistency was 10 out of 10 in each cohort individually and in the combined analysis. 
The permutation test p value for this three-locus model in the combined cohort was estimated to 
be <0.001. When we used cohort of origin as a covariate in the combined cohort analysis, instead 
of adjusting for it, the testing accuracy was 0.67, and the cross-validation consistency was 10 out 
of 10 (Appendix Table 5-4B). 
Analyses omitting rs877356 in the combined cohort did not result in any two or three-
locus model meeting the prerequisite MDR metric criteria for permutation test follow up. A two-
locus model rs6865443 and rs10833965 had a testing accuracy of 0.65 and a cross-validation of 
8 out of 10 in the Tanzanian cohort, but similar effects were not observed in the Ugandan cohort 
(Appendix Table 5-6).  
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Table 5-4. MDR metrics of the top model using all candidate gene variants associating with 
MTB infection in or near IL9 (rs877356), RAB6C (rs2521933), and SLC6A3 (rs17597967) 
 
Cohort 
Training balanced 
accuracy 
Testing balanced 
accuracy 
Cross-validation 
consistency 
Combined* 0.70 0.68 10/10 
Uganda 0.74 0.73 10/10 
Tanzania 0.68 0.60 10/10 
*adjusted for cohort of origin 
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Figure 5-3. Three locus MDR model of variants associating with MTB infection in or near IL9 
(rs877356), RAB6C (rs2521933), and SLC6A3 (rs17597967) in A) the combined cohort, B) the 
Ugandan cohort, and C) the Tanzanian cohort; each cell is labeled with counts of the listed allele 
and represents a three variant haplotype that is designated as “high risk” or “low risk” based on a 
hypothetical distribution of cases (left bar in cell) and controls (right bar in cell) 
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B) 
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C) 
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Logistic Regression 
 
In the combined cohort, logistic regression of MTB infection status was modeled with 
cohort of origin, rs877356, rs931709, and an interaction between the SNPs. Variants rs877356, 
rs931709 and cohort of origin were significant in this analysis (p values = 2.55x10
-5
, 0.042 and 
1.91x10
-21
, respectively), while the interaction term was not (p value = 0.24). 
To follow up on the top MDR three-locus interaction model in the combined cohort, 
logistic regression of MTB infection status was modeled with cohort of origin, variants 
rs877356, rs2521933, and rs17597967, all possible two-variant interaction terms and an 
interaction between the three SNPs. Cohort of origin, variant rs2521933, and the two-SNP 
interaction rs2521933*rs17597967 were significant in this analysis (p values = 1.64x10
-17
, 
2.43x10
-4
, and 0.044 respectively), while variants rs17597967, rs877356, two-locus interactions  
rs2521933*rs877356, rs877356*rs17597967, and the three-way interaction term were not (p 
values = 0.54, 0.15, 0.98, 0.12, and 0.44, respectively).  
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Discussion 
 
In analyses of variants on the same chromosome, the two-locus interaction between 
rs931709 and rs877356 had the best MDR metrics and a permutation p value <0.05. Variant 
rs931709 is near SLC6A3, a gene encoding a dopamine transporter previously associated with the 
phenotype
12,14
. No mechanism was proposed for how SLC6A3 affects MTB infection, although 
its deletion in mice has been associated with diminished delayed type hypersensitivity
174
.  
Variant rs877356 is in the newly discovered IL9 region, described in detail in Chapter IV Part A. 
Briefly, we posit that this polymorphism is associated with bronchial hyperresponsiveness. The 
over-reactive airway allows for MTB to be sequestered in the upper airway where microbicidal 
macrophages kill the bacteria before it can seed the alveolar spaces and multiply
20
. The lack of 
mechanistic information on the role of SLC6A3 prevents us from making an informed 
speculation about the nature of this interaction.  
In analyses of all available variants, a three-locus interaction between rs877356 near IL9 
on chromosome 5, rs2521933 in the 2q21 region, and rs17597967 near SLC6A3 had the most 
consistent results. The roles of IL9 and SLC6A3 have been discussed above. The closest gene to 
rs2521933 is RAB6C (~0.5mb away), which encodes for RAS-related protein Rab6C. This 
protein has been shown to interact with p53 and generate a pro-apoptotic phenotype in human 
cells
175
. While necrosis of macrophages furthers the spread of MTB, the apoptotic pathway limits 
the spread of the bacteria making RAB6C a possible candidate for preventing infection.  
Both the two and three-locus interactions identified here were consistent between the 
Ugandan and Tanzanian cohorts. Logistic regression analyses failed to validate these findings; 
however, this is expected considering the small sample size used in this study. A major obstacle 
in evaluating the potential effects of these interactions is the lack of well-defined gene targets in 
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the prior studies. The known loci associating with MTB infection are not as well defined as those 
for TB disease; therefore biological interpretation of significant interactions is more speculative. 
Even though biological mechanisms cannot be completely understood from these results, they 
suggest that preventing MTB infection occurs both on a macro level, with airway inflammation 
preventing the bacteria from reaching the lower lungs, and a micro level, with stimulation of 
genes which induce apoptosis of the infected macrophages.   
103 
 
CHAPTER VI 
GENETICS OF SRL 172 VACCINE RESPONSE 
 
 
 
Introduction  
 
The SRL 172 vaccine is the only placebo-controlled vaccine to show efficacy in 
preventing adult onset tuberculosis in HIV-positive patients
17
. In patients with a childhood BCG 
vaccination, the SRL 172 vaccine was shown to provide a 39% protection from definite 
tuberculosis.
 
Details of the vaccine trial, patient population and diagnostic criteria were reported 
in von Reyn et al
17
. Briefly, the vaccine trial recruited HIV-positive adults from Dar es Salaam, 
Tanzania, with CD4 cell counts >200 cells/mm
3
. Patients were randomly assigned into a placebo 
(n = 1007) and vaccine (n = 1006) arm, and were followed up every 3 months. Diagnoses of 
active tuberculosis were assessed via a thorough evaluation comprised of a physical examination, 
a chest radiograph, three sputum samples for staining and culture, as well as an automated 
mycobacterial blood culture. The biological determinants of the effectiveness of this 5 dose 
booster vaccination are still unclear. 
We hypothesized that human genetic variants influence the efficacy of the inactivated 
SRL 172 whole cell vaccine in preventing definite tuberculosis in an HIV-positive population 
living in an area endemic for Mycobacterium tuberculosis.  
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Methods 
 
Study population 
 
The original DarDar vaccine trail was concluded in 2008. At the time of our project 
design, surveillance of a 1535 patient extended follow up group continued. The number of 
patients in the DarDar extended follow up cohort who received the full regimen of SRL 172 
vaccine was 761, 17 of whom developed definite tuberculosis, and 50 who developed definite or 
probable tuberculosis. A priori power analyses were carried out in Quanto
72
.  
 
Statistical analyses 
 
The number of cases was prohibitive of a genome-wide association approach. We 
proposed a candidate gene approach, using the variants described in Chapter V, to assess whether 
genetic variants in the M. tuberculosis associated genes influence the efficacy of the vaccine. 
Using subjects who received the full regimen of 5 vaccine doses, we proposed logistic regression 
analyses to test for genetic differences between those who did and did not develop definite 
tuberculosis during the trial. Age, gender, and principal components calculated from available 
genetic data were proposed as relevant covariates. Linear regression analyses using the same 
independent variables, but enrollment level corrected IFN-γ levels as the dependent variable 
were proposed as a secondary outcome. 
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Results 
 
A summary of the a priori power analyses, assuming recruitment of all available cases of 
tuberculosis in the vaccine arm, is presented in Table 6-1A. Prior to recruitment, we were 
underpowered to pursue the aim of evaluating the genetic determinants of the effectiveness of the 
SRL 172 booster vaccine on the primary outcome of the DarDar vaccine trial, definite 
tuberculosis, as it required an odds ratio >5. We were, however, adequately powered to study the 
secondary DarDar vaccine trial outcome, a combined probable and definite tuberculosis outcome 
variable. We deemed an odds ratio of 2.5 reasonable enough to pursue this aim, especially since 
data were available and it did not require any additional clinical tests. This was the first study of 
the genetics of TB vaccine response; therefore we did not have an expected estimate of effect 
size in this study. 
The recruitment of DarDar extended follow up participants into this study occurred 
between August and December of 2013, five years after the conclusion of the vaccine trial. We 
recruited 151 patients from the vaccine arm of the DarDar trial, and 153 patients from the 
placebo arm. Importantly, only 4 of the recruited patients who finished the 5 dose regimen of the 
SRL 172 vaccine had definite tuberculosis during the trial. The case number increases to 14 if 
the phenotype is adjusted to include patients who developed either definite or probable 
tuberculosis. Following recruitment, we carried out a power analysis to determine the effect size 
needed to identify a single SNP association (Table 6-1 B). We found that an odds ratio >5 would 
have to be present for either definite tuberculosis, or definite/probable tuberculosis. A multiple 
testing adjustment would further lower the power of this approach. 
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Table 6-1. Odds ratio estimates for SRL 172 vaccinogenetics assuming an additive genetic 
model, an alpha level of 0.05, a minor allele frequency of 0.2, and 80% power in an A) a priori 
and B) post recruitment power analyses 
 
 A)  
Case definition Controls Cases Power Alpha Effect Size  
Definite TB 761 17 0.8 0.05 >5 
Definite or Probable TB 761 50 0.8 0.05 2.5 
 
B) 
Case definition Controls Cases Power Alpha Effect Size  
Definite TB 761 4 0.8 0.05 >5 
Definite or Probable TB 761 14 0.8 0.05 >5 
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Discussion 
 
We were unable to recruit enough cases in the vaccine arm of the DarDar trial to carry 
out this aim. The possible reasons for loss to follow up are manifold. Patients could have moved 
away from Dar es Salaam and a return to clinic was no longer feasible. Available contact 
information for patients or family members might have become obsolete. Given their HIV status, 
it is also possible that participants succumbed to tuberculosis or other AIDS diseases. 
We decided not to perform any association analyses for this aim due to the limitations of 
statistical comparisons with the available sample. Furthermore, even in the unlikely event that 
we found a SNP with an odds ratio large enough to be significant at a multiple-testing corrected 
level, we did not believe that a strong enough case about the importance of such an association 
could be made given either only 4 or 14 cases.    
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CHAPTER VII 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
A. Summary and Significance 
 
Mycobacterium tuberculosis is the second leading infectious cause of death from a single 
agent
1,2
. While the annual incidence of tuberculosis has remained constant in recent years, the 
burden of disease is very high and increases in the number of multidrug resistant tuberculosis 
necessitate novel pharmacological solutions
1,2
. Studies of genetic determinants of both 
tuberculosis disease and MTB infection provide promising drug and vaccine targets. This is 
especially important as evolution of MTB renders current treatment modalities obsolete.    
We proposed to study the genetics of an extreme TB resistance phenotype, to both 
disease and infection, as opposed to the more standard approaches tailored towards finding loci 
associated with susceptibility. We presented a novel approach to carrying out genome-wide 
association studies, also applicable to whole genome sequencing studies, where the use of an 
extreme resistance phenotype allowed us to identify large effect sizes and attain genome-wide 
significance in a relatively small sample size. The use of HIV status as a central feature of our 
hypothesis as opposed to a confounder or exclusion criterion is also unique to these studies.  
In Chapter III, we hypothesized that immunocompromised individuals living in MTB 
hyperendemic areas who do not develop TB disease represent an extreme resistance phenotype. 
Within our HIV-positive cohorts we found a genome-wide significant association of a common 
variant, rs4921437, with TB resistance in the IL12B region previously associated with 
susceptibility to disease. The effect size estimated for rs4921437 in the combined cohort (Odds 
ratio 0.3745) is larger than all previously associated common variants, a result detected with a 
sample size far below generally-accepted GWAS power criteria
10,11
. Furthermore, when we 
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imputed variants in the region, we discovered that the strongest association signal was indeed in 
close proximity and in linkage disequilibrium with rs4921437, and annotation of the region 
revealed a histone H3K27Ac mark encompassing both SNPs. We speculate that our resistance 
genotypes modulate this active enhancer element and lead to increased expression of IL12B. We 
also performed haplotype association analyses, and the most significant three-variant haplotype 
in the region was comprised of rs4921437, an intergenic SNP, and a variant in an intron of 
IL12B. We noticed substantial concordance of linkage disequilibrium patterns in patients from 
the Ugandan and Tanzanian cohorts in this genomic region, which is unusual for African, and 
especially East African populations. Using genetic data with denser coverage from nearby 
populations, we also demonstrated that the IL12B region has undergone selection. It is pertinent 
to point out, however, that due to the pleiotropic effects of the IL12 cytokine, we cannot 
definitively state that the observed signature of selection is a result of pressure from tuberculosis 
alone, as IL12 plays a role in the response to other infections. In conclusion, results from this 
chapter are noteworthy because they reveal an important novel association of resistance to TB 
with common variation in a putative regulatory region of IL12B, and also because they serve as a 
proof of principle for the utility of extreme phenotypes in genetic association studies.  
Rates of tuberculosis in Africa are high because of very high prevalence of HIV. 
Globally, most cases of tuberculosis are observed in Asia. We posit that if rs4921437 modulates 
IL12B and the variant is, therefore, truly protective, its absence of the protective allele in East 
Asia is at could be partially responsible for the high incidence of disease there despite low HIV 
rates. Furthermore, the IL12 cytokine is available as a pharmacological agent, experimentally 
used as an injectable therapy in cancer treatment. Therefore, our discovery of a protective role of 
IL12 suggests an alternative indication for the cytokine as a possible treatment modality for 
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active TB, which hypothetically would be most useful in Asia. Further studies of IL12 safety in 
cells and animal models as well as its effectiveness as an inhalant are merited.  
In Chapter IV, we hypothesized that HIV-positive individuals living in MTB 
hyperendemic areas who do not get infected with MTB also represent an extreme resistance 
phenotype. The MTB infection phenotype is nuanced in the HIV-positive patient population 
because immunosuppression can generate false negative results of the tuberculin skin test 
diagnostic. We were able to leverage additional immune data available in our patient populations 
and exclude those with suspected immune anergy to minimize confounding by 
immunosuppression. Part A of this chapter describes a genome-wide association study of both 
binary and continuous TST outcomes. We found a genome-wide significant association of a 
resistance variant, rs877356, with both the continuous and binary infection related outcomes. 
Variant rs877356 is near IL9, a gene with a substantial role in airway inflammation, bronchial 
asthma, and other respiratory infections. This is an exciting discovery, as observational studies of 
the inverse incidence of asthma and tuberculosis have been reported
133
. We speculate that over 
expression of IL9 prevents MTB infection by the same mechanism that leads to constitutive 
inflammation of the upper airway in the pathogenesis of asthma. MTB sequestered in the upper 
airway is killed by microbicidal macrophages, and is unable to establish a latent infection
20
. 
Of note, the MTB infection resistance variant, rs877356, was not significant at even the 
0.05 level in conferring resistance from active TB disease in Chapter III, with a p value of 0.537 
and an odds ratio of 0.907. While the odds ratio is still protective, this weak effect size for TB 
disease is not surprising. Over two billion people have been infected with MTB worldwide, but 
only about 10% will develop active TB over the course of their lifetime. Therefore, it stands to 
reason that the variants affecting infection differ from those modulating disease.  
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In Part B of Chapter IV, we used regression to fine map genes and regions previously 
associated with MTB infection through genome-wide linkage studies. We found variant 
rs10834029, in the chromosome 11p14 region, to be significantly associated with MTB infection 
using a multiple testing corrected adjustment for the number of independent SNPs in the 
region
115
. The position of the variant also overlaps with the second highest LOD score observed 
in the original study
12
. GAS2 is the closest gene to the SNP, and it plays a role in the induction of 
apoptosis. Programmed cell death deprives MTB of the intracellular nidus for infection; 
therefore this is a promising candidate for follow up. Overall, the fine mapping follow up was 
hindered by the broad target ranges defined in the original studies. The conventional 0.05 
statistical threshold for replication could not be used on account of type I error inflation, while a 
conservative Bonferroni adjusted threshold for SNPs in each region could not be attained.  
The immune response to both MTB infection and resultant TB disease is multifaceted, 
and the cells types, cytokines, and even affected tissues change during the course of the disease. 
It is, therefore, likely that single locus associations are not adequate to explain these phenotypes. 
In Chapter V, we used multifactorial dimensionality reduction software to explore higher order 
interactions between variants in candidate genes as they pertain to TB disease and MTB 
infection. In Part A of the chapter, looking at the genetic architecture of TB disease, we found a 
three way interaction between variants near IL12B, TNF-α, and CR1. The products of IL12B and 
TNF-α have some redundant and some concordant effects in the inflammatory response to MTB; 
therefore, their interaction is biologically plausible. CR1 plays a role in phagocytosis of MTB by 
macrophages, which is also a key step in immune response to MTB. Importantly, this interaction 
was consistent in the Ugandan and Tanzanian cohorts, which is rare in studies of epistasis. In 
Part B of the chapter, we evaluated higher order genetic architecture of MTB infection, and 
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found an interaction between variants near IL9, SLC6A3, and RAB6C. Of note, RAB6C interacts 
with p53 in a pro-apoptotic pathway; therefore it is a very good candidate for resistance to MTB 
infection. Unfortunately the mechanism of action of SLC6A3 as it pertains to MTB infection is 
still unclear.    
Statistical power considerations prevented us from studying genetic determinants of the 
SRL 172 vaccine, as briefly detailed in Chapter VI.  
 
B. Future Directions 
 
The findings of this project provide numerous avenues for follow up analyses. Based on 
the current and previous results, the role of the IL12B gene in tuberculosis pathogenesis appears 
to be well established; therefore further replication of this gene may not be necessary to 
substantiate its association with TB. However, the role of variants in or near the H3K27Ac mark 
has not been explored pertaining to TB disease. Since we posited that our genome-wide 
significant variants rs4921437 and rs10515780 might indeed be causal, a functional analysis 
relating variants in the H3K27Ac region to IL12B expression is a logical follow up. Since the 
histone mark was discovered in immunity related cell lines GM12878 and K562, from B-
lymphocytes and chronic myelogenous leukemia, respectively, they would be good candidates 
for initial functional experiments. Replication of the exact resistance loci we identified in 
different cohorts would also be suggestive of causality for variants in the region, especially in 
patient populations from different regions of the world. Deep resequencing of the IL12B region 
in our sample would allow us to evaluate any association of rare variants with TB. While we 
imputed the region to attain greater coverage, the procedure is not reliable for SNPs with very 
low minor allele frequencies, especially in non-European populations. Therefore, if the variants 
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we identified are in fact not causal, we would be able to discover other relevant SNPs by 
resequencing. Finally, it is also important to demonstrate that the rs4921437/H3K27Ac finding is 
consistent beyond the HIV-positive patient niche; therefore, replication in an HIV-negative 
population is worth pursuing. 
The association of variants in the IL9 region with resistance to MTB infection is a novel 
discovery; hence, follow up analyses examining this region are merited. Resequencing of the 
region is a logical follow up, as is a functional analysis of IL9 and SLC25A48 expression as it 
pertains to MTB infection, since either or both genes could possibly play a role in resistance. 
Again, replicating this association in cohorts from different populations and in an HIV-negative 
cohort would be optimal. A study linking variation in rs877356 with expression of IL9 or the 
other gene in the region, SLC25A48, would provide additional evidence that the variant is indeed 
causal and complement the suggested functional analyses.  
The epistatic effects discovered for both TB disease and MTB infection need to be 
corroborated in other cohorts. A functional analysis linking SLC6A3 to a mechanism of MTB 
infection resistance would facilitate interpretation of MDR results for these phenotypes. 
Candidate gene analyses of epistasis revealed that the replicating models in MDR include the 
best single hits from the TB disease and MTB infection studies, it is, therefore, a logical follow 
up assess the interaction of the respective large main effect SNPs with all other variants available 
on the chip. 
Finally, although we likely missed the window for recruiting the SRL 172 vaccine arm 
patients from the DarDar vaccine trial into our study, a new formulation of the vaccine is being 
tested. We plan to obtain blood samples and consent patients for genetic analyses on enrollment 
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into this study, which would guarantee a much larger sample size, and permit us to carry out the 
vaccinogenetics aim in the new cohort.    
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APPENDIX 
 
Appendix Table 3-1. Single nucleotide polymorphisms associating with active tuberculosis below a 5x10
-5
 p value in the combined 
cohort using a dominant model 
 
SNP CHR 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs4921437 5 T 0.21 0.34 (0.23, 0.50) 1.14E-07 UBLCP1/IL12B 
rs11652378 17 A 0.34 0.40 (0.27, 0.58) 2.21E-06 TUSC5 
rs10826834 10 C 0.32 2.48 (1.69, 3.62) 2.74E-06 LYZL2 
rs8028149 15 C 0.42 0.40 (0.27, 0.59) 4.93E-06 VPS13C 
rs12636260 3 T 0.26 2.42 (1.65, 3.54) 5.95E-06 ZPLD1* 
rs1537434 13 G 0.27 0.43 (0.29, 0.63) 1.73E-05 RPL21 
rs57568 2 G 0.41 0.42 (0.28, 0.62) 1.80E-05 LTBP1 
rs1437747 2 T 0.32 0.44 (0.30, 0.64) 1.81E-05 CAMKMT 
rs1616723 6 G 0.20 0.42 (0.28, 0.63) 2.03E-05 GLO1 
rs1525738 7 A 0.40 0.43 (0.29, 0.64) 2.31E-05 AGR3 
rs10938264 4 G 0.33 2.25 (1.54, 3.28) 2.79E-05 GRXCR1 
rs12693365 2 A 0.32 0.45 (0.31, 0.66) 3.77E-05 NUP35* 
rs844669 7 G 0.30 0.46 (0.32, 0.67) 4.89E-05 CALN1 
*>500kb away 
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Appendix Table 3-2. Single nucleotide polymorphisms associating with active tuberculosis below a 5x10
-5
 p value using a dominant 
model in the A) Ugandan and B) Tanzanian (rs4921437 added) cohorts 
 
A) 
SNP CHR 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs4921437 5 T 0.21 0.23 (0.12, 0.42) 3.68E-06 UBLCP1/IL12B 
rs859063 1 G 0.35 4.57 (2.40, 8.72) 4.01E-06 SLC44A3 
rs11800062 1 C 0.40 0.18 (0.084, 0.39) 1.58E-05 CDC42BPA 
rs11811176 1 G 0.47 0.13 (0.051, 0.33) 2.14E-05 CDC42BPA 
rs12429777 13 C 0.21 0.27 (0.15, 0.50) 2.40E-05 KLHL1 
rs293392 15 G 0.32 3.84 (2.04, 7.23) 3.17E-05 ABHD2 
rs2006724 6 G 0.47 3.93 (2.05, 7.55) 3.92E-05 BC035400 
rs2395300 6 A 0.25 4.13 (2.09, 8.13) 4.20E-05 HLA-DOA 
rs4724086 7 G 0.28 3.83 (2.01, 7.28) 4.23E-05 GLI3 
rs345397 7 A 0.22 0.28 (0.15, 0.51) 4.95E-05 SEPT7 
 
B) 
SNP CHR 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs9566115 13 T 0.48 0.26 (0.14, 0.48) 1.07E-05 SLITRK6 
rs8111608 19 A 0.33 3.39 (1.95, 5.89) 1.58E-05 SLC1A6 
rs11733040 4 G 0.26 0.28 (0.16, 0.50) 1.60E-05 PCDH18* 
rs557438 5 T 0.37 0.31 (0.18, 0.53) 1.63E-05 MCC 
rs2807348 1 C 0.26 0.30 (0.17, 0.52) 2.18E-05 WNT4 
rs1158059 6 T 0.20 3.09 (1.80, 5.29) 3.99E-05 SNAP91 
… … … … … … … … 
rs4921437 5 T 0.21 0.45 (0.26, 0.78) 4.66E-03 UBLCP1/IL12B 
*>500kb away 
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Appendix Table 3-3. Single nucleotide polymorphisms associating with active tuberculosis below a 5x10
-5
 p value using a recessive 
model in the A) combined, B) Tanzanian, and C) Ugandan cohort 
 
A) 
SNP CHR 
Minor 
Allele 
MAF Odds Ratio 
95% Confidence 
Interval 
p value Gene 
rs1573219 9 T 0.43 0.34 (0.20, 0.56) 2.29E-05 NTRK2 
rs3763787 10 A 0.33 0.25 (0.13, 0.48) 2.77E-05 ACBD7 
rs955263 4 T 0.34 3.41 (1.91, 6.06) 3.10E-05 SORBS2 
 
B) 
SNP CHR 
Minor 
Allele 
MAF Odds Ratio 
95% Confidence 
Interval 
p value Gene 
rs10521221 16 T 0.30 5.74 (2.55, 12.94) 2.49E-05 SALL1 
rs7797545 7 T 0.43 3.90 (2.07, 7.34) 2.57E-05 PKD1L1 
rs10203511 2 A 0.45 3.44 (1.92, 6.17) 3.41E-05 NRXN1 
 
C) 
SNP CHR 
Minor 
Allele 
MAF Odds Ratio 
95% Confidence 
Interval 
p value Gene 
rs1573219 9 T 0.43 0.19 (0.096, 0.40) 6.22E-06 NTRK2 
rs3763787 10 A 0.36 0.16 (0.064, 0.38) 3.51E-05 ACBD7 
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Appendix Table 3-4. Power calculation using a log additive model, a genetic effect of 2.0, a 
baseline risk of 0.1, an alpha of 0.05, and power of 0.8 in A) Uganda with a 2 to 1 case to control 
ratio and B) Tanzania with a 1 to 2 case to control ratio 
 
A) 
Minor allele frequency N cases needed 
0.05 203 
0.10 112 
0.15 82 
0.20 68 
0.25 60 
 
B) 
Minor allele frequency N cases needed 
0.05 432 
0.10 236 
0.15 172 
0.20 141 
0.25 124 
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Appendix Table 3-5. Summary of self-reported tribal membership in the Ugandan cohort 
  
Tribe Count 
Muganda 151 
Mutooro 10 
Mufumbira 8 
Mukiga 7 
Ankole 4 
Musoga 3 
Munyarwanda 5 
Tanzanian 3 
Muhororo 1 
Lugbara 2 
Soga 1 
Alur 2 
Lugwara 1 
Mwamba 1 
Munyoro 7 
Nyankole 7 
Rwandese 2 
Nkole 4 
Chapadhola 3 
Munyankole 7 
Langi 4 
Itesof 1 
Toro 1 
Acholi 1 
Kakwa 1 
Luo 1 
total n 238 
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Appendix Table 3-6. Association of principal components with self-reported tribal membership 
in the Ugandan cohort using logistic regression predicting Muganda versus other 
  
Variable OR 95% CI p value 
PC1 1.22E-13 (5.42E-17, 2.73E-10) 4.79E-13 
PC2 0.004 (4.50E-05, 0.34) 0.015 
PC3 0.002 (6.67E-06, 0.58) 0.032 
PC4 0.17 (0.0014, 22.08) 0.478 
PC5 1.07 (0.017, 65.17) 0.975 
PC6 7659 (80, 742677) 1.28E-4 
PC7 2.65E-04 (9.26-07, 0.076) 0.004 
PC8 4.97 (0.075, 330.09) 0.454 
PC9 1.40 (0.021, 92.46) 0.876 
PC10 0.12 (0.0016, 8.20) 0.322 
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Appendix Table 3-7. Single nucleotide polymorphisms associating with active tuberculosis below a 5x10
-5
 p value in the A) Ugandan 
and B) Tanzanian (rs4921437 also listed) cohorts 
 
A) 
SNP CHR 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs4921437 5 T 0.21 0.28 (0.17, 0.47) 1.18E-06 UBLCP1/IL12B 
rs7297313 12 C 0.34 0.35 (0.22, 0.55) 8.6E-06 GRIN2B 
rs859063 1 G 0.35 3.06 (1.82, 5.13) 2.40E-05 SLC44A3 
 
B) 
SNP CHR 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs2681052 7 T 0.39 2.65 (1.72, 4.09) 1.07E-05 THSD7A 
rs17048476 3 A 0.42 2.43 (1.62, 3.66) 1.91E-05 AK124857 
rs2587469 10 C 0.46 0.42 (0.28, 0.63) 2.26E-05 ADAMTS14 
rs9893385 17 G 0.47 0.41 (0.28, 0.62) 2.26E-05 ABCA8 
rs3860173 9 T 0.36 2.28 (1.56, 3.33) 2.27E-05 RGS3 
rs1524713 1 T 0.28 2.43 (1.59, 3.69) 3.47E-05 DAB1 
rs2807348 1 C 0.26 0.35 (0.22, 0.58) 3.48E-05 WNT4 
rs4700255 5 G 0.32 2.34 (1.56, 3.50) 3.87E-05 ACTBL2 
rs16870583 5 C 0.25 2.32 (1.55, 3.47) 4.35E-05 IRX2 
rs930205 5 G 0.29 2.39 (1.57, 3.64) 4.64E-05 SH3TC2 
rs557438 5 T 0.37 0.41 (0.27, 0.63) 4.70E-05 MCC 
… … … … … … … … 
rs4921437 5 T 0.21 0.48 (0.30, 0.79) 3.84E-03 UBLCP1/IL12B 
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Appendix Table 3-8. Association of imputed SNPs in the rs4921437 +/-1 mb window on chromosome 5 with active tuberculosis in 
the combined cohort  
 
SNP 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
Imputation 
Certainty 
Uganda 
Imputation 
Certainty 
Tanzania 
p value Gene 
rs10515780 C 0.19 0.34 (0.24, 0.49) 0.99 0.99 6.21E-09 intron UBLCP1 
rs4921437 T 0.21 0.37 (0.27, 0.53) Not Imputed Not Imputed 2.11E-08 intron UBLCP1 
rs56296726 A 0.18 0.37 (0.25, 0.53) 0.97 0.97 8.46E-08 ~6kb upstr. UBLCP1 
rs7736656 A 0.15 0.33 (0.22, 0.50) 0.97 0.97 9.32E-08 intron UBLCP1 
rs6895626 T 0.15 0.33 (0.22, 0.50) 0.97 0.97 9.32E-08 ~1kb dwnstr. UBLCP1 
rs73307745 G 0.14 0.35 (0.23, 0.53) 0.96 0.97 5.82E-07 ~2kb upstr. UBLCP1 
rs73307742 T 0.13 0.35 (0.23, 0.54) 0.96 0.97 1.21E-06 ~6kb upstr. UBLCP1 
rs200213893 INS 0.32 0.55 (0.42, 0.73) 0.97 0.97 3.88E-05 ~4kb upstr. UBLCP1 
rs10040411 C 0.46 0.57 (0.43, 0.74) 0.97 0.98 3.93E-05 ~54kb upstr. IL12B 
rs115740168 G 0.10 0.38 (0.24, 0.60) 0.95 0.96 4.39E-05 intron IL12B 
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Appendix Table 3-9. Association of imputed SNPs in the rs4921437 +/-1 mb window on chromosome 5 with active tuberculosis in 
the A) Ugandan and B) Tanzanian cohort 
 
A) 
SNP 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
Imputation 
Certainty Uganda 
p value Gene 
rs10515780 C 0.19 0.27 (0.16, 0.55) 0.99 9.92E-07 intron UBLCP1 
rs4921437 T 0.21 0.28 (0.17, 0.47) Not Imputed 1.18E-06 intron UBLCP1 
rs56296726 A 0.19 0.28 (0.17, 0.48) 0.97 3.49E-06 ~6kb upstr. UBLCP1 
rs6895626 T 0.15 0.27 (0.16, 0.48) 0.97 8.36E-06 ~1kb downstr. UBLCP1 
rs7736656 A 0.15 0.27 (0.16, 0.48) 0.97 8.36E-06 intron UBLCP1 
rs73307742 T 0.14 0.27 (0.15, 0.48) 0.96 1.25E-05 ~6kb upstr. UBLCP1 
rs115740168 G 0.11 0.22 (0.11, 0.44) 0.95 1.46E-05 intron IL12B 
rs73307745 G 0.15 0.29 (0.16, 0.51) 0.96 1.99E-05 ~2kb upstr. UBLCP1 
rs10077752 T 0.47 0.37 (0.24, 0.60) 0.99 3.97E-05 ~65kb upstr. UBLCP1 
  
B) 
SNP 
Minor 
Allele 
MAF 
Odds 
Ratio 
95% Confidence 
Interval 
Imputation 
Certainty Uganda 
p value Gene 
rs58574384 A 0.25 0.47 (0.29, 0.76) 0.86 0.0021 ~112kb downstr. UBLCP1 
rs10515780 C 0.18 0.43 (0.25, 0.74) 0.99 0.0021 intron UBLCP1 
rs56318149 A 0.18 2.00 (1.27, 3.15) 0.93 0.0027 ~200kb downstr. UBLCP1 
rs7736656 A 0.15 0.40 (0.22, 0.73) 0.97 0.0029 intron UBLCP1 
rs6895626 T 0.15 0.40 (0.22, 0.73) 0.97 0.0029 ~1kb downstr. UBLCP1 
rs6556400 T 0.16 2.07 (1.27, 3.37) 0.91 0.0036 ~111kb upstr. UBLCP1 
rs6883501 C 0.17 0.44 (0.25, 0.77) 0.95 0.0037 ~100kb downstr. UBLCP1 
rs4921437 T 0.21 0.48 (0.30, 0.79) Not Imputed 0.0038 intron UBLCP1 
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Appendix Table 3-10. Association of the rs4921437 and rs4921468 haplotype in A) the 
combined cohort, B) Tanzanian and C) Ugandan cohorts, and the rs4921437 and rs3213094 
haplotype in D) the combined cohort, E) Tanzanian and F) Ugandan cohorts 
 
A) 
Haplotype Case Control Ca-Freq Co-Freq 
C-A 102 108 0.19 0.17 
C-G 356 353 0.67 0.56 
T-A 4 7 0.01 0.01 
T-G 72 160 0.13 0.25 
Likelihood ratio chisq = 34.2397 df = 3 p-value = 1.76328E-007* 
 
B) 
Haplotype Case Control Ca-Freq Co-Freq 
C-A 42 87 0.21 0.18 
C-G 131 283 0.66 0.58 
T-A 0 4 0.00 0.01 
T-G 27 112 0.14 0.23 
Likelihood ratio chisq = 12.3668 df = 3 p-value = 0.00622658^ 
 
C) 
Haplotype Case Control Ca-Freq Co-Freq 
C-A 60 21 0.18 0.15 
C-G 225 70 0.67 0.50 
T-A 4 3 0.01 0.02 
T-G 45 48 0.13 0.34 
Likelihood ratio chisq = 39.023 df = 3 p-value = 1.71634E-008^ 
 
D) 
Haplotype Case Control Ca-Freq Co-Freq 
C-T 247 229 0.46 0.36 
C-C 211 232 0.40 0.37 
T-T 6 13 0.02 0.02 
T-C 70 154 0.13 0.24 
Likelihood ratio chisq = 37.3328 df = 3 p-value = 3.91261E-008* 
   
E) 
Haplotype Case Control Ca-Freq Co-Freq 
C-T 97 182 0.49 0.37 
C-C 76 188 0.38 0.39 
T-T 1 9 0.01 0.02 
T-C 26 107 0.13 0.22 
Likelihood ratio chisq = 14.8324 df = 3 p-value = 0.0019656^ 
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F) 
Haplotype Case Control Ca-Freq Co-Freq 
C-T 150 47 0.45 0.33 
C-C 135 44 0.40 0.31 
T-T 5 4 0.01 0.03 
T-C 44 47 0.13 0.33 
Likelihood ratio chisq = 45.0414 df = 3 p-value = 9.0671E-010^ 
 * adjusted for principal components, sex, and cohort of origin 
^ adjusted for principal components and sex 
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Appendix Table 3-11. Chi squared comparison of haplotypes between the study samples from 
Uganda and Tanzania with African origin samples from Phase 3 HapMap using A) rs4921437 
and rs3213094, B) rs4921437 and rs4921468, and C) rs4921437, rs3213094, and rs4921468 
 
A) 
Population 
Comparisons 
p value using full 
Ugandan, 
Tanzanian cohorts 
p value using 
Tanzanian, Ugandan 
cases only 
p value using for 
Tanzanian, Ugandan 
controls only 
Uganda v Tanzania 0.93 0.65 0.04 
Uganda v YRI 0.001 1.41E-06 0.066 
Tanzania v YRI 0.001 4.06E-05 0.016 
Uganda v LWK 0.91 0.25 0.028 
Tanzania v LWK 0.98 0.23 0.73 
Uganda v MKK 1.08E-05 2.12E-05 1.34E-06 
Tanzania v MKK 1.57E-05 3.96E-05 7.71E-05 
Uganda v ASW 0.077 0.016 0.039 
Tanzania v ASW 0.067 0.003 0.20 
 
B) 
Population 
Comparisons 
p value using full 
Ugandan, 
Tanzanian cohorts 
p value using 
Tanzanian, Ugandan 
cases only 
p value using for 
Tanzanian, Ugandan 
controls only 
Uganda v Tanzania 0.15 0.20 0.033 
Uganda v YRI 0.026 3.27E-05 0.81 
Tanzania v YRI 0.011 0.00019 0.20 
Uganda v LWK 0.65 0.13 0.024 
Tanzania v LWK 0.86 0.17 0.76 
Uganda v MKK 7.71E-08 1.23E-07 1.35E-06 
Tanzania v MKK 3.74E-06 0.001 3.79E-06 
Uganda v ASW 0.14 0.011 0.01 
Tanzania v ASW 0.50 0.065 0.48 
 
C) 
Population 
Comparisons 
p value using full 
Ugandan, 
Tanzanian cohorts 
p value using 
Tanzanian, Ugandan 
cases only 
p value using for 
Tanzanian, Ugandan 
controls only 
Uganda v Tanzania 0.12 0.085 0.088 
Uganda v YRI 0.002 3.98E-06 0.20 
Tanzania v YRI 0.002 6.14E-05 0.025 
Uganda v LWK 0.87 0.41 0.067 
Tanzania v LWK 0.30 0.12 0.17 
Uganda v MKK 2.34E-08 2.84E-08 7.14E-07 
Tanzania v MKK 2.52E-08 3.07E-06 3.1E-07 
Uganda v ASW 0.19 0.035 0.12 
Tanzania v ASW 0.24 0.024 0.46 
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Appendix Table 3-12. Chi squared comparison of haplotypes between the study samples from 
Uganda and Tanzania with non-African origin samples from Phase 3 HapMap using A) 
rs4921437 and rs3213094, B) rs4921437 and rs4921468, and C) rs4921437, rs3213094, and 
rs4921468 
 
A) 
Population 
Comparisons 
p value using full 
Ugandan, 
Tanzanian cohorts 
p value using 
Tanzanian, Ugandan 
cases only 
p value using for 
Tanzanian, Ugandan 
controls only 
Uganda v CEU 5.93E-10 7.42E-10 7.64E-08 
Tanzania v CEU 5.45E-10 1.71E-09 2.18E-08 
Uganda v CHB 1.57E-08 1.86E-05 7.37E-14 
Tanzania v CHB 1.57E-08 3.83E-05 2.16E-09 
Uganda v GIH 0.001 0.008 1.23E-06 
Tanzania v GIH 0.001 0.007 0.001 
Uganda v MEX NA NA NA 
Tanzania v MEX NA NA NA 
Uganda v TSI 2.95E-06 1.48E-05 9.93E-07 
Tanzania v TSI 3.58E-06 1.46E-05 1.61E-05 
Uganda v JPT 1.96E-09 5.32E-08 9.90E-16 
Tanzania v JPT 1.19E-09 1.03E-05 6.19E-11 
 
B) 
Population 
Comparison 
p value using full 
Ugandan, 
Tanzanian cohorts 
p value using 
Tanzanian, Ugandan 
cases only 
p value using for 
Tanzanian, Ugandan 
controls only 
Uganda v CEU 0.01 0.002 0.001 
Tanzania v CEU 0.14 0.11 0.067 
Uganda v CHB 4.62E-08 3.94E-05 1.45E-13 
Tanzania v CHB 1.02E-07 0.000665 4.6E-09 
Uganda v GIH 0.035 0.29 7.24E-06 
Tanzania v GIH 0.023 0.31 0.004 
Uganda v MEX 6.71E-05 0.002 7.6E-07 
Tanzania v MEX 3.62E-04 0.025 8.17E-05 
Uganda v TSI 8.79E-07 5.01E-06 2.19E-06 
Tanzania v TSI 1.77E-05 0.002 9.82E-06 
Uganda v JPT <1.1E-16 1.07E-11 <1.1E-16 
Tanzania v JPT <1.1E-16 1.01E-10 <1.1E-16 
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C) 
Population 
Comparisons 
p value using full 
Ugandan, 
Tanzanian cohorts 
p value using 
Tanzanian, Ugandan 
cases only 
p value using for 
Tanzanian, Ugandan 
controls only 
Uganda v CEU 1.99E-09 1.54E-09 1.7E-07 
Tanzania v CEU 1.49E-08 2.76E-08 1.32E-09 
Uganda v CHB 3.07E-09 9.26E-06 1.46E-12 
Tanzania v CHB 5.63E-07 0.001 8.32E-08 
Uganda v GIH 2.02E-05 0.001 4.65E-07 
Tanzania v GIH 3.23E-05 0.001 7.93E-05 
Uganda v MEX NA NA NA 
Tanzania v MEX NA NA NA 
Uganda v TSI 1.98E-07 9.2E-07 1.27E-06 
Tanzania v TSI 3.7E-07 1.88E-05 1.85E-06 
Uganda v JPT 1.05E-09 3.56E-06 2.12E-14 
Tanzania v JPT 4.31E-08 0.000249 1.52E-09 
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Appendix Table 3-13. Minor allele frequencies of rs4921437 in the HapMap Phase 3 
populations  
 
Population 
MAF (T allele) Proportion CC 
Proportion 
CT 
Proportion TT 
ASW 0.24 0.63 0.27 0.10 
CEU 0.20 0.63 0.33 0.04 
CHB 0.01 0.98 0.03 0 
GIH 0.13 0.77 0.21 0.02 
HCB 0.02 0.95 0.05 0 
JPT 0.01 0.99 0.01 0 
LWK 0.21 0.64 0.30 0.06 
MEX 0.07 0.86 0.14 0 
MKK 0.17 0.68 0.29 0.03 
TSI 0.16 0.70 0.29 0.01 
YRI 0.31 0.49 0.41 0.10 
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Appendix Table 3-14. Minor allele frequencies of rs4921437 in the 1000 Genomes Project 
populations 
 
Population Alleles C Alleles T Genotypes C|C Genotypes C|T Genotypes T|T 
All Populations 0.86 0.14 0.75 0.22 0.03 
ACB 0.79 0.21 0.62 0.34 0.04 
All African Populations 0.74 0.26 0.57 0.35 0.08 
All American Populations 0.90 0.11 0.81 0.16 0.02 
All East Asian Populations 1.00 0 1.00 0   
ASW 0.74 0.26 0.56 0.36 0.08 
BEB 0.84 0.16 0.67 0.33   
CDX 1.00   1.00     
CEU 0.80 0.20 0.63 0.34 0.03 
CHB 1.00 0.01 0.99 0.01   
CHS 1.00   1.00     
CLM 0.82 0.18 0.69 0.26 0.05 
ESN 0.73 0.27 0.53 0.40 0.07 
All European Populations 0.83 0.17 0.68 0.30 0.02 
FIN 0.87 0.13 0.76 0.23 0.01 
GBR 0.82 0.18 0.68 0.29 0.03 
GIH 0.89 0.11 0.81 0.17 0.03 
GWD 0.76 0.24 0.61 0.30 0.09 
IBS 0.80 0.20 0.63 0.35 0.03 
ITU 0.89 0.11 0.80 0.18 0.02 
JPT 1.00   1.00     
KHV 1.00   1.00     
LWK 0.83 0.17 0.70 0.26 0.04 
MSL 0.64 0.37 0.44 0.40 0.17 
MXL 0.93 0.07 0.86 0.14   
PEL 0.94 0.06 0.89 0.09 0.01 
PJL 0.87 0.14 0.75 0.23 0.02 
PUR 0.90 0.10 0.83 0.15 0.02 
All South Asian Populations 0.87 0.13 0.76 0.23 0.02 
STU 0.86 0.14 0.75 0.22 0.03 
TSI 0.79 0.21 0.62 0.34 0.04 
YRI 0.74 0.26 0.57 0.35 0.08 
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Appendix Table 3-15. 2 SNPs in the 0.1 percentile of the distribution of absolute values of 
normalized iHS scores in 2 African populations, along with corresponding values for rs4921437  
 
SNP |iHS| in the Datog |iHS| in the Niger 
Kordofanian West 
|iHS| in the Western 
Pygmy 
rs3213093 3.915 3.591 2.599 
rs2421047 3.088 3.616 2.636 
rs4921437 0.391 0.742 0.997 
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Appendix Table 3-16. DarDar vaccine trial CD4 count, Interferon Gamma Release Assay and Lymphocyte Proliferation Assay data 
in cases versus controls; B – baseline values, F – final values upon completion of the trial, pi – proliferation index 
 
Variable  n n cases TB cases mean (st. dev) n controls TB controls mean (st. dev.) p value 
CD4 count 288 36 580.78 (224.90) 252 540.68 (235.30) 0.34 
B IFN med 243 29 148.64 (211.20) 214 204.73 (471.08) 0.53 
B IFN pha 243 29 10778.93 (13367.56) 214 21028.32 (31904.27) 0.09 
B IFN mvs 243 29 201.36 (345.97) 214 334.20 (976.42) 0.47 
B IFN ag85 243 29 341.78 (482.99) 214 735.60 (2062.01) 0.31 
B IFN esat 240 29 1254.02 (3482.90) 211 1637.08 (6131.51) 0.74 
B IFN wcl 204 22 2748.05 (4200.48) 182 2145.87 (3855.69) 0.50 
B lam 304 36 0.4976 (0.32) 268 0.5040 (0.45) 0.93 
B lpa med 281 36 2154.06 (2513.33) 245 3774.52 (4787.78) 0.05 
B lpa pha 281 36 11163.05 (11912.21) 245 15313.85 (13652.40) 0.08 
B lpa mvs pi 281 36 1.85 (1.12) 245 1.71 (1.49) 0.58 
B lpa ag85 pi 281 36 3.91 (8.07) 245 2.68 (5.43) 0.24 
B lpa esat pi 279 36 2.58 (6.24) 243 2.47 (5.17) 0.91 
B lpa wcl pi 281 36 8.14 (15.20) 245 5.67 (10.76) 0.23 
F IFN mvs 204 22 203.67 (263.75) 182 445.67 (2008.17) 0.57 
F IFN ag85 204 22 387.38 (812.68) 182 536.79 (1319.86) 0.60 
F IFN esat 204 22 474.15 (1008.68) 182 952.11 (3359.77) 0.51 
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Appendix Figure 3-1. Locus zoom plot of IL12B region in the Ugandan cohort 
 
   
134 
 
Appendix Figure 3-2. Locus zoom plot of IL12B region in the Tanzanian cohort 
 
  
135 
 
Appendix Figure 3-3. QQ plot of logistic regression results using an additive model for the combined Ugandan and Tanzanian 
datasets 
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Appendix Figure 3-4. Manhattan plot of logistic regression using an additive model for the combined Ugandan and Tanzanian 
datasets. Red – genome-wide significance threshold.  
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Appendix Figure 3-5. Manhattan plot chromosome 5 only using an additive model for the combined Ugandan and Tanzanian 
datasets. Red – genome-wide significance threshold. 
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Appendix Figure 3-6. Locus zoom plot of IL12B region in the combined cohort 
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Appendix Figure 3-7. Haploview plots of D’ the IL12B region (94 kb range) in non-African 
Phase 3 HapMap populations A) CEU, B) CHD, C) TSI, D) GIH, E) JPT, F) MEX, and G) CHB 
A) 
  
B) 
  
C) 
  
D) 
  
 
 
E) 
  
F) 
  
G) 
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Appendix Figure 3-8. Extended Haploview plot of D’ in the IL12B region (433 kb range) in participants from the Uganda cohort 
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Appendix Figure 3-9. Extended Haploview plot of D’ in the IL12B region (433 kb range) in participants from the Tanzanian cohort  
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Appendix Figure 3-10. Minor allele frequencies of rs4921437, from the HGDP genome browser
116,117
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Appendix Table 4-1. Power calculation using a log additive model, a genetic effect of 2.0, a 
baseline risk of 0.33, an alpha of 0.05, and power of 0.8 in A) Uganda with a 3 to 1 case to 
control ratio and B) Tanzania with a 1 to 2 case to control ratio 
 
A) 
Minor allele frequency N cases needed 
0.05 699 
0.10 374 
0.15 267 
0.20 215 
0.25 185 
 
B) 
Minor allele frequency N cases needed 
0.05 240 
0.10 130 
0.15 94 
0.20 76 
0.25 66 
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Appendix Table 4-2. Single nucleotide polymorphisms associating with continuous tuberculin skin test induration below a 5x10
-5
 p 
value in a dominant genetic model in A) the combined cohort*, B) the Ugandan cohort^, and C) the Tanzanian cohort^  
 
A) 
SNP Chr. 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.23 469 -4.14 (-5.55, -2.74) 1.45E-08 SLC25A48/IL9 
rs7239554 18 A 0.28 469 -3.01 (-4.44, -1.59) 3.97E-05 C18orf10 
rs6974557 7 T 0.26 469 -2.98 (-4.39, -1.57) 4.05E-05 Loc646614 
rs6733728 2 C 0.38 469 -3.04 (-4.49, -1.60) 4.13E-05 Loc402093 
rs2389096 13 T 0.24 468 3.03 (1.58, 4.47) 4.69E-05 GPC6 
rs267280 3 G 0.47 469 -3.29 (-4.86, -1.72) 4.70E-05 LARS2 
 
B) 
SNP Chr. 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value Gene 
rs7326145 13 A 0.23 199 4.95 (2.81, 7.09) 1.01E-05 COL4A2 
rs7837658 8 T 0.45 199 5.12 (2.86, 7.39) 1.62E-05 RNF19A 
rs877356 5 T 0.23 199 -4.72 (-6.82, -2.61) 1.84E-05 SLC25A48/IL9 
rs7944514 11 C 0.41 199 4.83 (2.65, 7.00) 2.19E-05 POLD3 
rs2839520 21 A 0.27 199 4.45 (2.38, 6.56) 4.01E-05 UBASH3A 
rs16872344 5 A 0.22 199 4.51 (2.40, 6.63) 4.51E-05 IRX1 
rs13174381 5 A 0.23 199 4.47 (2.37, 6.58) 4.86E-05 IRX1 
rs10085086 5 C 0.20 197 -4.76 (-7.01, -2.52) 4.90E-05 Loc391738 
 
C) 
SNP Chr. 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value Gene 
rs17062122 6 C 0.33 270 -4.69 (-6.56, -2.82) 1.54E-06 Loc285735 
rs903281 10 G 0.29 270 -4.36 (-6.21, -2.51) 6.28E-06 RAB18 
rs331086 5 C 0.46 270 -4.58 (-6.67, -2.49) 2.52E-05 FBN2 
145 
 
rs7137335 12 T 0.33 269 -4.02 (-5.89, -2.15) 3.53E-05 SLC16A7 
rs7074813 10 G 0.33 270 -4.02 (-5.89, -2.14) 3.84E-05 RAB18 
… … … … … … … … … 
rs877356 5 T 0.23 270 -3.59 (-5.52, -1.67) 3.09E-04 SLC25A48/IL9 
* adjusted for 10 principal components, sex, and cohort of origin 
^ adjusted for 10 principal components and sex 
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Appendix Table 4-3. Single nucleotide polymorphisms associating with case/control tuberculin skin test induration status (< versus ≥ 
5mm) below a 5x10
-5
 p value in an additive genetic model in A) the combined cohort*, B) the Ugandan cohort^, and C) the Tanzanian 
cohort^  
A) 
SNP Chr. 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.23 469 0.33 (0.22, 0.49) 5.45E-08 SLC25A48/IL9 
rs7808481 7 A 0.22 469 2.31 (1.60, 3.34) 8.67E-06 Loc340268 
rs10804666 3 G 0.44 469 2.04 (1.47, 2.84) 2.28E-05 NMNAT3 
rs8179938 3 A 0.37 469 2.01 (1.45, 2.79) 2.77E-05 Loc643634 
rs4705073 5 C 0.45 469 1.91 (1.41, 2.59) 2.79E-05 MIRN145 
rs964739 4 T 0.38 469 1.93 (1.41, 2.63) 3.67E-05 KLHL8 
 
B) 
SNP Chr. 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.23 199 0.23 (0.12, 0.44) 1.41E-05 SLC25A48/IL9 
rs9989936 21 G 0.40 199 0.25 (0.13, 0.48) 3.07E-05 SAMSN1 
 
C) 
SNP Chr. 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs642774 1 G 0.44 270 0.37 (0.24, 0.57) 6.26E-06 UOX 
rs6589880 11 C 0.40 270 2.23 (1.52, 3.28) 4.18E-05 Loc283155 
rs7808481 7 A 0.23 270 2.53 (1.62, 3.95) 4.74E-05 Loc340268 
… … … … … … … … … 
rs877356 5 T 0.23 270 0.38 (0.23, 0.65) 3.14E-04 SLC25A48/IL9 
* adjusted for 10 principal components, sex, and cohort of origin 
^ adjusted for 10 principal components and sex 
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Appendix Table 4-4. Single nucleotide polymorphisms associating with continuous tuberculin skin test induration below a 5x10
-5
 p 
value in an additive genetic model in A) the combined cohort*, B) the Ugandan cohort^, and C) the Tanzanian cohort^  
 
A) 
SNP Chr. 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.23 469 -3.34 (-4.53, -2.14) 6.95E-08 SLC25A48/IL9 
rs7082209 10 G 0.40 469 -2.56 (-3.66, -1.46) 6.45E-06 CXCL12 
rs7163504 15 G 0.43 467 -2.27 (-3.26, -1.28) 9.51E-06 NEO1 
rs8179938 3 A 0.37 469 2.37 (1.30, 3.43) 1.56E-05 Loc643636 
rs10881240 1 T 0.37 469 -2.23 (-3.25, -1.21) 2.25E-05 Loc642337 
rs290185 11 A 0.46 469 2.18 (1.17, 3.19) 2.66E-05 CCDC89 
rs7239554 18 A 0.28 469 -2.45 (-3.59, -1.32) 2.80E-05 C18orf10 
rs11120119 1 G 0.45 466 -2.15 (-3.14, -1.15) 2.89E-05 RPS6KC1 
rs7808481 7 A 0.22 469 2.57 (1.37, 3.77) 3.05E-05 Loc340268 
rs6780136 3 T 0.33 468 -2.21 (-3.24, -1.18) 3.12E-05 CPNE4 
rs12634351 3 C 0.33 469 -2.21 (-3.25, -1.18) 3.50E-05 CPNE4 
rs10804666 3 G 0.44 469 2.25 (1.18, 3.31) 4.06E-05 NMNAT3 
rs7326145 13 A 0.25 469 2.48 (1.30, 3.66) 4.29E-05 COL4A2 
 
B) 
SNP Chr. 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value Gene 
rs7326145 13 A 0.23 199 4.30 (2.44, 6.15) 1.00E-05 COL4A2 
rs10085086 5 C 0.20 197 -4.21 (-6.13, -2.29) 2.80E-05 Loc391738 
rs6545560 2 G 0.40 199 -3.20 (-4.68, -1.73) 3.15E-05 CCDC85A 
… … … … … … … … … 
rs877356 5 T 0.23 199 0.23 (0.12, 0.44) 1.25E-04 SLC25A48/IL9 
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C) 
SNP Chr. 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value Gene 
rs642774 1 G 0.44 270 -3.10 (-4.46, -1.74) 1.11E-05 UOX 
rs2727529 7 C 0.38 270 2.93 (1.60, 4.25) 2.07E-05 PRKAG2 
rs312305 5 G 0.43 269 2.90 (1.57, 4.22) 2.55E-05 GABRG2 
rs2141372 2 G 0.40 270 -3.10 (-4.52, -1.68) 2.62E-05 ZNF512 
rs7808481 7 A 0.23 270 3.35 (1.80, 4.90) 3.06E-05 Loc340268 
rs8103597 19 A 0.26 270 3.26 (1.74, 4.77) 3.48E-05 SIPA1L3 
rs17062122 6 C 0.33 270 -3.13 (-4.60, -1.67) 3.85E-05 Loc285735 
rs12469734 2 A 0.45 270 2.99 (1.58, 4.41) 4.58E-05 ARL4C 
rs7906180 10 T 0.36 270 2.98 (1.57, 4.39) 4.81E-05 Loc100128641 
… … … … … … … … … 
rs877356 5 T 0.23 270 -3.05 (-4.65, -1.45) 2.22E-04 SLC25A48/IL9 
* adjusted for 10 principal components, sex, and cohort of origin 
^ adjusted for 10 principal components and sex 
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Appendix Table 4-5. Single nucleotide polymorphisms associating with case/control tuberculin skin test induration status (< versus ≥ 
5mm) below a 5x10
-5
 p value in a recessive genetic model in A) the combined cohort*, B) the Ugandan cohort^, and C) the Tanzanian 
cohort^  
 
A) 
SNP Chr. 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs1293940 6 A 0.32 469 0.17 (0.080, 0.37) 7.21E-06 ESR1 
rs2285513 19 A 0.40 469 0.26 (0.14, 0.49) 2.58E-05 SBSN 
rs2434785 5 G 0.46 469 0.32 (0.18, 0.55) 3.73E-05 Loc266786 
rs10804666 3 G 0.44 469 3.57 (1.95, 6.54) 3.94E-05 NMNAT3 
rs4705073 5 C 0.45 469 2.99 (1.77, 5.05) 4.14E-05 MIRN145 
rs2489772 1 C 0.43 469 3.43 (1.90, 6.20) 4.53E-05 KAZN 
 
B) 
SNP Chr. 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs4989483 16 G 0.49 199 0.16 (0.069, 0.38) 2.94E-05 FLJ32252 
rs12412686 10 A 0.33 199 0.090 (0.028, 0.29) 4.81E-05 CLRN3 
 
C) 
SNP Chr. 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
 
Gene 
rs7239336 18 C 0.48 270 3.94 (1.91, 6.37)  4.52E-05  MIRN924 
* adjusted for 10 principal components, sex, and cohort of origin 
^ adjusted for 10 principal components and sex 
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Appendix Table 4-6. Single nucleotide polymorphisms associating with continuous tuberculin skin test induration below a 5x10
-5
 p 
value in a recessive genetic model in A) the combined cohort*, B) the Ugandan cohort^, and C) the Tanzanian cohort^  
 
A) 
SNP Chr. 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value Gene 
rs2520696 13 A 0.47 469 -4.00 (-5.64, -2.36) 2.51E-06 FRY 
rs2333021 14 A 0.33 469 5.16 (2.95, 7.36) 5.77E-06 ZFYVE1 
rs10804666 3 G 0.44 469 4.30 (2.41, 6.19) 1.07E-05 NMNAT3 
rs798957 13 A 0.37 469 -4.49 (-6.48, -2.51) 1.15E-05 FRY 
rs2434785 5 G 0.46 469 -3.88 (-5.62, -2.15) 1.46E-05 Loc266786 
rs2489772 1 C 0.43 469 4.22 (2.33, 6.11) 1.50E-05 KAZN 
rs10957982 8 T 0.26 468 -6.27 (-9.18, -3.35) 3.05E-05 ZBTB10 
rs753927 20 C 0.35 469 4.64 (2.48, 6.80) 3.07E-05 FERMT1 
rs2285513 19 A 0.40 469 -4.22 (-6.19, -2.25) 3.33E-05 SBSN 
rs1293940 6 A 0.32 469 -4.74 (-6.96, -2.52) 3.50E-05 ESR1 
rs10776801 1 C 0.31 469 -5.09 (-7.48, -2.70) 3.53E-05 Loc100130948 
rs10881240 1 T 0.37 469 -4.27 (-6.27, -2.26) 3.73E-05 Loc642337 
rs7623698 3 A 0.24 469 -6.58 (-9.70, -3.46) 4.27E-05 Loc285303 
 
B) 
SNP Chr. 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value 
 
Gene 
rs10800363 1 T 0.44 199 -6.03 (-8.77, -3.29) 2.61E-05 
 
XCL1 
rs8014986 14 A 0.23 199 -8.27 (-12.04, -4.50) 2.73E-05  HHIPL1 
rs7873440 9 T 0.41 199 -6.69 (-9.8, -3.58) 3.80E-05  RG9MTD3 
rs4989483 16 G 0.49 199 -5.51 (-8.07, -2.95) 3.81E-05  FLJ32252 
rs7676378 4 T 0.25 199 -8.99 (-13.21, -4.77) 4.60E-05  FAT4 
rs7340961 4 C 0.41 199 -6.08 (-8.95, -3.21) 4.94E-05  AGPAT9 
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C) 
SNP Chr. 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value 
 
Gene 
rs2333021 14 A 0.37 270 6.74 (4.05, 9.43) 1.61E-06 
 
ZFYVE1 
rs4462385 12 A 0.25 270 8.01 (4.41, 11.61) 1.88E-05  SLC16A7 
rs8019592 14 T 0.20 270 11.53 (6.30, 16.75) 2.19E-05  RAD51L1 
rs2395015 7 A 0.29 270 8.33 (4.52, 12.14) 2.56E-05  SMURF1 
rs5767477 22 G 0.37 270 5.55 (2.96, 8.13) 3.64E-05  TBC1D22A 
* adjusted for 10 principal components, sex, and cohort of origin 
^ adjusted for 10 principal components and sex 
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Appendix Table 4-7. Association of SNPs with binary tuberculin skin test induration (at and above 5mm versus below) in the 
imputed SLC25A48/IL9 region of the combined cohort in a A) dominant and B) additive genetic model; adjusting for 10 principal 
components, sex, and cohort of origin 
 
A) 
SNP Chr. Position 
Minor 
Allele 
Imputation 
Certainty 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
rs17169187 5 135163758 C 0.99 0.24 469 0.25 (0.16, 0.40) 4.57E-09 
rs17169180 5 135161055 C 0.99 0.24 469 0.26 (0.17, 0.42) 9.36E-09 
rs13167664 5 135162467 G 0.99 0.24 469 0.26 (0.17, 0.42) 9.36E-09 
rs35520957 5 135163307 T 0.99 0.24 469 0.26 (0.17, 0.42) 9.36E-09 
rs877356 5 135161418 T Not Imputed 0.24 469 0.27 (0.17, 0.42) 1.22E-08 
  
B) 
SNP Chr. Position 
Minor 
Allele 
Imputation 
Certainty 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value 
rs17169187 5 135163758 C 0.99 0.24 469 0.32 (0.21, 0.48) 2.56E-08 
rs17169180 5 135161055 C 0.99 0.24 469 0.33 (0.22, 0.49) 4.47E-08 
rs13167664 5 135162467 G 0.99 0.24 469 0.33 (0.22, 0.49) 4.47E-08 
rs35520957 5 135163307 T 0.99 0.24 469 0.33 (0.22, 0.49) 4.47E-08 
rs877356 5 135161418 T Not Imputed 0.24 469 0.33 (0.22, 0.49) 5.45E-08 
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Appendix Table 4-8. Association of SNPs with continuous tuberculin skin test induration in the imputed SLC25A48/IL9 region of the 
combined cohort in a A) dominant and B) additive genetic model; adjusting for 10 principal components, sex, and cohort of origin 
 
A) 
SNP Chr. Position 
Minor 
Allele 
Imputation 
Certainty 
MAF n Beta 
95% Confidence 
Interval 
p value 
rs17169187 5 135163758 C 0.99 0.24 469 -4.29 (-5.69, -2.88) 4.58E-09 
rs17169180 5 135161055 C 0.99 0.24 469 -4.16 (-5.56, -2.75) 1.35E-08 
rs13167664 5 135162467 G 0.99 0.24 469 -4.16 (-5.56, -2.75) 1.35E-08 
rs35520957 5 135163307 T 0.99 0.24 469 -4.16 (-5.56, -2.75) 1.35E-08 
rs877356 5 135161418 T Not Imputed 0.24 469 -4.14 (-5.55, -2.74) 1.45E-08 
  
B) 
SNP Chr. Position 
Minor 
Allele 
Imputation 
Certainty 
MAF n Beta 
95% Confidence 
Interval 
p value 
rs17169187 5 135163758 C 0.99 0.24 469 -3.43 (-4.62, -2.24) 2.84E-08 
rs17169180 5 135161055 C 0.99 0.24 469 -3.34 (-4.53, -2.15) 6.65E-08 
rs13167664 5 135162467 G 0.99 0.24 469 -3.34 (-4.53, -2.15) 6.65E-08 
rs35520957 5 135163307 T 0.99 0.24 469 -3.34 (-4.53, -2.15) 6.65E-08 
rs877356 5 135161418 T Not Imputed 0.24 469 -3.34 (-4.53, -2.14) 6.95E-08 
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Appendix Table 4-9. Interferon gamma release assay results by TST case/control status in A) 
the Ugandan cohort and B) the Tanzanian cohort 
 
A) 
IGRA Antigen Mean PPD Negative Mean PPD Positive p value  
n 25 89   
MEDIA 45.27 (75.76) 43.07 (116.80) 0.93 
ESAT-6 30.14 (34.32) 143.73 (498.86) 0.30 
CXFT 101.91 (205.62) 1495 (422.05) 0.18 
CFP10 69.62 (123.05) 190.69 (713.37) 0.41 
 
B) 
IGRA Antigen Mean PPD Negative Mean PPD Positive p value  
n 161 79   
PHA 18708.11 (27709.84) 22263.52 (35855.16) 0.40 
MEDIA 184.85 (412.16) 227.66 (522.57) 0.49 
ESAT-6 444.77 (1598.35) 4027.45 (9705.44) 8.60E-06 
Ag85 335.01 (1273.74) 1387.03 (2772.05) 0.0001 
MVS 220.40 (416.09) 525.32 (1494.13) 0.017 
WCL 1366.25 (3454.75) 7711.33 (14517.40) 3.21E-07 
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Appendix Table 4-10. Single nucleotide polymorphisms associating with A) tuberculin skin test induration case/control status (< 
versus ≥ 5mm) and B) continuous tuberculin skin test induration using a dominant genetic model in the combined cohort, below a 
5x10
-5
 p value after removing patients with possible false negative TST results; adjusted for 10 principal components, sex, and cohort 
of origin 
 
A) 
SNP CHR 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.22 453 0.27 (0.17, 0.42) 1.77E-08 SLC25A48/IL9 
rs7808481 7 A 0.22 453 2.64 (1.69, 4.16) 2.14E-05 Loc340268 
rs697635 12 T 0.24 453 0.39 (0.25, 0.61) 3.14E-05 ANKRD33 
rs2389096 13 T 0.24 452 2.53 (1.62, 3.95) 4.14E-05 GPC6 
rs1880386 10 A 0.21 453 2.52 (1.62, 3.93) 4.51E-05 GRID1 
rs9584956 13 G 0.24 453 2.43 (1.58, 3.73) 4.92E-05 DOCK9 
  
B) 
SNP CHR 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.22 453 -4.22 (-5.69, -2.78) 1.68E-08 SLC25A48/IL9 
rs697635 12 T 0.24 453 -3.20 (-4.65, -1.75) 1.95E-05 ANKRD33 
rs7239554 18 A 0.28 453 -3.19 (-4.64, -1.74) 1.97E-05 C18orf10 
rs7808481 7 A 0.22 453 3.17 (1.70, 4.65) 3.04E-05 Loc340268 
rs9920077 15 A 0.46 453 3.43 (1.83, 5.04) 3.37E-05 KIAA1024 
rs12454816 18 A 0.23 453 3.11 (1.65, 4.57) 3.50E-05 CDH20 
rs2389096 13 T 0.24 452 3.12 (1.65, 4.60) 3.95E-05 GPC6 
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Appendix Table 4-11. Single nucleotide polymorphisms associating with A) tuberculin skin test induration case/control status (< 
versus ≥ 5mm) and B) continuous tuberculin skin test induration using a dominant genetic model in the combined cohort, below a 
5x10
-5
 p value after removing patients with possible false positive TST reaction to a childhood BCG vaccine; adjusted for 10 principal 
components, sex, and cohort of origin 
 
A) 
SNP CHR 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.23 449 0.27 (0.17, 0.44) 5.58E-08 SLC25A48/IL9 
rs1880386 10 A 0.22 449 2.59 (1.66, 4.04) 2.93E-05 GRID1 
rs7239554 18 A 0.28 449 0.40 (0.26, 0.61) 3.16E-05 C18orf10 
 
B) 
SNP CHR 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.23 449 -3.86 (-5.30, -2.42) 2.25E-07 SLC25A48/IL9 
rs6733728 2 C 0.38 449 -3.23 (-4.69, -1.76) 1.91E-05 Loc402093 
rs12454816 18 A 0.23 449 3.16 (1.71, 4.61) 2.46E-05 CDH20 
rs9345216 6 C 0.22 449 3.11 (1.65, 4.57) 3.60E-05 Loc100129847 
rs7239554 18 A 0.28 449 -3.07 (-4.52, -1.62) 3.91E-05 C18orf10 
rs6744638 2 G 0.44 449 -3.19 (-4.70, -1.69) 3.93E-05 Loc402093 
rs697635 12 T 0.24 449 -3.04 (-4.48, -1.58) 4.90E-05 ANKRD33 
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Appendix Table 4-12. Single nucleotide polymorphisms associating with A) tuberculin skin test induration case/control status (< 
versus ≥ 5mm) and B) continuous tuberculin skin test induration using a dominant genetic model in the combined cohort, below a 
5x10
-5
 p value after removing patients with possible false positive TST reaction to a childhood BCG vaccine and possible false 
negative TST reactions; adjusted for 10 principal components, sex, and cohort of origin 
 
A) 
SNP CHR 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.23 433 0.27 (0.17, 0.44) 7.44E-08 SLC25A48/IL9 
rs7239554 18 A 0.28 433 0.38 (0.25, 0.59) 1.87E-05 C18orf10 
rs1880386 10 A 0.22 433 2.65 (1.68, 4.18) 2.67E-05 GRID1 
rs697635 12 T 0.25 433 0.38 (0.24, 0.60) 3.25E-05 ANKRD33 
rs12473869 2 T 0.23 433 2.64 (1.67, 4.18) 3.51E-05 Loc100131048 
rs7326145 13 A 0.25 433 2.58 (1.64, 4.05) 3.84E-05 COL4A2 
rs492479 12 C 0.23 433 0.39 (0.25, 0.61) 4.00E-05 KSR2 
rs10263964 7 C 0.36 433 0.40 (0.25, 0.62) 4.77E-05 CNTNAP2 
 
B) 
SNP CHR 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.23 433 -3.95 (-5.42, -2.48) 2.39E-07 SLC25A48/IL9 
rs12454816 18 A 0.23 433 3.40 (1.91, 4.88) 9.27E-06 CDH20 
rs697635 12 T 0.25 433 -3.31 (-4.79, -1.83) 1.52E-05 ANKRD33 
rs9345216 6 C 0.25 433 3.28 (1.78, 4.77) 2.14E-05 Loc100129847 
rs7239554 18 A 0.28 433 -3.25 (-4.72, -1.76) 2.14E-05 C18orf10 
rs6733728 2 C 0.38 433 -3.16 (-4.66, -1.67) 3.99E-05 Loc402093 
rs9920077 15 A 0.46 433 3.44 (1.80, 5.07) 4.49E-05 KIAA1024 
rs10263964 7 C 0.36 433 -3.12 (-4.61, -1.63) 4.75E-05 CNTNAP2 
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Appendix Table 4-13. Association of SNPs with A) case/control tuberculin skin test induration status (< versus ≥ 5mm) and B) 
continuous tuberculin skin test induration in the combined cohort using a dominant genetic model; adjusting for 10 principal 
components, sex, cohort of origin, and missing IGRA  
A) 
SNP Chr. 
Minor 
Allele 
MAF n 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.23 469 0.27 (0.17, 0.43) 1.78E-08 SLC25A48/IL9 
rs7808481 7 A 0.22 469 2.55 (1.64, 3.95) 3.00E-05 Loc340268 
rs12781609 10 T 0.32 469 0.41 (0.27, 0.63) 4.37E-05 C10orf93 
rs2389096 13 T 0.24 468 2.48 (1.60, 3.83) 4.49E-05 GPC6 
 
B) 
SNP Chr. 
Minor 
Allele 
MAF n Beta 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.23 469 -4.09 (-5.50, -2.69) 2.12E-08 SLC25A48/IL9 
rs6974557 7 T 0.26 469 -3.06 (-4.47, -1.66) 2.44E-05 Loc100128056 
rs2389096 13 T 0.24 468 3.06 (1.62, 4.51) 3.68E-05 GPC6 
rs7239554 18 A 0.28 469 -3.00 (-4.42, -1.58) 4.08E-05 C18orf10 
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Appendix Table 4-14. Association of SNPs with A) case/control tuberculin skin test induration status (< versus ≥ 5mm) and B) 
continuous tuberculin skin test induration using a dominant genetic model in the combined cohort, including patients with prior TB; 
adjusting for 10 principal components, sex, and cohort of origin 
 
A) 
SNP Chr. 
Minor 
Allele 
MAF 
n 
Odds 
Ratio 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.23 481 0.27 (0.17, 0.43) 1.56E-08 SLC25A48/IL9 
rs12781609 10 T 0.32 481 0.42 (0.27, 0.63) 3.82E-05 C10orf93 
rs7808481 7 A 0.21 481 2.47 (1.60, 3.81) 4.06E-05 Loc340268 
 
B) 
SNP Chr. 
Minor 
Allele 
MAF 
n Beta 
95% Confidence 
Interval 
p value Gene 
rs877356 5 T 0.23 481 -4.05 (-5.44, -2.67) 1.70E-08 SLC25A48/IL9 
rs6733728 2 C 0.38 481 -2.99 (-4.40, -1.57) 4.19E-05 Loc402093 
rs16827624 2 A 0.24 481 -2.92 (-4.31, -1.52) 4.84E-05 Loc100131051 
rs10051419 5 C 0.49 480 3.41 (1.78, 5.04) 4.86E-05 OR7H2P 
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Appendix Table 4-15. Association of the rs877356-rs2069885 haplotype using additive genetic 
models for both SNPs with TST induration case/control status (< versus ≥ 5mm) in the 
SLC25A48/IL9 region in A) the combined cohort, B) the Ugandan cohort and C) the Tanzanian 
cohort 
 
A) 
Haplotype Case Control Ca-Freq Co-Freq 
C-A 43 17 0.09 0.04 
C-G 360 301 0.74 0.67 
T-A 7 12 0.01 0.03 
T-G 76 120 0.16 0.27 
Likelihood ratio chisq = 42.90 df = 3 p-value = 2.59E-09* 
 
B) 
Haplotype Case Control Ca-Freq Co-Freq 
C-A 26 3 0.09 0.03 
C-G 216 60 0.72 0.61 
T-A 2 4 0.01 0.04 
T-G 56 31 0.19 0.32 
Likelihood ratio chisq = 25.84 df = 3 p-value = 1.03E-05^ 
 
C) 
Haplotype Case Control Ca-Freq Co-Freq 
C-A 18 14 0.10 0.04 
C-G 143 241 0.74 0.67 
T-A 4 8 0.01 0.03 
T-G 21 89 0.16 0.27 
Likelihood ratio chisq =  22.06 df = 3 p-value = 6.34E-05^ 
* adjusted for 10 principal components, sex, and cohort of origin 
^ adjusted for 10 principal components and sex 
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Appendix Table 4-16. Single nucleotide polymorphisms associating with TST induration 
case/control status (< versus ≥ 5mm) in the GAS2 region in the combined cohort, adjusted for 10 
principal components, sex, and cohort of origin 
 
SNP Position  
Minor 
Allele 
Odds 
Ratio 
95% Confidence 
Interval  p value 
rs141215155 22716709 C 0.32 (0.14, 0.72) 0.0061 
rs147337656 22717086 A 0.32 (0.14, 0.72) 0.0061 
rs140137885 22722819 G 0.32 (0.14, 0.72) 0.0061 
rs143310525 22724201 C 0.32 (0.14, 0.72) 0.0061 
rs147250499 22751877 T 0.32 (0.14, 0.72) 0.0061 
rs149974430 22711780 A 0.35 (0.16, 0.77) 0.0097 
rs146563332 22711993 C 0.35 (0.16, 0.77) 0.0097 
rs113171697 22712670 A 0.52 (0.31, 0.87) 0.013 
rs148539033 22822106 T 0.37 (0.17, 0.82) 0.013 
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Appendix Figure 4-1. QQ plot of results from a logistic regression association of case/control tuberculin skin test induration status (< 
versus ≥ 5mm) with a dominant genetic model of available SNPs for the combined Ugandan and Tanzanian datasets 
 
 
163 
 
Appendix Figure 4-2. Manhattan plot of results from a logistic regression association of case/control tuberculin skin test induration 
status (< versus ≥ 5mm) with a dominant genetic model of available SNPs for the combined Ugandan and Tanzanian datasets; blue 
line – Bonferroni adjusted significance threshold, red line – genome-wide significance threshold 
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Appendix Figure 4-3. Locus zoom plot of results from a logistic regression of case/control tuberculin skin test induration status (< 
versus ≥ 5mm) with SNPs in the SLC25A48/IL9 region using a dominant genetic model in the combined cohort, adjusted for 10 
principal components, sex, and cohort of origin 
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Appendix Figure 4-4. Locus zoom plot of results from a logistic regression association of case/control tuberculin skin test induration 
status (< versus ≥ 5mm) with a dominant genetic model of SNPs in the SLC25A48/IL9 region in the Ugandan cohort, adjusted for 10 
principal components and sex 
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Appendix Figure 4-5. Locus zoom plot of results from a logistic regression association of case/control tuberculin skin test induration 
status (< versus ≥ 5mm) with a dominant genetic model of SNPs in the SLC25A48/IL9 region in the Tanzanian cohort, adjusted for 10 
principal components and sex 
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Appendix Figure 4-6. Haploview plots of the rs877356 region (384 kb range) using the D’ metric in A) the Tanzanian cohort and B) 
the Ugandan cohort 
 
A) 
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B) 
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Appendix Figure 4-7. Haploview plots of the rs877356 region (384 kb region) using the r
2
 metric in A) the Tanzanian cohort and B) 
the Ugandan cohort 
 
A) 
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B) 
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Appendix Table 5-1. MDR metrics of the top model associating with TB disease using 
A) variants in or near IL12B (rs4921437), and SLC6A3 (rs7737692) and cohort of origin 
as covariates and B) variants in or near IL12B (rs4921437), TNF-α (rs2242656), and CR1 
(rs2940252) and cohort of origin as covariates 
 
A) 
Cohort Testing balanced accuracy Cross-validation consistency 
Combined 0.68 10/10 
 
B) 
Cohort Testing balanced accuracy Cross-validation consistency 
Combined 0.66 10/10 
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Appendix Table 5-2. MDR metrics of top loci and interactions associating with TB 
disease for variants on chromosome 5 omitting rs4921437 from analyses in A) two-locus 
and B) three-locus analyses 
 
A) 
SNP1 SNP2 
Training 
Balanced 
Accuracy 
Testing 
Balanced 
Accuracy 
Cross-
Validation 
Consistency 
Cohort 
rs460000 rs7704367 0.63 0.48 3/10 Tanzania 
rs460000 rs6869411 0.66 0.46 2/10 Uganda  
rs460000 rs7704367 0.61 0.54 4/10 Combined*  
*adjusted for cohort of origin 
 
B) 
SNP1 SNP2 SNP3 
Training 
Balanced 
Accuracy 
Testing 
Balanced 
Accuracy 
Cross-
Validation 
Consistency 
Cohort 
rs31489 rs460000 rs7704367 0.70 0.49 4/10 Tanzania 
rs2853672 rs460000 rs4921227 0.73 0.44 3/10 Uganda 
rs7737692 rs1295686 rs6869411 0.66 0.55 2/10 Combined* 
*adjusted for cohort of origin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
173 
 
Appendix Table 5-3. MDR metrics of the top models for all available SNPs associating with TB 
disease omitting variant rs4921437 in A) two-locus and B) three-locus analyses 
 
A) 
SNP1 SNP2 
Training 
Balanced 
Accuracy 
Testing 
Balanced 
Accuracy 
Cross-
Validation 
Consistency 
Cohort 
rs6436917  rs36987 0.64 0.47 4/10 Tanzania 
rs3129943  rs12788021 0.71 0.70 10/10 Uganda 
rs4680367  rs7496458  0.61 0.54 4/10 Combined* 
*adjusted for cohort of origin 
 
B) 
SNP1 SNP2 SNP3 
Training 
Balanced 
Accuracy 
Testing 
Balanced 
Accuracy 
Cross-
Validation 
Consistency 
Cohort 
rs16827657 rs7704367 rs4808737 0.69 0.41 1/10 Tanzania 
rs6793453 rs1265761 rs12788021 0.76 0.68 4/10 Uganda 
rs460000 rs6887695 rs372889 0.66 0.53 1/10  Combined* 
*adjusted for cohort of origin 
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Appendix Table 5-4. MDR metrics of the top model associating with TB disease using A) 
variants near IL9 (rs877356), and SLC6A3 (rs931709) and cohort of origin as covariates and B) 
variants in or near IL9 (rs877356), RAB6C (rs2521933), SLC6A3 (rs17597967) and cohort of 
origin as covariates 
 
A) 
Cohort Testing balanced accuracy Cross-validation consistency 
Combined 0.66 10/10 
 
B) 
Cohort Testing balanced accuracy Cross-validation consistency 
Combined 0.67 10/10 
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Appendix Table 5-5. MDR metrics of top loci and interactions associating with MTB infection for variants on chromosome 5 
omitting rs877356 from analyses in A) two-locus and B) three-locus analyses 
 
A) 
SNP1 SNP2 
Training 
Balanced 
Accuracy 
Testing 
Balanced 
Accuracy 
Cross-
Validation 
Consistency 
Cohort 
rs1835874 rs17169129 0.64 0.49 4/10 Tanzania 
rs872015 rs6865443 0.67 0.45 3/10 Uganda 
rs931709 rs17169129 0.61 0.56 7/10 Combined* 
*adjusted for cohort of origin 
 
B) 
SNP1 SNP2 SNP3 
Training 
Balanced 
Accuracy 
Testing 
Balanced 
Accuracy 
Cross-
Validation 
Consistency 
Cohort 
rs401681 rs7705049 rs1835874 0.71 0.53 4/10 Tanzania 
rs12523324 rs981883 rs2304075 0.75 0.44 2/10 Uganda 
rs12515850 rs981883 rs17169129 0.66 0.63 9/10 Combined* 
*adjusted for cohort of origin 
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Appendix Table 5-6. MDR metrics of the top models for all available SNPs associating with 
MTB infection omitting variant rs877356 in A) two-locus and B) three-locus analyses 
 
A) 
SNP1 SNP2 
Training 
Balanced 
Accuracy 
Testing 
Balanced 
Accuracy 
Cross-
Validation 
Consistency 
Cohort 
rs4848628 rs17005295 0.64 0.50 5/10 Tanzania 
rs6865443 rs10833965 0.71 0.65 8/10 Uganda 
rs2215813 rs17234274 0.63 0.59 6/10 Combined* 
*adjusted for cohort of origin 
 
B) 
SNP1 SNP2 SNP3 
Training 
Balanced 
Accuracy 
Testing 
Balanced 
Accuracy 
Cross-
Validation 
Consistency 
Cohort 
rs4848628 rs17005295 rs27061 0.70 0.53 3/10 Tanzania 
rs3094419 rs2521930 rs10833965 0.77 0.52 2/10 Uganda 
rs2521920 rs2521933 rs6865443  0.68 0.58 2/10 Combined* 
*adjusted for cohort of origin 
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